Drug-related deaths reported by Coroners in England, Wales, Northern Ireland, Guernsey, Jersey and the Isle of Man; police forces in Scotland; & the Northern Ireland Statistics and Research Agency; annual report January-December 2009. by Ghodse, Hamid et al.
Drug-related
deaths in the UK
Hamid Ghodse
John Corkery
Kapil Ahmed
Vinesha Naidoo
Adenekan Oyefeso
Fabrizio Schifano
National Programme on
Substance Abuse Deaths
(np-SAD)
International Centre for
Drug Policy (ICDP)
St George’s,
University of London, UK
Annual Report 2010
np-SAD
International Centre for Drug Policy ii
Published by
International Centre for Drug Policy,
St George’s, University of London
Cranmer Terrace, London SW17 0RE
Telephone +44 (0)20 8725 2623 & Fax +44 (0)20 8266 6494
E-mail: npsad@sgul.ac.uk
© 2010 International Centre for Drug Policy
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system,
or transmitted in any form, without the written permission of the publisher.
ISBN: 978 1 897778 73 9
The views expressed in this report are those of the authors, not necessarily
those of the Department of Health (nor do they reflect Government policy).
np-SAD
International Centre for Drug Policyiii
national programme on Substance
Abuse Deaths
(np-SAD)
Drug-related deaths reported by Coroners in
England, Wales, Northern Ireland, Guernsey,
Jersey and the Isle of Man; Police forces in
Scotland; & the Northern Ireland Statistics and
Research Agency
Annual Report January-December 2009
Hamid Ghodse
John Corkery
Kapil Ahmed
Vinesha Naidoo
Adenekan Oyefeso
Fabrizio Schifano
np-SAD
International Centre for Drug Policy iv
Contents
Preface vi
Acknowledgements vii
Annual Report for January-December 2009
Executive summary 1
Introduction 3
Chapter 1 Drug-related deaths in England 4
 Demography
 Substances implicated in death
 Drug abuse/dependence
 Changes between 2008 – 2009
 Deaths per 100,000 population by area
 Profile of cases meeting criteria for
monitoring the Government’s drug strategy
 Ten year trends in death 2000-2009
 Breakdown for English regions
 Commentary
Chapter 2 Drug-related deaths in Wales 48
 Demography
 Substances implicated in death
 Regional data
 Commentary
Chapter 3 Drug-related deaths in Northern Ireland 54
 Demography
 Substances implicated in death
 Commentary
Chapter 4 Drug-related deaths in Scotland 58
 Demography
 Substances implicated in death
 Regional data
 Commentary
Chapter 5 Drug-related deaths in the Islands 63
 Demography
 Substances implicated in death
 Commentary
Chapter 6 Drug-related deaths in UK 68
 Number of deaths
 Demography
 Substances implicated
 Commentary
Chapter 7 Commentary & Emerging Themes 76
np-SAD
International Centre for Drug Policyv
Chapter 8 Role of drugs in death 79
References 85
Appendices
1: The national programme on Substance Abuse Deaths 89
2: Definitions of drug-related death 92
3: Coroner’s jurisdictions/police force areas reporting 94
drug-related deaths, United Kingdom & Islands
4: np-SAD data collection form 101
np-SAD
International Centre for Drug Policy vi
Preface
The Annual Report on drug-related deaths in the United Kingdom published by the national
programme on Substance Abuse Deaths (np-SAD) is used by the UK Government, national and
international agencies, academics, and commissioners and service providers as an indicator of
the extent and nature of drug misuse, and makes a contribution towards the prevention of
substance abuse problems.
The Programme could not achieve its goals and objectives without the invaluable voluntary
collaboration and co-operation of coroners and their officers across England, Wales, Northern
Ireland, Guernsey, Jersey, and the Isle of Man. Scottish drug–related deaths data is provided by
the Scottish Crime and Drug Enforcement Agency. Additional data is provided by the Northern
Ireland Statistics and Research Agency on drug-related poisonings from the General Mortality
Register. The contributions from all are important as it enables the Programme to maintain a UK-
wide reporting and surveillance system. We thank them all for their active participation and
support.
The findings show an increase in deaths in 2009 reported directly to np-SAD by coroners from
England, Wales, Northern Ireland and the Islands when compared to the number reported in last
year’s report. Deaths in Scotland have remained stable. The np-SAD has an on-going
programme of visits to a representative sample of coroner areas to monitor the quality, accuracy
and comprehensiveness of the data received on drug-related death.
As in previous years, the statistics in this report are intended to inform authorities at the local,
regional and national levels, as well as health professionals and the general public, about the
serious consequences of drug abuse, especially polydrug use. This year’s report provides a
more detailed analysis for ‘drug misuse’ deaths for England and looks in particular at differences
between age-groups, the mortality of drug users aged over 40, and polysubstance implication in
death.
The report also provides a number of indications of changes in patterns of drug abuse, trends
over time, and emerging issues from our surveillance activities so that appropriate and timely
action can be taken.
The Programme would like to express their thanks to the Department of Health for its support for
this very important programme.
Professor A. Hamid Ghodse
Director
International Centre for Drug Policy
St George’s, University of London
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Executive summary
This eleventh annual report presents information on drug-related deaths that occurred during 2009 and
for which Coronial inquests and similar formal investigations have been completed. The main purpose of
the Annual Report from the national programme on Substance Abuse Deaths (np-SAD) is to inform the
Government’s monitoring of this important public health issue. The Programme’s principal function is to
provide high-quality and consistent surveillance, and to detect and identify emerging trends and issues in
respect of this phenomenon. In this way, it contributes to the reduction and prevention of drug-related
deaths in the UK due to the misuse of both licit and illicit drugs.
As in previous years, the data and analysis in this report is intended also to inform authorities at the local,
regional, and national country levels, as well as health professionals and the general public, about the
serious consequences of drug abuse. The report provides also a number of indicators of drug abuse
patterns, trends, and early warnings on emerging drug problems so that appropriate and timely action can
be taken.
Key findings for the UK and Islands
There were 2,182 notifications of drug-related deaths occurring in 2009 in the UK and Islands, this
represents an increase of 230 (11.8%) over the same reporting period in 2008. Data were provided by
105 of the 115 coroners’ jurisdictions in England & Wales; a response rate of about 92%.
The highest rates of drug-related deaths per 100,000 population aged 16 and over in 2009 were in the
following areas: Brighton & Hove (23.6); East Lancashire (14.0); North Tyneside (13.0); Tayside (12.0);
Liverpool (11.7); Swansea (11.7); and Strathclyde (11.1).
The principal demographic characteristics of those dying have remained consistent with previous reports.
The majority of cases were males (78%), under the age of 45 years (74%), and White (95%). Most deaths
(75%) occurred at a private residential address.
The main underlying cause(s) of death were: accidental poisoning (72%); intentional self-poisoning (9%);
and poisoning of undetermined intent (9%). This pattern represents an increase in accidental overdoses
in the previous year (64%) with consequent falls in other types of overdose deaths.
Accidental poisoning still remains the most frequent underlying cause of death amongst all age-groups,
and older females are more likely to die of intentional self-poisoning than males.
The overall pattern in the types of psychoactive drugs implicated in death has remained similar to
previous years. Heroin/morphine continues to be the principal substance implicated in death in the UK
and Islands. The proportions of deaths involving this and methadone showed small increase, and the
actual number of deaths in which they were implicated rose substantially.
The proportion of cases in which hypnotics/sedatives (mainly the benzodiazepines, diazepam and
temazepam) and alcohol-in-combination with other substances remained stable, but the actual number of
deaths in which they were implicated increased.
The increasing involvement of multiple substances in death demonstrated in this report for England, a
trend found across the UK as a whole, underlines the risks associated the co-ingestion of substances,
especially central nervous system depressants such as opiates/opioids, alcohol and benzodiazepines.
There has been a decline in deaths reported in 2009 from stimulants (cocaine, amphetamines, and
ecstasy-type drugs). This is true both in terms of the proportion of all deaths in which stimulants were
implicated, as well as the actual number of deaths.
The number of deaths involving piperazines and GBL/GHB continued to increase during 2009. The first
death involving mephedrone (a methcathinone) was also reported to np-SAD; this fatality happened
towards the end of 2009. Others have occurred in 2010 and will be included in next year’s report.
np-SAD
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Regional key findings
England
A total of 1,524 deaths were reported for 2009 (1374 in 2008). The demographic and drug profiles
remained stable. The most common prescribed medications implicated in death were anti-depressants
(54%) followed by hypnotics/sedatives (41%). There was an increase in the number of deaths persons of
Black ethnicity, from 14 in 2008 to 31 in 2009.
Wales
Notifications of 102 deaths were reported for 2009 (62 in 2008); there was improved compliance during
the past year. The demographic and drug profiles remained stable. There was a higher ratio of male to
female drug-related deaths in Wales during 2009 than in other countries within the UK;
Scotland
The number of deaths reported to police in Scotland remained stable in 2009 (n = 479). Opiates play a
larger role in Scottish deaths than in other regions. Alcohol-in-combination with other substances and
hypnotics/sedatives (mostly diazepam and temazepam) also feature prominently.
Northern Ireland
The number of cases reported was 65 (30 in 2008); this increase is due mostly to improved case
identification methods and reporting arrangements. The male to female ratio is more equal than in other
parts of the UK. The drug profile remained similar to recent years; heroin/morphine and methadone are
less prominent than elsewhere.
The Islands
Seven deaths occurred on the Isle of Man, 5 on Jersey, but none on Guernsey during 2009. The general
demographic profile of cases in the Islands is in line with the pattern in the UK as a whole. There are
proportionately fewer deaths involving cocaine and methadone; but there is a greater role played by other
opiate/opioid analgesics; heroin/morphine; and anti-depressants.
Key messages
Whilst there have been no major changes during the past in the principal illicit drugs and prescribed
medications implicated in drug-related deaths, some shifts in direction can be observed. Opiates and
opioids continue to increase their role in causing premature mortality, but towards the end of 2009 there
was a noticeable decline in the number and proportion of cases involving stimulants.
Substances such as piperazines, ketamine and GBL which at the time of last year’s report were ‘legal
highs’ but are now controlled drugs, continue to be present in post-mortem toxicology reports - although
possibly stabilising. However, towards the end of 2009 new substances, chiefly methcathinones such as
mephedrone started to appear in reports to np-SAD. The speed with which these and other new
substances are replacing established recreational drugs appears to accelerating. It is therefore important
that surveillance and monitoring of the situation continues.
np-SAD
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Introduction
This eleventh annual report continues the series of
reports published by the national programme on
Substance Abuse Deaths (np-SAD). It covers
deaths occurring between January and December
2009 reported to the Programme, as well as
presenting information on emerging trends, and
seeking to identify future potential issues that need
monitoring.
There is a chapter for each constituent part of the
UK (England, Wales, Scotland, Northern Ireland
and Guernsey, Jersey and Isle of Man) with data
tables. Chapter 1 provides a substantive
description of the situation regarding drug-related
deaths in England during 2009, including data
tables for a detailed breakdown of areas within
England. Chapters 2 to 5 cover the other parts of
the UK and Islands, with Chapter 6 presenting
findings for the UK as a whole. A commentary and
emerging issues is given in Chapter 7. Chapter 8
describes the role of drugs in death and has been
written to assist coroners, pathologists,
toxicologists and clinicians and others involved in
investigating suspected drug-related deaths.
The appendices provide information on the
Programme (Appendix 1), drug-related death
definitions (Appendix 2), the areas reporting,
(Appendix 3), and the Programme’s data collection
form (Appendix 4).
Quality Assurance of Data
The Programme has given consideration as to how
it can ensure the quality, accuracy and
comprehensiveness of the data collected in order
to improve both the quality of information collected
and to establish if all relevant cases are being
identified and notified. Following a pilot phase in
2008-9, a continuous rolling programme of visits to
a sample of geographically representative
coroners’ areas in England and Wales was
undertaken in 2009-10.
The on-going survey helps to establish the extent
to which cases are being correctly identified. This
makes it possible to extrapolate from the deaths
notified by participating areas to the expected
number of cases if all coroners were reporting all
cases, thereby providing a much more precise
estimate of drug-related deaths (DRDs) for policy
and intervention planning.
This activity also provides insights into the quality
and accuracy of the information submitted to the
Programme, and has provided a firm basis for a
continuous process of audit in the future, thereby
ensuring the consistent validation of the
Programme’s surveillance’s work. This work also
facilitates the drawing up of detailed guidance for
coroners and their staff in identifying and reporting
relevant cases to np-SAD.
The methodology used for this study was to select
and examine completed inquests for deaths,
available in coroners’ offices, occurring in 2008. A
statistically representative sample of 150 DRDs
reported to the Programme was drawn for the
quality assurance aspect based on cases reported
by coroners in England and Wales.
To ascertain the accuracy of case identification
and reporting, a 10% sample of records was drawn
randomly from files for all completed inquest (for
whatever reason) for each selected coroner’s area.
A total of 375 such completed inquests on all types
of death in 2008 were examined.
Geographical representativeness was based on
selecting one coroner’s area in each of the ten
Strategic Health Authority (SHA) areas in England
and two in Wales. For England there was a two-
stage sampling process. In the first stage, three
coroners’ areas from each SHA area was selected
on the basis of the highest number of inquests
completed. The second stage consisted of
randomly selecting one of these three areas for
investigation.
The key findings from this survey show that the
information received by the Programme from
coroners is consistent with the coronial inquest file
papers. This exercise did not identify any ‘false
positives’ i.e. any over-reporting.
In 2008 five cases, where one or more controlled
drugs or psychoactive substances were
mentioned, were not reported to np-SAD. An
extrapolation of these five cases projects an
increase of 50 in the number of reported cases
from coroners in England and Wales in 2008. The
degree of under reporting in both the 2007 and
2008 cases is comparable (3.9% and 3.3%
respectively). This underlines the consistency in
reporting.
np-SAD
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Chapter 1 Drug-related deaths in England
This chapter looks at drug-related deaths
which occurred in England in 2009, and also
examines trends over the past decade for illicit
substances and prescribed medications
implicated in death. Responses were received
from a total of 94 out of 102 coroners'
jurisdictions in England. This is a coverage
rate of about 92%. The first section in this
chapter examines cases that capture a range
of psychoactive drugs, and covers the history
of drug use irrespective of the cause of death.
Included within this section is a comparison of
those with a history of drug use against those
without. This section highlights any changes
made between 2008 and 2009 including
figures for the jurisdictions and a breakdown
for the English regions. The second section
describes cases that meet the definition used
by the Government for monitoring its drug
strategy i.e. ‘drug misuse’ (Appendix 2). An
examination of trends over the last decade
using this definition is then presented. The
distinctions between different age-groups,
older drug users, and polysubstances have
been given a special emphasis in this chapter.
Demographic profile
1. Demography
There were 1,524 drug-related deaths
reported to the Programme in 2009. Seventy-
eight percent of cases were male and 22%
female (Table 1.1 and Figure 1.1). Half (49%)
were unemployed. Seventy percent of deaths
occurred for those less than 45 years old.
There were similar proportions living alone
(42%) or with others (40%), and 3% were of
no fixed abode. Where ethnicity was known,
the majority were White (93.4%); the rest (n =
101) were Black (2.8%), Asian (1.7%), and
Other (2.1%).
Table 1.1: Demographic variables for np-SAD drug-related deaths, England, 2009
Variable Category Number (%)
Total 1,524 (100.0)
Gender Male 1,187 (77.9)
Female 337 (22.1)
Employment status Unemployed 753 (49.4)
Employed 409 (26.8)
Childcare/houseperson 23 (1.5)
Student 28 (1.8)
Retired/sickness/invalidity 149 (9.8)
Other 4 (0.3)
Not known 158 (10.4)
Living arrangements Alone 641 (42.1)
With others 606 (39.8)
No fixed abode 41 (2.7)
Other 76 (5.0)
Not known 160 (10.5)
np-SAD
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Figure 1.1: np-SAD drug-related deaths by age and gender, England, 2009
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2. Age
Most deaths in England during 2009 occurred
amongst those aged 35 years and over (65%),
one-quarter (28%) were aged 25-34, and only
7% were 15-24 years old, and less than one
percent for those less than 15 years of age
(Figure 1.2). The median age at death was
39.0 years (semi-interquartile range = 7.5).
Older male, White drug users are at most risk
of drug-related deaths (Bird et al, 2003;
Ghodse et al, 2009). Of the 1,524 cases that
died in England in 2009, 108 were under 24
years old, and 295 were 50 and over.
3. Older age-groups
Exposure to a history of drug use or addiction
increased with age. Older drug users are
defined here as those aged over 40 years at
the time of death, and with a known history of
drug use or addiction. However, they need not
necessarily have been known to treatment
services. The survival rate of older drug users
has increased over the years from 463 cases
in 2000 to 739 in 2009. The median age at
death of those with a history of drug abuse
was 32 years in 2000; by 2009 this had risen
to 37 years.
Over the past decade there was little
significant change in the main demographic
characteristics of drug users aged over 40;
more than half were unemployed compared
with about 25% employed and 10% retired. In
2009, half of such cases lived alone, whilst
32% lived with others, compared to 42% and
40% respectively of all-age cases in 2009.
Males accounted for between 75-85% of
deaths in drug users over 40 during the past
decade. For this age-group the number of
deaths declined as age rose; the oldest
individuals were 90 years of age.
When looking at manner of death (see
Appendix 1 for how this is defined), over the
past decade accidental deaths accounted for
the largest proportion (55%) amongst all age-
groups. Those aged 51-60 experienced the
highest intentional overdoses out of those
aged over 40; in 2009 suicides accounted for
5% of deaths for those aged 51-60, and 1%
for those aged 41-50. By comparison, in 2008
suicides accounted for 8% of deaths for those
aged 51-60, and 3% for those aged 41-50.
There were more deaths in the 41-50 years
age-group compared to older age-groups. This
pattern remained constant over the past
decade.
There was a steady year on year increase
during the past decade in deaths amongst
those aged over 40 years (Figure 1.3). In
addition, more deaths have been reported for
those with a drug history, and those injecting.
np-SAD
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Figure 1.2: np-SAD drug-related deaths by age-group, England, 2009
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Figure 1.3: np-SAD drug-related deaths of drug users, aged over 40 years, England,
2000-9
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In the past ten years, older drug users (41+
years) were most commonly prescribed
hypnotics/sedatives: 41-50 (25%), 51-60
(33%); and 71 and over (29%). The exception
was in the 61-70 age-group, where anti-
depressants were the more frequently
prescribed substances (39%). Hypnotics/
sedatives were the second most commonly
prescribed medication (33%) for the 61-70
years age-group. Methadone was prescribed
to just under a quarter amongst the 41-50 and
51-60 age-groups compared to 12% for those
aged 61-70, and was not prescribed to those
aged 71 and over. The prescribing of other
opiates/opioid analgesics increased with age;
10% for those aged 41-50 years and 20% for
those aged 51 and over. Heroin/morphine was
prescribed not more than 3% over the decade
np-SAD
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irrespective of age with an exception for those
aged 71 and over for whom it was 8%.
Seventy-three percent of cases involved
prescribed medication which was also
implicated in the death. Seven percent of older
drug users (41+ years) were prescribed anti-
depressants which were implicated in death
(Figure 1.4). Five percent of younger drug
users (less than 40 years old) were prescribed
anti-depressants implicated in death. Eight
percent of older drug users were prescribed
hypnotics/sedatives which were implicated in
death whilst 6% of younger drug users were
prescribed hypnotics/sedatives. Sixteen
percent of older drug users were prescribed
methadone which was implicated in death,
compared to 10% of younger drug users.
Figure 1.4: Comparison of prescribed psychoactive drugs implicated in np-SAD deaths
amongst drug users, England, 2000-9
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Figure 1.5 shows that 85% of older drug users
(over 40 years) prescribed heroin/morphine
had that same medication implicated in death.
Prescribed methadone was implicated in 73%
of deaths of those to whom it was prescribed;
for those prescribed other opiates/opioid
analgesics the proportion was 52%.
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Figure 1.5: Prescribed medication implicated vs. non-implicated in np-SAD deaths of drug
users aged over 40 years, England, 2000-9
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4. Location of death
In 2009 73% of cases died either at the
deceased’s home address or another private
residential address, 18% died in hospital, and
8% died elsewhere (e.g. public open space,
public facilities, or railway station).
5. Underlying cause(s) of death
The categories of underlying cause(s) of death
for coding within ICD-10 (Appendix 1) were as
follows:
 Accidental poisoning (X40-X47): 66.0%
 Intentional self-poisoning (X60-X67):
11.4%
 Poisonings of undetermined intent (Y10-
Y15): 10.2%
 Other (e.g. natural causes, drowning,
hanging, unascertained): 12.4%
Males were significantly more likely than
females to die of accidental poisoning (70%
vs. 52%) (Proportion Ratio PR: = 1.4, 95%
Confidence Interval CI: = 1.2 – 1.5). Females,
by contrast, were significantly more likely than
males to die of intentional self-poisoning (23%
vs. 8%) (PR = 2.8, 95% CI = 2.1 – 3.7), and
poisoning of undetermined intent (16% vs. 9%)
(PR = 1.9, 95% CI = 1.4 – 2.5).
Deaths of those aged less than 45 years were
more likely than older cases to die of
accidental poisoning (74% vs. 49%) (PR = 1.5,
95% CI = 1.4 – 1.7). This said, the most
frequent underlying cause of death within each
group was accidental: under 18 (57%); 18-24
(68%); 25-29 (76%); 30-34 (75%); 35-39
(74%); 40-49 (69%); and over 50 (41%).
There were 505 accidental poisonings by
narcotics and psychodysleptics for those aged
35 and over. There were 286 for the 25-34
age-group, and 63 for those aged 15-24 years.
Accidental poisoning by hypnotics/sedatives,
anti-depressants and psychotropic substances
were again highest amongst those aged 35
years and over (77), compared to those aged
25-34 (20) and 15-24 (8). Studies in Australia
have shown that a reduction in registering for
opioid pharmacotherapy for those aged les
than 35 years is greater than those aged 35
and over. A 41% drop was experienced
amongst the 25-34 age-group and a 26% drop
for 15-24 year-olds, when compared to those
aged 35 and over, where no change in levels
was experienced (Degenhardt et al, 2005).
In England, those aged 45 years or over were
more likely than younger cases to die of
intentional self-poisoning (24% vs. 6%) (PR =
3.9, 95% CI = 2.9 – 5.0), and poisoning of
undetermined intent (14% vs. 11%) (PR = 1.8,
95% CI = 1.3 – 2.4).
For those aged over 50 intentional overdoses
accounted for half of the overall total of such
deaths in all age-groups (88/175). The main
mechanism of death (as given in the first line
np-SAD
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of the cause of death field on the death
certificate) for intentional overdoses for those
aged 50 and over involved either anti-
depressants, or sedatives/hypnotics (23)
rather than narcotics and pyschodysleptics
(15). Intentional hanging was greatest for age
groups 25-29 (7), and 18-24 (6), compared to
those aged over 50 (2). Asphyxiation was the
most frequent cause of death which was non-
substance related, amongst older age-groups,
as well as respiratory failure/depression and
bronchopneumonia.
6. Manner of death
The results for 2009 cases are as follows:
 Natural: 3.2%
 Accidental: 70.2%
 Suicidal: 14.5%
 Homicidal: 0.1%
 Undetermined: 10.8%
 Unclassified/not specified: 1.2%
Males were more likely than females to die an
accidental death (75% vs. 54%) (PR = 1.4,
95% CI = 1.2 - 1.5). Conversely, females were
more likely than males to die of suicide (25%
vs. 11%) (PR = 2.3, 95% CI = 1.8 – 2.9), or a
death where the manner was undetermined
(15% vs. 10%) (PR = 1.5, 95% CI = 1.1 – 2.1).
Cases aged less than 45 years were more
likely than older cases to die accidentally (78%
vs. 53%) (PR = 1.5, 95% CI = 1.4 - 1.6). Those
aged 45 years or over were more likely than
younger cases to die intentionally (26% vs.
10%) (PR = 2.7, 95% CI = 2.2 – 3.5), or in a
manner that was undetermined (15% vs. 9%)
(PR = 1.6, 95% CI = 1.2 – 2.2).
Substances implicated in death
1. All substances
Of the 1,524 cases reported, 1,419 were
directly implicated to psychoactive drugs.
Seven percent (n = 105) were not included, as
no psychoactive drug was implicated in the
cause of death, however there could be a
history of drug abuse. The principal
substances implicated were heroin/morphine
(49%), alcohol in combination with other
substances (32%), other opiates/opioid
analgesics (21%), methadone (20%),
hypnotics/sedatives (19%); anti-depressants
(18%), and cocaine (10%) shown in Table 1.2.
Heroin/morphine was the most frequently
identified substance implicated (either as a
single drug or in combination) in death for
most age-groups: less than 18 (14%); 18-24
(47%); 25-29 (48%); 30-34 (58%); 35-39
(54%); and 40-49 (47%); followed by
methadone and other opiate/opioid analgesics
(Figure 1.6). For the over 50s other
opiate/opioid analgesics (37%) was the most
frequently identified substance implicated,
followed by anti-depressants (27.8%),
heroin/morphine (26%), and hypnotics/
sedatives (18%).
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Table 1.2: Psychoactive substances implicated in np-SAD deaths, England, 2009
Drug category Number (%) of cases
where no other
substance was implicated
Number (%) of cases
where drug was
implicated
Total 1,419 (100.0) 1,419 (100.0)
Alcohol - 447 (31.5)
Amphetamines 16 (1.1) 33 (2.3)
Anti-depressants 74 (5.3) 262 (18.4)
Anti-epileptics 2 (0.1) 17 (1.3)
Anti-Parkinson’s 2 (0.1) 4 (0.4)
Anti-psychotics 11 (0.8) 51 (3.6)
Cannabis 4 (0.3) 22 (1.6)
Cocaine 27 (1.9) 142 (10.0)
Ecstasy-type drugs 2 (0.1) 6 (0.4)
GHB 6 (0.4) 15 (1.0)
Heroin/morphine 238 (16.8) 698 (49.2)
Hypnotics/sedatives 18 (1.3) 275 (19.4)
Methadone 56 (3.9) 282 (19.8)
Other opiates/opioid analgesics 71 (5.0) 301 (21.2)
Notes: Column totals may sum to more than 100% since more than one substance may be implicated in a death. Not
all cases had drugs directly implicated in death; these are excluded from this table.
Other opiates/opioid analgesics was
implicated in 24% of deaths for those aged 35
and over (Figure 1.7), 18% for deaths within
the age-group 25-34, and just 11% for those
aged 15-24. Alcohol-in-combination with
another substance accounted for 64% of
deaths for those aged over 35, whilst it more
than halved for 25-34 (30%) and 15-24 (23%).
For those aged 35 and over, alcohol-in-
combination was implicated in 21% of total
deaths.
Figure 1.6: Principal substances implicated in death, by selected age-groups, England,
2009
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Figure 1.7: Principal substances implicated in deaths, by selected age-groups, England,
2009
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For all age-groups heroin/morphine was
identified as the most frequent single
substance implicated in death, except for
those aged 55 and over where other
opiates/opioid analgesics was more frequent
(Table 1.3).
Table 1.3: Age-group and psychoactive drug implicated in death, np-SAD cases, England,
2009
Age-group (years) Number (%)
where drug
was implicated
Drug category (alone or in combination)
most frequently implicated in each age
group
All ages 1,419 (100.0) Heroin/morphine (49.2%)
15–24 92 (6.5) Heroin/morphine (53.3%)
25-34 398 (28.0) Heroin/morphine (57.0%)
35-44 503 (35.4) Heroin/morphine (56.9%)
45-54 246(17.3) Heroin/morphine (39.0%)
55-64 118 (8.3) Other opiates/opioid analgesics (39.8%)
65 & over 62 (4.4) Other opiates/opioid analgesics (53.2%)
The pattern of drug-specific fatality is
somewhat different in male and female cases.
Among males, the most frequently mentioned
drugs were: heroin/morphine (50%); alcohol-
in-combination (30%); methadone (19%);
hypnotic/sedatives (18%); other opiates/opioid
analgesics (17%); anti-depressants (13%) and
cocaine (10%). Furthermore, there is a higher
proportion of cases of drug-specific fatality
among males compared to females in respect
of heroin/morphine, amphetamine, cannabis,
cocaine, and GHB.
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Among female cases, the most frequently
mentioned drugs were: anti-depressants
(31%); heroin/morphine (30%); other opiates/
opioid analgesics (29%); alcohol-in-
combination (27%); hypnotic/sedatives (20%);
and methadone (17%). Amongst females,
there are a greater proportion of cases
involving anti-depressants, other opiates/
opioid analgesics, and anti-psychotics.
2. Polysubstances
Over the past decade, one-fifth (21%) of drug-
related deaths has involved heroin/morphine in
combination with alcohol. Ten percent of
deaths involved other opiates/opioid
analgesics combined with alcohol, and 9% of
deaths heroin/morphine and other
opiates/opioid analgesics were combined.
Opiates and opioids including heroin/morphine
accounted for 70% of deaths where a
psychoactive substance was involved. This
pattern has remained stable for the past
decade. The combination of heroin/morphine
and other opiates/opioid analgesics fluctuated
between 6% and 11% over the past ten years.
The most prevalent substance combinations
implicated during 2000-9 were: heroin/
morphine with alcohol (21%); heroin/morphine
with hypnotics/sedatives (12%); and
hypnotics/sedatives with alcohol (11%). Over
the last decade alcohol-in-combination with
two other stimulants constantly featured.
Combinations of drugs, with or without alcohol,
pose greater risks for mortality (Chapter 8).
The most frequent combinations of prescribed
psychoactive drugs in 2000 were also the
most common in 2009. Prescribed hypnotics/
sedatives in combination with anti-depressants
accounted for 12% of cases in 2000 and 14%
in 2009. Hypnotics/sedatives in combination
with other opiates/opioid analgesics accounted
for 7% of cases in 2000 compared to 6% in
2009. Again, hypnotics/sedatives together with
anti-psychotics accounted for 5% in 2000 and
6% of cases in 2009.
3. Single substances
The following substances, as the sole
implicated drug, accounted for 533 (38%)
deaths: heroin/morphine (17%), other
opiates/opioid analgesics (5%), anti-
depressants (5%), methadone (4%), cocaine
(2%), hypnotic/sedatives (1.3%),
amphetamines (1.1%), anti-psychotics (0.8%)
barbiturates (0.4%), cannabis (0.4%), GHB
(0.4%), and ecstasy-type drugs (0.1%).
4. Prescribed psychoactive drugs
Altogether, 814 cases were reported to be
receiving prescribed psychoactive drugs at the
time of their death (Table 1.4). Within this
group, prescribed drugs reported were: anti-
depressants (54%); hypnotic/sedatives (41%);
other opiate/opioid analgesics (24%); anti-
psychotics (21%) and methadone (18%).
‘Polypharmacy’, i.e. multiple prescriptions of
psychoactive drugs, occurred in 71% of these
cases.
Prescribing medical history was directly
related to age for those on prescribed
medication at the time of their death. The
result shows: under 18 (0.1%), 18-24 (4%),
25-29 (9%), 30-34 (13%), 35-39 (19%), 40-49
(30%), and 50 and over (25%). The most
common prescribed medications were anti-
depressants (29%) followed by hypnotics/
sedatives (22%). These prescribed
medications increased with advancing age.
Three-quarters of those aged 35 and over
were on prescribed medication compared to
other age-groups. For those aged 35 years
and older hypnotics/sedatives were 46%
higher compared to 25-34 age-group, and
88% higher than those aged 15-24 years old.
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Table 1.4: Prescribed psychoactive medication, np-SAD cases, England, 2009
Drug category
Number (%) of cases on
prescribed
psychoactive medication
Number (%) of cases
where same drug was
implicated in death
Total 814 (100.0)
Amphetamines 5 (0.6) 0 (0.0)
Anti-depressants 441 (54.1) 185 (42.0)
Anti-epileptics 87 (10.7) 13 (14.9)
Anti-psychotics 173 (21.3) 43 (24.9)
Heroin/morphine 41 (5.0) 32 (78.0)
Hypnotic/sedatives 335 (41.1) 114 (34.0)
Methadone 144 (17.7) 97 (67.4)
Other opiates/opioid analgesics 197 (24.2) 111 (56.3)
Note: Column totals may sum to more than 100% since more than one substance may be prescribed to an individual
and more than one substance may be implicated in a death.
The following paragraphs take a closer look at
the relationship between deaths and the
involvement of prescribed medication.
Methadone, alone and in combination with
other drugs, was implicated in 282 cases. Of
these, 66% may have obtained methadone
from illicit sources, compared to 34% who
were known to be receiving prescribed
methadone prior to their death (PR = 1.9, 95%
CI = 1.6 - 2.3).
Methadone alone was implicated in 56 cases.
Of these, 54% may have obtained the drug
from illicit sources, compared to 46% who
were known to be receiving prescribed
methadone, compared to (PR = 1.2, 95% CI =
0.8 – 1.7).
Hypnotic/sedatives, alone and in combination
with other drugs, were implicated in 275
cases. Of these, 59% may have obtained
them illicitly, compared to the 41% who were
known to be receiving a prescription for this
class of drug (PR = 1.4, 95% CI = 1.2 – 1.7).
Eighteen cases had hypnotic/sedatives alone
implicated in their death, of whom 7 (39%) had
received the drug on prescription, compared to
11 (61%) who may have obtained it illicitly (PR
= 1.6, 95% CI = 0.8 – 3.1).
Anti-depressants, alone and in combination
with other drugs, were implicated in 262
cases. Of these, 71% were known to be
receiving prescribed anti-depressants at the
time of their death, compared to 29% who may
have used drugs prescribed for others (PR =
2.4, 95% CI = 2.0 – 2.9).
Anti-depressants alone were implicated in 74
cases. Of these, 62% were known to be
receiving prescribed anti-depressants,
compared to 38% who may have used drugs
prescribed for others (PR = 1.6, 95% CI = 1.1
– 2.3).
Other opiates/opioid analgesics (e.g.
dihydrocodeine, dextropropoxyphene) alone
and in combination with other drugs, were
implicated in 301 cases. Of these, 63% may
have obtained the drug by other means,
compared to the 37% who were known to be
receiving prescribed opiate/opioid analgesics
prior to their death (PR = 1.7, 95% CI = 1.4 -
2.0).
Other opiate/opioid analgesics alone were
implicated in 71 cases. Of these, the drugs
were apparently obtained by other means in
52% of cases, compared to being prescribed
in 48% of cases (PR = 1.1, 95% CI = 0.7 -
1.9).
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Drug abuse/dependence
Cases reported with a history of drug
abuse/dependence or recreational drug use
(DAs) accounted for 69% (n = 772). Those
without such a history, non drug abusers
(NDAs) accounted for 31% (n = 341). Four
hundred and ten cases (27%) were reported
as “not known” with respect to history of drug
abuse/dependence. These cases were
excluded from further analysis.
1. Demography
The cases were more likely to be male (PR =
1.4 95% CI = 1.2 - 1.5) and less than 45 years
of age, 77% compared to 49% (PR = 1.6, 95%
CI = 1.4 - 1.8). The median age at death for
DAs was 37.6 years (semi-interquartile range
= 6.1), while that for NDAs was 44.0 years
(semi-interquartile range = 11.1) (Mann-
Whitney U = 93,559.0 p < 0.0005).
2. Location of death
There was no significant difference between
DAs (72%) and NDAs (75%) with respect to
the location of their death. In both groups the
majority died at home or in a defined
residential address. Hospital deaths accounted
for a similar proportion of both DA (19%) and
NDA (18%) deaths. A higher proportion of DAs
(9%) died in temporary accommodation or in
public places than NDAs (5.8%). However, this
difference was not statistically significant.
3. Underlying cause(s) of death
DAs were more likely than NDAs to die of
accidental poisoning (79% vs. 40%) (PR = 2.0,
95% CI = 1.7 - 2.2) - see Figure 1.8. NDAs, by
contrast, were more likely than DAs to die of
intentional self-poisoning (32% vs. 2%) (PR =
17.6, 95% CI = 10.2 - 30.3), and poisoning of
undetermined intent (17% vs. 6%) (PR = 3.0,
95% CI = 2.1-– 4.3).
4. Manner of death
A similar pattern is exhibited with regard to
manner of death. DAs were more likely than
NDAs to die an accidental death (83% vs.
44%) (PR = 1.9, 95% CI = 1.7 - 2.1).
Conversely, NDAs were more likely than DAs
to die of suicide (36% vs. 5%) (PR = 7.8, 95%
CI = 5.1- 11.1), or a death where the manner
was undetermined (15% vs. 7%) (PR = 2.2,
95% CI = 1.5 - 3.2).
Figure 1.8: Principal underlying cause(s) of death by drug abuse/dependence history, np-
SAD cases, England, 2009
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Changes between 2008 and 2009
The following section compares deaths in
2009 with those that occurred in 2008. Deaths
in 2009 are reported as 1,524. During the
same time-frame in 2008, 1,374 cases were
reported. This is an increase in reporting of
11% in 2009. Figures for 2009 (and 2008, to a
lesser extent) can be expected to increase as
further inquests on drug-related deaths are
completed and reported to the Programme.
The figures for 2009, therefore, cannot be
compared directly with those in previous np-
SAD publications.
1. Demography
Whilst there were small changes between
2008 and 2009, the demographic profile of
cases remained stable with no significant
changes in age, gender, and employment
status distributions. Ethnicity remained similar
except for those of Black ethnicity the number
of whom doubled from 14 in 2008 to 31 in
2009. There was a decrease in the proportion
of cases of no fixed abode (from 5.8% to
2.7%). A small increase was observed in the
proportion of deaths occurring in residential
premises (from 70% to 73%).
2. Underlying cause(s) of death
The proportion of accidental deaths remained
stable at 66% in 2009 (65% in 2008). Whilst
intentional self-poisoning deaths decreased
slightly from 13% in 2008 to 11% in 2009, and
poisonings of undetermined intent decreased
from 11% to 10%, deaths from other causes
increased slightly from 11% to 12%.
3. Manner of death
The relatively stable patterns observed for
underlying cause(s) of death were echoed for
the manner of death. The only change of note
was a small decrease in the proportion of
undetermined deaths from 13% to 11%.
4. Substances implicated in death
4.1 Multiple substances
In 2009 there were 1,419/1524 deaths that
involved psychoactive substances; 105 cases
were excluded from the following analyses as
they did not involve psychoactive substances.
The number of 2008 cases examined was
1,286. Heroin/morphine remained the most
frequently mentioned drug in 2009, having
been implicated in 49% of deaths 946% in
2008). There were increases both in the
number and proportion of mentions for
heroin/morphine, methadone, anti-depressants
cannabis, hypnotic/sedatives, and other
opiates/opioid analgesics (Table 1.5).
4.2 Single substance
There were slight changes between 2008 and
2009 in the proportions accounted for by
fatalities involving a single psychoactive
substance. There were decreases in the
proportions accounted for by methadone,
cocaine, ecstasy-type drugs, other opiates/
opioid analgesics, anti-epileptics, anti-
Parkinson’s, and anti-psychotics. There were
increases for anti-depressants, cannabis,
GHB, heroin/morphine and hypnotics/
sedatives (Table 1.6).
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Table 1.5: Changes in proportions of psychoactive substances implicated in multiple
substance deaths, np-SAD cases, England, 2008 and 2009
Substance 2008
(N =
1,286) ‡
2008
(N =
1,592) †
2009
(N =
1,419)
Percentage
Ratio (PR)
95% CI Change
(percentage
points)
Alcohol-in-
combination
32.7 31.0 31.5 1.0 0.9 - 1.2 - 1.2
Amphetamines 4.2 3.9 2.3 1.8 1.2 – 2.8 - 1.9
Anti-depressants 18.0 18.7 18.5 1.0 0.9 - 1.2 + 0.5
Anti-epileptics 1.8 1.8 1.3 1.3 0.7 – 2.4 - 0.5
Anti-Parkinson’s 0.4 0.3 0.4 1.1 0.3 - 3.6 -
Anti-psychotics 4.6 4.9 3.6 1.3 0.9 – 1.8 - 1.0
Cannabis 1.4 1.6 1.6 1.1 0.6 - 2.1 + 0.2
Cocaine 14.0 13.7 10.0 1.4 1.1 – 1.7 - 4.0
Ecstasy-type drugs 2.3 2.3 0.4 5.3 2.2 – 12.8 - 1.9
GHB 1.0 0.9 1.0 1.1 0.5 - 2.3 -
Heroin/morphine 45.5 43.5 49.2 1.1 1.0 - 1.2 + 3.7
Hypnotic/sedatives 15.9 15.5 19.4 1.2 1.0 - 1.4 + 3.5
Methadone 19.5 19.4 19.8 1.0 0.9 - 1.2 + 0.3
Other opiates/ opioid
analgesics
20.6 20.2 21.2 1.0 0.9 - 1.2 + 1.4
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death.
†On average approximately 300 cases of inquest from the year of death are not completed and are added to next year.
‡ The PR and CI are based on the year on year 2008 figure
Table 1.6: Changes in proportions of psychoactive substances implicated in single
substance deaths, np-SAD cases, England, 2008 and 2009
Substance 2008
(N =
1,286)
‡
2008
(N =
1,592)
†
2009
(N =
1,419)
Percentage
Ratio (PR)
95% CI Change
(percentage
points)
Amphetamines 1.2 1.1 1.1 1.0 0.5 – 1.9 - 0.1
Anti-depressants 5.1 5.4 5.2 1.0 0.7 - 1.4 + 0.1
Anti-epileptics 0.5 0.4 0.1 3.3 0.7 – 16.4 - 0.4
Anti-Parkinson’s 0.2 0.1 0.1 1.1 0.2 – 7.8 - 0.1
Anti-psychotics 0.9 1.1 0.8 1.1 0.5 – 2.5 - 0.1
Cannabis 0.2 0.3 0.3 1.8 0.3 – 9.9 + 0.1
Cocaine 3.5 3.5 1.9 1.8 1.2 – 2.9 - 1.6
Ecstasy-type drugs 0.8 0.8 0.1 5.5 1.2 – 25.1 - 0.7
GHB 0.2 0.3 0.4 2.3 0.4 – 11.7 + 0.2
Heroin/morphine 16.3 15.3 16.8 1.0 0.9 – 1.2 + 0.5
Hypnotic/sedatives 1.1 1.1 1.3 1.2 0.6 – 2.3 + 0.2
Methadone 5.9 6.0 3.9 1.5 1.1 – 2.1 - 2.0
Other opiates/ opioid
analgesics
5.7 5.8 5.0 1.1 0.8 – 1.5 - 0.7
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death.
†On average approximately 300 cases of inquest from the year of death are not completed and are added to next year.
‡ The PR and CI are based on the year on year 2008 figure
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Deaths per 100,000 population by area
This section provides information by different
geographical units for the number of deaths per
100,000 population aged 16 years and older.
Tables A and B provide information by
coroners’ jurisdiction, Tables C and D provide
breakdown by DA(A)T area, and Table E by
Primary Care Trust area.
Jurisdictions with highest rates in 2009
The following coroner’s jurisdictions in England
reported annual drug-related death rates higher
than 10/100,000 population in 2009: Brighton &
Hove (23.55); East Lancashire (13.97); North
Tyneside (13.03) and Liverpool (11.72). Of
these four areas, Brighton & Hove showed a
small increase (from 21.2), the rest showed
significant increases from 2008; East
Lancashire (8.84); North Tyneside (5.88) and
Liverpool (8.93).
Jurisdictions with lowest rates in 2009
The following jurisdictions reported annual
drug-related death rates of less than 1/100,000
population in 2009: West Sussex (0.16); Avon
(0.23); North Yorkshire Eastern (0.49); Essex &
Thurrock (0.73); and Eastern Somerset (0.92).
The following areas experienced decreases in
death rates from 2008; West Sussex (4.43);
Avon (0.46); North Yorkshire Eastern (2.43);
and Eastern Somerset (5.07). Essex &
Thurrock (0.73) increased from 2008 (0.27).
The following areas reported that there had
been no relevant cases: Isle of Scilly; Spilsby &
Louth and Great Yarmouth.
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Table A: England cases in 2009 by coroner’s jurisdiction (16 years and over) and deaths
in 2008 reported in 2009/10
Coroner’s Jurisdiction & county
district
np-SAD
deaths
Jan-Dec 2009
Annual death
rate per
100,000
population (1)
np-SAD 2008
deaths
reported in
2009/10 (2)
Queen's Household 0 0.00 0
ENGLAND
AVON 2 0.23 3
BEDFORDSHIRE 21 4.44 1
BERKSHIRE 7 1.06 1
BUCKINGHAMSHIRE
Buckinghamshire 10 2.56 0
Milton Keynes - - -
CAMBRIDGESHIRE
North & East Cambridgeshire - - -
Peterborough 7 5.42 1
South & West Cambridgeshire - - -
CHESHIRE 27 3.32 24
CORNWALL
Cornwall 21 4.79 10
Isles of Scilly 0 0.00 0
CUMBRIA
North & West Cumbria 11 4.97 0
South & East Cumbria 6 3.17 0
DERBYSHIRE
Derby & South Derbyshire 19 3.94 1
North Derbyshire 15 4.56 1
DEVON
Exeter & Greater Devon 21 4.93 11
Plymouth & South West Devon 7 2.90 0
Torbay & South Devon 2 1.01 0
DORSET
Bournemouth, Poole & Eastern
Dorset
25 6.26 0
Western Dorset 4 2.11 0
DURHAM
Darlington & South Durham 4 1.79 1
North Durham 4 1.47 0
EAST SUSSEX
Brighton & Hove 50 23.55 1
East Sussex 23 5.51 3
ESSEX
Essex & Thurrock 8 0.73 2
Southend & South East Essex 15 5.54 1
GLOUCESTERSHIRE 9 1.90 5
GREATER MANCHESTER
Manchester 33 8.83 16
North Manchester 27 5.63 15
South Manchester 20 3.50 1
West Manchester 19 3.00 1
HAMPSHIRE
Central Hampshire 14 5.02 2
North East Hampshire 7 2.22 0
Portsmouth & South East Hampshire 26 5.68 8
Southampton & New Forest 26 7.69 0
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Coroner’s Jurisdiction & county
district
np-SAD
deaths
Jan-Dec 2009
Annual death
rate per
100,000
population (1)
np-SAD 2008
deaths
reported in
2009/10 (2)
HEREFORDSHIRE 5 3.40 0
HERTFORDSHIRE 18 2.11 1
HUMBERSIDE
East Riding & Hull 20 4.13 1
ISLE OF WIGHT 6 5.17 1
KENT
Central & South East Kent 11 4.14 10
Mid Kent & Medway 6 1.45 4
North East Kent 24 8.87 0
North West Kent 5 1.35 1
LANCASHIRE
Blackburn, Hyndburn & Ribble Valley 20 9.15 0
Blackpool & the Fylde 10 5.53 0
East Lancashire 20 10.28 1
Preston & West Lancashire 37 6.39 1
LEICESTERSHIRE
Leicester City & South Leicestershire 12 2.86 0
Rutland & North Leicestershire 13 3.55 0
LINCOLNSHIRE
Boston & Spalding 6 6.97 0
North Lincolnshire & Grimsby 17 6.63 0
Spilsby & Louth 0 0.00 0
Stamford - - -
West Lincolnshire 6 2.75 0
LONDON
City of London 1 13.97 0
Eastern London 15 1.71 0
Inner North London 54 7.86 2
Inner South London 41 4.92 2
Inner West London 16 2.12 0
Northern London 13 1.23 1
Southern London 11 1.31 8
Western London 77 7.39 37
MERSEYSIDE
Knowsley, St Helens & Sefton 5 1.02 0
Liverpool 42 11.72 1
Wirral 8 3.19 0
NORFOLK
Greater Norfolk 36 5.80 8
Great Yarmouth 0 0.00 0
NORTHAMPTONSHIRE 21 3.86 10
NORTHUMBERLAND
North Northumberland 1 1.05 2
South Northumberland 7 4.34 0
NORTH YORKSHIRE
North Yorkshire Eastern 1 0.49 0
North Yorkshire Western 6 2.11 0
York - - -
NOTTINGHAMSHIRE 29 3.33 3
OXFORDSHIRE 16 3.11 2
SHROPSHIRE
Mid & North Shropshire 2 1.25 4
South Shropshire 1 1.27 0
The Wrekin 6 4.68 0
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Coroner’s Jurisdiction & county
district
np-SAD
deaths
Jan-Dec 20098
Annual death
rate per
100,000
population (1)
np-SAD 2007
deaths
reported in
2009/10 (2)
SOMERSET
Eastern Somerset 2 0.92 3
Western Somerset 9 4.29 0
SOUTH YORKSHIRE
South Yorkshire East 12 2.74 2
South Yorkshire West 20 3.24 1
STAFFORDSHIRE
South Staffordshire 17 3.44 3
Stoke-on-Trent & North Staffordshire 18 4.79 2
SUFFOLK 17 2.95 0
SURREY 25 2.82 5
TEESSIDE
Hartlepool 3 4.10 5
Teesside 26 6.90 8
TYNE & WEAR
Gateshead & South Tyneside 10 3.57 0
Newcastle-upon-Tyne 3 1.33 0
North Tyneside 21 13.03 13
Sunderland 8 3.48 10
WARWICKSHIRE 12 2.80 5
WEST MIDLANDS
Birmingham 48 5.05 34
Black Country 10 1.48 0
Coventry 4 1.62 0
Wolverhampton - - 7
WEST SUSSEX 1 0.16 0
West YORKSHIRE
West Yorkshire Eastern 56 6.31 10
West Yorkshire Western 36 4.17 5
WILTSHIRE 13 2.52 3
WORCESTERSHIRE 17 3.75 20
Note that (0) refers to either no drug-related deaths or death rates of less than 0.01, whilst (–) indicates that no reports
were submitted for the specific period from that jurisdiction or area. In subsequent reports these rates may increase as
more inquests on deaths in 2009 are held and/or notified to the np-SAD. These rates should therefore be regarded as
minimum rates. Rows for administrative counties have been shaded where there are coroner’s areas located within
them; coroners’ areas which correspond to a complete administrative county have not been shaded.
(1) The rate per 100,000 population is based on published mid-year population estimates for local government
administrative areas for the years in question. However, the areas covered by 23 of the coroners' jurisdictions in
England and Wales are not co-terminous with these boundaries and cover parts of such areas (see Appendix 3).
Where administrative areas are split between jurisdictions, the estimated population has been divided into two or
three as applicable. However, this means that the population of some coroners' jurisdictions may be either over- or
under-estimated. It is necessary to make such assumptions until more accurate figures can be obtained or
calculated.
(2) Notified after the publication of the np-SAD Annual Report, 2009.
(3) The amalgamations of the following coroner’s jurisdictions during the period covered by this report mean that rates
for the new areas have been calculated retrospectively based on published figures: High Peak and Scarsdale were
merged to form North Derbyshire (1 February 2006); Gloucester and Cheltenham merged to form Gloucestershire
(1 April 2006). In Norfolk, King’s Lynn and Norwich & Central Norfolk to form Greater Norfolk (6 April 2007); in
Cumbria, the three jurisdictions of North East Cumbria, Southern Cumbria & Furness, and Western Cumbria to form
two new areas - North & West Cumbria and South & East Cumbria (1 May 2007).
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Table B: Changes in annual death rate per 100,000 population for np-SAD cases (16 years
old and over), and annual percentage of all inquests held, 2008 and 2009
Coroner’s Jurisdiction &
county district
Number
of np-
SAD
deaths
2008
Annual
death
rate per
100,000
populati
on
2008 (1)
Annual
% of all
inquest
s held
in 2008
(2)
Number
of np-
SAD
deaths
2009
Annual
death
rate per
100,000
populati
on
2009 (1)
Annual
% of all
inquest
s held
in 2009
(2)
Queen's Household 0 0.00 0.00 0 0.00 0.00
ENGLAND
AVON 4 0.46 0.57 2 0.23 0.29
BEDFORDSHIRE 34 7.19 14.17 21 4.44 10.88
BERKSHIRE 1 0.15 0.32 7 1.06 2.36
BUCKINGHAMSHIRE
Buckinghamshire 10 2.56 5.88 10 2.56 9.80
Milton Keynes 6 3.34 5.77 - - -
CAMBRIDGESHIRE
North & East Cambridgeshire 1 0.71 1.49 - - -
Peterborough 5 3.87 4.67 7 5.42 8.43
South & West
Cambridgeshire
14 4.03 7.29 - - -
CHESHIRE 44 5.41 5.68 27 3.32 3.25
CORNWALL
Cornwall 24 5.48 7.04 21 4.79 6.42
Isles of Scilly 0 0.00 0.00 0 0.00 0.00
CUMBRIA
North & West Cumbria 11 4.97 7.80 11 4.97 11.96
South & East Cumbria 5 2.64 2.84 6 3.17 3.61
DERBYSHIRE
Derby & South Derbyshire 20 4.14 6.78 19 3.94 6.91
North Derbyshire 11 3.34 3.57 15 4.56 5.34
DEVON
Exeter & Greater Devon 38 6.76 9.87 21 4.93 5.38
Plymouth & South West
Devon
6 4.76 1.55 7 2.90 1.46
Torbay & South Devon 10 6.76 6.29 2 1.01 1.67
DORSET
Bournemouth, Poole &
Eastern Dorset
27 6.76 15.08 25 6.26 16.34
Western Dorset 9 4.76 9.18 4 2.11 4.88
DURHAM
Darlington & South Durham 5 2.24 3.57 4 1.79 3.01
North Durham 6 2.21 2.69 4 1.47 1.62
EAST SUSSEX
Brighton & Hove 45 21.20 18.99 50 23.55 22.94
East Sussex 9 2.16 2.76 23 5.51 7.14
ESSEX
Essex & Thurrock 3 0.27 0.59 8 0.73 2.24
Southend & South East
Essex
11 4.06 7.91 15 5.54 11.03
GLOUCESTERSHIRE 17 3.58 3.96 9 1.90 2.46
GREATER MANCHESTER
Manchester 57 15.26 7.67 33 8.83 4.37
North Manchester 39 8.13 9.92 27 5.63 5.68
South Manchester 8 1.40 1.31 20 3.50 3.06
West Manchester 3 0.47 0.46 19 3.00 2.99
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Coroner’s Jurisdiction &
county district
Number
of np-
SAD
deaths
2008
Annual
death
rate per
100,000
populati
on
2008 (1)
Annual
% of all
inquest
s held
in 2008
(2)
Number
of np-
SAD
deaths
2009
Annual
death
rate per
100,000
populati
on
2009 (1)
Annual
% of all
inquest
s held
in 2009
(2)
HAMPSHIRE
Central Hampshire 11 3.94 6.11 14 5.02 7.18
North East Hampshire 1 0.32 0.83 7 2.22 6.36
Portsmouth & South East
Hampshire
26 5.68 8.41 26 5.68 6.18
Southampton & New Forest 19 5.62 8.72 26 7.69 12.62
HEREFORDSHIRE 4 2.72 4.76 5 3.40 5.38
HERTFORDSHIRE 35 4.11 8.47 18 2.11 4.49
HUMBERSIDE
East Riding & Hull 20 4.13 6.83 20 4.13 6.90
ISLE OF WIGHT 4 3.45 4.49 6 5.17 8.33
KENT
Central & South East Kent 23 8.65 14.02 11 4.14 5.82
Mid Kent & Medway 19 4.58 7.72 6 1.45 2.33
North East Kent 22 8.13 11.22 24 8.87 11.32
North West Kent 19 5.11 10.11 5 1.35 2.17
LANCASHIRE
Blackburn, Hyndburn &
Ribble Valley
19 8.70 6.40 20 9.15 5.62
Blackpool & the Fylde 13 7.19 10.24 10 5.53 8.20
East Lancashire 13 6.68 8.84 20 10.28 12.20
Preston & West Lancashire 31 5.36 6.95 37 6.39 8.58
LEICESTERSHIRE
Leicester City & South
Leicestershire
7 1.67 1.05 12 2.86 1.89
Rutland & North
Leicestershire
5 1.36 2.94 13 3.55 7.51
LINCOLNSHIRE
Boston & Spalding 1 1.16 1.69 6 6.97 10.17
North Lincolnshire & Grimsby 16 6.24 12.60 17 6.63 11.97
Spilsby & Louth 5 3.85 8.93 0 0.00 0.00
Stamford 0 0.00 0.00 - - -
West Lincolnshire 4 1.83 3.13 6 2.75 5.31
LONDON
City of London 0 0.00 0.00 1 13.97 5.00
Eastern London 13 1.48 3.46 15 1.71 4.53
Inner North London 41 5.97 8.91 54 7.86 9.25
Inner South London 49 5.88 8.51 41 4.92 8.60
Inner West London 21 2.78 4.93 16 2.12 4.21
Northern London 35 3.30 6.84 13 1.23 2.69
Southern London 21 2.51 7.09 11 1.31 4.47
Western London 91 8.73 20.09 77 7.39 16.85
MERSEYSIDE
Knowsley, St Helens &
Sefton
7 1.43 2.59 5 1.02 2.01
Liverpool 32 8.93 6.29 42 11.72 8.68
Wirral 6 2.39 2.25 8 3.19 3.27
NORFOLK
Greater Norfolk 44 7.09 10.65 36 5.80 7.86
Great Yarmouth 0 0.00 0.00 0 0.00 0.00
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Coroner’s Jurisdiction &
county district
Number
of np-
SAD
deaths
2008
Annual
death
rate per
100,000
populati
on
2008 (1)
Annual
% of all
inquest
s held
in 2008
(2)
Number
of np-
SAD
deaths
2009
Annual
death
rate per
100,000
populati
on
2009 (1)
Annual
% of all
inquest
s held
in 2009
(2)
NORTHAMPTONSHIRE 37 6.80 12.37 21 3.86 7.22
NORTHUMBERLAND
North Northumberland 3 3.15 2.83 1 1.05 0.84
South Northumberland 0 0.00 0.00 7 4.34 7.29
NORTH YORKSHIRE
North Yorkshire Eastern 5 2.43 4.00 1 0.49 0.88
North Yorkshire Western 6 2.11 4.76 6 2.11 5.08
York 3 1.85 2.86 - - -
NOTTINGHAMSHIRE 16 1.84 3.73 29 3.33 7.38
OXFORDSHIRE 4 0.78 1.46 16 3.11 6.13
SHROPSHIRE
Mid & North Shropshire 5 3.12 4.55 2 1.25 2.41
South Shropshire 0 0.00 0.00 1 1.27 2.27
The Wrekin 3 2.34 3.75 6 4.68 7.69
SOMERSET
Eastern Somerset 11 5.07 7.14 2 0.92 1.43
Western Somerset 10 4.77 6.37 9 4.29 5.88
SOUTH YORKSHIRE
South Yorkshire East 13 2.96 3.55 12 2.74 4.43
South Yorkshire West 42 6.80 8.77 20 3.24 4.39
STAFFORDSHIRE
South Staffordshire 17 3.44 4.80 17 3.44 4.56
Stoke-on-Trent & North
Staffordshire
17 4.52 3.54 18 4.79 4.44
SUFFOLK 35 6.07 13.36 17 2.95 6.34
SURREY 27 3.04 6.96 25 2.82 6.01
TEESSIDE
Hartlepool 6 8.21 10.53 3 4.10 6.00
Teesside 30 7.97 8.60 26 6.90 9.22
TYNE & WEAR
Gateshead & South Tyneside 15 5.35 6.15 10 3.57 4.95
Newcastle-upon-Tyne 9 4.00 3.06 3 1.33 1.03
North Tyneside 13 8.07 5.88 21 13.03 9.91
Sunderland 12 5.22 3.54 8 3.48 2.25
WARWICKSHIRE 5 1.17 2.07 12 2.80 5.77
WEST MIDLANDS
Birmingham 34 3.58 3.03 48 5.05 4.99
Black Country 12 1.77 3.49 10 1.48 3.76
Coventry 1 0.41 0.47 4 1.62 1.96
Wolverhampton 7 3.69 3.66 - - -
WEST SUSSEX 28 4.43 7.89 1 0.16 0.38
West YORKSHIRE
West Yorkshire Eastern 72 8.11 12.31 56 6.31 10.89
West Yorkshire Western 32 3.70 6.34 36 4.17 7.93
WILTSHIRE 5 0.97 1.44 13 2.52 3.33
WORCESTERSHIRE 20 4.41 6.64 17 3.75 4.97
Note that (0) refers to either no drug-related deaths or death rates of less than 0.01, whilst (–) indicates that no reports
were submitted for the specific period from that jurisdiction or area. In subsequent reports these rates may increase as
more inquests on deaths in 2009 are held and/or notified to the np-SAD. These rates should therefore be regarded as
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minimum rates. Rows for administrative counties have been shaded where there are coroner’s areas located within
them; coroners’ areas which correspond to a complete administrative county have not been shaded.
(1) The rate per 100,000 population is based on published mid-year population estimates for local government
administrative areas for the years in question. However, the areas covered by 23 of the coroners' jurisdictions in
England and Wales are not co-terminous with these boundaries and cover parts of such areas (see Appendix 3).
Where administrative areas are split between jurisdictions, the estimated population has been divided into two or
three as applicable. However, this means that the population of some coroners' jurisdictions may be either over-
or under-estimated. It is necessary to make such assumptions until more accurate figures can be obtained or
calculated.
(2) Inquests held on all ages.
(3) The amalgamations of the following coroner’s jurisdictions during the period covered by this report mean that rates
for the new areas have been calculated retrospectively based on published figures: High Peak and Scarsdale were
merged to form North Derbyshire (1 February 2006); Gloucester and Cheltenham merged to form Gloucestershire
(1 April 2006). In Norfolk, King’s Lynn and Norwich & Central Norfolk to form Greater Norfolk (6 April 2007); in
Cumbria, the three jurisdictions of North East Cumbria, Southern Cumbria & Furness, and Western Cumbria to
form two new areas - North & West Cumbria and South & East Cumbria (1 May 2007).
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Table C: np-SAD cases in 2009 by Drug and Alcohol Action Team area (16 years and over)
– number and rate per 100,000 population
Drug and Alcohol Action Team Number and annual
death rate per 100,000
population – usual area
of residence
Number and annual
death rate per 100,000
population – place of
death
No Rate No Rate
ENGLAND
NORTH EAST
County Durham 10 2.41 8 1.93
Darlington 1 1.24 0 0.00
Gateshead 11 7.03 10 6.39
Hartlepool 3 4.10 3 4.10
Middlesbrough 11 9.95 13 11.76
Newcastle upon Tyne 2 0.89 3 1.33
North Tyneside 24 14.90 25 15.52
Northumberland 4 1.56 4 1.56
Redcar and Cleveland 7 6.18 7 6.18
South Tyneside 0 0.00 0 0.00
Stockton on Tees 6 3.93 6 3.93
Sunderland 7 3.05 8 3.48
NORTH WEST
Blackburn with Darwen 13 12.39 15 14.07
Blackpool 7 6.01 8 6.87
Bolton 16 7.71 16 7.71
Bury 7 4.78 7 4.78
Cheshire 12 2.14 12 2.14
Cumbria 17 4.14 16 3.90
Halton 5 5.26 3 3.16
Knowsley 0 0.00 1 0.83
Lancashire 62 6.53 61 6.43
Liverpool 39 10.88 42 11.72
Manchester 31 8.30 33 8.83
Oldham 6 3.51 6 3.51
Rochdale 14 8.63 16 9.86
Salford 2 1.12 3 1.68
Sefton 6 2.65 4 1.77
St Helens 2 1.39 2 1.39
Stockport 4 1.75 4 1.75
Tameside 15 8.71 14 8.13
Trafford 3 1.76 1 0.59
Warrington 10 6.36 11 6.99
Wigan 1 0.40 1 0.40
Wirral 8 3.19 8 3.19
YORKSHIRE AND HUMBER
Barnsley 4 2.20 4 2.20
Bradford 22 5.71 23 5.97
Calderdale 1 0.62 1 0.62
Doncaster 10 4.26 9 3.83
East Riding of Yorkshire 9 3.27 10 3.63
Kingston upon Hull 12 5.75 11 5.27
Kirklees 14 4.40 12 3.77
Leeds 36 5.75 39 6.23
North East Lincolnshire 8 6.29 8 6.29
North Lincolnshire 6 4.65 5 3.87
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Drug and Alcohol Action Team Number and annual
death rate per 100,000
population – usual area
of residence
Number and annual
death rate per 100,000
population – place of
death
No Rate No Rate
North Yorkshire 10 2.04 8 1.63
Rotherham 4 1.96 3 1.47
Sheffield 18 4.13 18 4.13
Wakefield 16 6.12 16 6.12
York* - - - -
EAST MIDLANDS
Derby 14 7.32 12 6.27
Derbyshire 21 3.39 20 3.23
Leicester 10 4.32 10 4.32
Leicestershire 14 2.68 15 2.87
Lincolnshire* 13 2.28 15 2.63
Northamptonshire 19 3.49 20 3.68
Nottingham 12 5.03 14 5.86
Nottinghamshire 16 2.53 15 2.37
Rutland 0 0.00 0 0.00
WEST MIDLANDS
Birmingham 38 4.83 42 5.34
Coventry 5 2.03 4 1.62
Dudley 3 1.21 5 2.02
Herefordshire 4 2.72 4 2.72
Sandwell 5 2.19 3 1.32
Shropshire 3 1.26 4 1.68
Solihull 6 3.66 6 3.66
Staffordshire 25 3.70 24 3.55
Stoke-on-Trent 8 4.13 10 5.17
Telford and Wrekin 6 4.68 5 3.90
Walsall 4 1.99 2 0.99
Warwickshire 12 2.80 12 2.80
Wolverhampton* - - - -
Worcestershire 18 3.97 17 3.75
EAST
Bedfordshire 14 4.29 13 3.99
Cambridgeshire* 0 0.00 0 0.00
Essex 16 1.43 16 1.43
Hertfordshire 19 2.23 19 2.23
Luton 10 6.81 8 5.44
Norfolk 37 5.30 35 5.02
Peterborough 7 5.42 7 5.42
Southend-on-Sea 6 4.58 6 4.58
Suffolk 17 2.95 18 3.12
Thurrock 1 0.85 1 0.85
LONDON
Inner London
Camden 15 7.67 19 9.71
City of London 0 0.00 1 13.97
Hackney 13 7.96 15 9.19
Hammersmith and Fulham 17 11.76 20 13.84
Haringey 2 1.11 1 0.55
Islington 13 8.27 15 9.54
Kensington and Chelsea 10 6.63 8 5.30
Lambeth 14 6.23 20 8.90
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Drug and Alcohol Action Team Number and annual
death rate per 100,000
population – usual area
of residence
Number and annual
death rate per 100,000
population – place of
death
No Rate No Rate
Lewisham 7 3.38 7 3.38
Newham 0 0.00 1 0.53
Southwark 10 4.44 8 3.56
Tower Hamlets 5 2.92 8 4.68
Wandsworth 2 0.84 1 0.42
Westminster 7 3.44 7 3.44
Outer London
Barking and Dagenham 4 3.16 1 0.79
Barnet 5 1.90 3 1.14
Bexley 1 0.56 1 0.56
Brent 0 0.00 3 1.37
Bromley 3 1.24 3 1.24
Croydon 5 1.86 7 2.60
Ealing 11 4.45 11 4.45
Enfield 3 1.33 4 1.78
Greenwich 5 2.84 4 2.27
Harrow 0 0.00 0 0.00
Havering 4 2.16 4 2.16
Hillingdon 17 8.54 17 8.54
Hounslow 13 7.38 14 7.90
Kingston-upon-Thames 5 3.87 5 3.87
Merton 0 0.00 0 0.00
Redbridge 5 2.50 6 3.00
Richmond-upon-Thames 9 6.22 10 6.91
Sutton 0 0.00 0 0.00
Waltham Forest 3 1.72 3 1.72
SOUTH EAST
Bracknell Forest* 1 1.11 1 1.11
Brighton and Hove 48 22.61 48 22.61
Buckinghamshire 8 2.05 10 2.56
East Sussex 22 5.27 23 5.51
Hampshire 40 3.87 41 3.97
Isle of Wight 6 5.17 6 5.17
Kent 44 3.92 44 3.92
Medway towns 2 1.00 2 1.00
Milton Keynes* - - - -
Oxfordshire 17 3.30 17 3.30
Portsmouth 12 7.33 12 7.33
Reading* 2 1.70 4 3.39
Slough* 3 3.19 2 2.13
Southampton 18 9.33 20 10.37
Surrey 24 2.71 24 2.71
West Berkshire* 1 0.84 0 0.00
West Sussex 5 0.79 3 0.47
Windsor and Maidenhead* 0 0.00 0 0.00
Wokingham* 1 0.80 0 0.00
SOUTH WEST
Bath and North East Somerset* 0 0.00 0 0.00
Bournemouth 16 11.64 18 13.09
Bristol* 2 0.58 2 0.58
Cornwall & Isles of Scilly 21 4.77 21 4.77
Devon 24 3.85 22 3.53
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Drug and Alcohol Action Team National and annual
death rate per 100,000
population – usual area
of residence
National and annual
death rate per 100,000
population – place of
death
No Rate No Rate
Dorset 6 1.78 5 1.48
Gloucestershire 9 1.90 9 1.90
North Somerset* 0 0.00 0 0.00
Plymouth 6 2.91 7 3.39
Poole 6 5.28 6 5.28
Somerset 11 8.00 11 2.58
South Gloucestershire* 1 0.00 0 0.00
Swindon 6 3.95 6 3.95
Torbay 1 0.90 1 0.90
Wiltshire 8 2.20 7 1.93
Note: In addition there were a number of cases that could not be allocated to specific DA(A)T areas because they were
of no fixed abode and/or the jurisdiction in which the inquest was held covers more than one DA(A)T. Some cases were
usually resident outside the UK. Some DA(A)Ts are covered by coroner’s jurisdictions that did not submit information or
only partial information) to the np-SAD; they are marked thus - *.
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Table D: np-SAD cases in 2009 by Drug and Alcohol Action Team area (16 years and over)
– demographics and drugs implicated
Drug and
Alcohol Action
Team
No Gender Age group Ethnicity Main Drug Strategy drug
implicated
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ENGLAND
NORTH EAST
County Durham 8 6 2 1 2 3 1 1 0 3 0 0 0 5 4 0 3 5 0 0
Darlington 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Gateshead 10 10 0 2 7 1 0 0 0 8 0 0 0 2 6 4 3 6 0 0
Hartlepool 3 3 0 0 2 1 0 0 0 3 0 0 0 0 1 0 3 0 0 0
Middlesbrough 13 13 0 0 4 3 3 3 0 13 0 0 0 0 5 1 4 1 0 0
Newcastle upon
Tyne
3 2 1 1 1 0 1 0 0 3 0 0 0 0 1 1 0 1 0 0
North Tyneside 25 15 10 3 10 5 2 3 2 22 0 0 0 3 6 5 9 8 0 0
Northumberland 4 3 1 2 1 1 0 0 0 3 0 0 0 1 3 0 4 1 0 0
Redcar and
Cleveland
7 5 2 1 2 3 1 0 0 7 0 0 0 0 3 1 2 1 0 0
South Tyneside 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Stockton on
Tees
6 5 1 0 5 1 0 0 0 5 0 0 0 1 1 3 1 4 0 0
Sunderland 8 8 0 3 2 2 1 0 0 8 0 0 0 0 2 0 2 0 0 0
NORTH WEST
Blackburn with
Darwen
15 10 5 1 4 6 3 1 0 11 0 1 0 3 3 5 5 0 8 0
Blackpool 8 6 2 1 5 1 1 0 0 8 0 0 0 0 2 2 1 0 3 1
Bolton 16 11 5 4 3 4 4 1 0 2 0 0 0 14 9 4 0 1 9 0
Bury 7 7 0 0 1 4 1 0 1 1 0 1 0 5 1 2 2 1 3 0
Cheshire 12 8 4 0 2 4 5 1 0 2 0 0 0 10 2 3 2 0 4 0
Cumbria 16 14 2 1 5 10 0 0 0 14 0 1 0 1 5 3 8 1 13 0
Halton 3 2 1 0 2 1 0 0 0 3 0 0 0 0 2 2 0 0 2 0
Knowsley 1 1 0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0
Lancashire 61 45 16 5 15 16 13 7 5 22 0 0 0 39 24 8 18 4 42 0
Liverpool 42 26 16 1 12 14 7 7 1 39 0 0 0 3 15 20 4 12 19 0
Manchester 33 20 13 2 6 13 5 3 4 25 0 0 1 7 13 5 4 1 17 0
Oldham 6 5 1 0 1 4 0 0 1 0 0 0 0 6 1 1 0 0 2 0
Rochdale 16 13 3 1 1 6 3 5 0 3 0 1 0 12 6 4 4 0 10 0
Salford 3 3 0 0 0 3 0 0 0 2 0 0 1 3 1 1 0 1 3 0
Sefton 4 3 1 0 0 3 1 0 0 4 0 0 0 1 1 1 0 1 0 0
St. Helens 2 2 0 0 1 1 0 0 0 2 0 0 0 0 1 0 0 0 1 0
Stockport 4 2 2 1 0 0 2 1 0 0 0 0 0 4 2 1 3 0 5 0
Tameside 14 9 5 0 6 2 4 2 0 6 0 0 0 8 5 0 1 0 6 0
Trafford 1 1 0 0 0 1 0 0 0 0 0 0 0 1 1 0 0 0 1 0
Warrington 11 8 3 0 6 3 1 0 1 4 0 0 0 7 3 0 1 0 4 0
Wigan 1 1 0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0
Wirral 8 7 1 0 1 5 2 0 0 5 0 0 1 2 3 3 0 0 3 0
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Drug and
Alcohol Action
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YORKSHIRE
AND HUMBER
Barnsley 4 2 2 2 1 0 1 0 0 4 0 0 0 0 2 2 1 1 0 0
Bradford 23 21 2 2 5 8 8 0 0 21 1 0 1 0 17 5 0 3 0 0
Calderdale 1 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0
Doncaster 9 9 0 1 1 4 3 0 0 9 0 0 0 0 5 3 0 0 1 0
East Riding of
Yorkshire
10 6 4 0 4 4 1 1 0 5 0 0 0 5 6 1 2 0 0 0
Kingston upon
Hull
11 7 4 1 1 8 0 1 0 6 0 0 0 5 8 4 2 0 1 0
Kirklees 12 12 0 0 8 3 0 1 0 11 0 0 0 1 7 6 1 2 1 0
Leeds 39 30 9 1 10 18 4 4 2 33 2 1 0 3 15 11 5 0 1 0
North East
Lincolnshire
8 8 0 0 5 1 2 0 0 8 0 0 0 0 6 0 2 0 0 0
North Lincolnshire 5 5 0 2 1 1 1 0 0 3 0 0 0 2 3 2 2 0 0 0
North Yorkshire 8 8 0 2 2 4 0 0 0 2 0 0 0 6 7 2 2 2 0 0
Rotherham 3 2 1 0 2 0 1 0 0 3 0 0 0 0 1 2 0 0 0 0
Sheffield 18 17 1 1 4 11 2 0 0 15 0 0 0 3 8 5 4 2 0 0
Wakefield 16 10 6 1 3 9 2 1 0 13 0 0 0 3 5 3 2 2 0 0
York* - - - - - - - - - - - - - - - - - - - -
EAST
MIDLANDS
Derby 12 8 4 1 1 6 4 0 0 11 1 0 0 0 3 1 0 0 0 0
Derbyshire 20 15 5 1 4 6 4 4 1 20 0 0 0 0 9 5 2 0 0 0
Leicester 10 8 2 0 5 3 0 2 0 6 0 1 1 2 4 5 1 1 1 0
Leicestershire 15 12 3 1 4 6 1 1 2 11 0 0 0 4 12 3 5 0 0 0
Lincolnshire* 15 15 0 2 3 8 1 1 0 9 1 0 0 5 10 4 3 1 0 0
Northamptonshire 20 13 7 1 8 4 2 3 2 15 1 0 0 4 5 5 6 2 0 1
Nottingham 14 12 2 2 8 2 1 1 0 11 0 0 0 3 9 1 1 2 2 1
Nottinghamshire 15 12 3 0 3 4 6 1 1 15 0 0 0 0 6 0 3 0 1 0
Rutland 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
WEST
MIDLANDS
Birmingham 42 38 4 5 7 17 10 3 0 25 1 4 0 12 23 10 4 22 0 1
Coventry 4 4 0 0 1 1 1 1 0 2 0 0 0 2 1 2 1 4 0 0
Dudley 5 5 0 0 2 2 0 1 0 5 0 0 0 0 3 2 2 2 0 0
Herefordshire 4 3 1 0 3 0 0 1 0 3 0 0 0 1 2 1 1 2 0 0
Sandwell 3 3 0 0 1 1 1 0 0 1 0 1 1 0 3 0 0 0 0 0
Shropshire 4 3 1 0 1 1 0 1 1 2 0 0 0 2 1 1 3 3 0 0
Solihull 6 5 1 0 1 3 0 2 0 3 0 1 0 2 5 0 2 2 0 0
Staffordshire 24 18 6 5 8 4 1 3 3 24 0 0 0 0 12 3 4 3 0 0
Stoke-on-Trent 10 9 1 2 6 0 2 0 0 10 0 0 0 0 8 2 1 2 0 0
Telford and
Wrekin
5 4 1 0 0 4 0 1 0 3 0 0 0 2 1 0 0 2 0 0
Walsall 2 1 1 0 1 1 0 0 0 2 0 0 0 0 1 0 0 0 0 0
Warwickshire 12 10 2 1 4 3 2 2 0 9 0 0 0 3 10 4 6 7 0 0
Wolverhampton* - - - - - - - - - - - - - - - - - - - -
Worcestershire 17 13 4 1 6 10 0 0 0 16 0 0 0 1 10 0 1 1 0 0
EAST
Bedfordshire 13 10 3 1 3 2 5 1 1 13 0 0 0 0 6 2 4 0 0 0
Cambridgeshire* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Essex 16 11 5 1 2 7 0 3 3 10 0 0 0 6 7 0 3 5 0 0
Hertfordshire 19 15 4 0 5 6 6 0 2 1 0 0 0 18 10 2 6 5 1 0
Luton 8 5 3 2 1 1 4 0 0 7 1 0 0 0 4 0 0 2 0 0
Norfolk 35 27 8 2 13 7 10 0 3 10 0 0 0 25 16 4 5 0 0 0
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Peterborough 7 5 2 0 3 2 1 1 0 6 0 0 1 0 5 2 0 1 0 0
Southend-on-Sea 6 3 3 1 2 2 1 0 0 5 0 0 1 0 0 3 2 0 0 0
Suffolk 18 13 5 1 6 9 1 1 0 9 0 0 0 9 9 5 4 1 0 0
Thurrock 1 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 1 0 0 0
LONDON
Inner London
Camden 19 16 3 0 4 6 5 2 2 12 3 0 1 3 8 4 1 2 0 0
City of London 1 1 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0
Hackney 15 11 4 0 5 7 1 2 0 8 2 0 0 5 11 2 0 4 0 0
Hammersmith
and Fulham
20 18 2 0 5 7 6 1 1 15 1 0 3 1 11 5 2 4 1 0
Haringey 1 1 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0
Islington 15 12 3 1 2 7 4 1 0 8 1 1 0 5 5 2 3 2 0 0
Kensington and
Chelsea
8 6 2 0 3 3 2 0 0 8 0 0 0 0 2 2 0 6 0 0
Lambeth 20 19 1 0 8 9 2 1 0 8 0 0 2 10 13 3 3 5 0 0
Lewisham 7 7 0 0 3 2 2 0 0 1 0 0 0 6 1 1 0 2 0 0
Newham 1 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0
Southwark 8 8 0 0 1 4 3 0 0 6 1 0 0 1 8 5 0 2 0 0
Tower Hamlets 8 7 1 0 4 3 1 0 0 8 0 0 0 0 5 2 1 2 0 0
Wandsworth 1 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
Westminster 7 7 0 0 1 2 3 1 0 3 0 0 2 2 2 2 1 5 0 0
Outer London
Barking and
Dagenham
1 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0
Barnet 3 3 0 0 1 0 1 1 0 2 0 0 1 0 2 2 0 0 0 0
Bexley 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0
Brent 3 2 1 0 1 1 1 0 0 2 0 0 0 1 2 0 1 1 0 0
Bromley 3 2 1 0 2 1 0 0 0 2 1 0 0 0 1 0 0 1 0 0
Croydon 7 6 1 1 3 2 1 0 0 1 0 0 0 6 6 1 2 2 0 0
Ealing 11 9 2 0 3 4 3 1 0 6 1 1 0 3 3 1 2 0 0 0
Enfield 4 2 2 0 0 4 0 0 0 2 1 0 0 1 0 1 0 0 0 0
Greenwich 4 4 0 0 1 3 0 0 0 2 0 0 0 2 4 0 0 0 0 0
Harrow 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Havering 4 4 0 0 2 1 0 1 0 3 0 0 0 1 2 1 1 3 0 0
Hillingdon 17 16 1 2 2 9 3 1 0 12 1 2 1 1 3 0 2 5 0 0
Hounslow 14 11 3 3 1 4 2 1 2 8 1 2 2 1 6 3 1 1 0 0
Kingston-upon-
Thames
5 3 2 0 2 3 0 0 0 4 0 0 1 0 4 1 0 2 0 0
Merton 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Redbridge 6 5 1 1 2 3 0 0 0 5 1 0 0 0 3 1 1 3 0 0
Richmond-upon-
Thames
10 6 4 1 1 5 1 0 2 9 0 0 0 1 4 1 0 1 0 0
Sutton 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Waltham Forest 3 3 0 0 1 1 0 1 0 2 0 0 0 1 2 0 0 0 0 0
SOUTH EAST
Bracknell Forest* 1 1 0 0 0 0 1 0 0 0 0 0 1 0 1 1 0 0 0 0
Brighton and
Hove
48 33 15 5 10 15 10 4 4 47 0 0 0 1 22 5 23 3 0 2
Buckinghamshire 10 9 1 0 4 2 4 0 0 8 1 0 0 1 8 1 0 1 0 0
East Sussex 23 17 6 1 8 7 6 1 0 21 2 0 0 0 16 3 8 3 0 0
Hampshire 41 27 14 1 9 14 3 8 6 39 1 0 0 1 10 3 6 3 0 0
Isle of Wight 6 5 1 0 1 0 5 0 0 6 0 0 0 0 1 3 0 0 1 0
Kent 44 30 14 2 10 16 8 4 4 10 0 0 0 34 17 6 7 2 1 0
Medway towns 2 2 0 0 0 1 1 0 0 0 0 0 0 2 0 0 0 0 0 0
Milton Keynes* - - - - - - - - - - - - - - - - - - - -
np-SAD
International Centre for Drug Policy 32
Drug and
Alcohol Action
Team
N
o
Gender Age group Ethnicity Main Drug Strategy drug
implicated
To
ta
l
M
al
e
Fe
m
al
e
15
-2
4
25
-3
4
35
-4
4
45
-5
4
55
-6
4
>6
4
W
hi
te
B
la
ck
A
si
an
O
th
er
N
ot
kn
ow
n
H
er
oi
n/
m
or
ph
in
e
M
et
ha
do
ne
H
yp
no
tic
s/
se
da
tiv
es
C
oc
ai
ne
A
m
ph
et
am
in
e
Ec
st
as
y-
ty
pe
Oxfordshire 17 13 4 3 5 6 1 2 0 15 0 0 0 2 14 3 0 1 0 0
Portsmouth 12 9 3 2 6 3 0 0 1 12 0 0 0 0 3 1 2 0 0 0
Reading* 4 4 0 1 0 1 2 0 0 2 1 0 0 1 2 0 0 2 0 0
Slough* 2 1 1 0 1 0 0 1 0 1 0 1 0 0 1 0 0 0 0 0
Southampton 20 13 7 1 5 7 2 3 2 19 0 0 0 1 8 1 1 6 3 0
Surrey 24 22 2 1 7 6 8 2 0 8 0 0 0 16 12 4 6 3 0 0
West Berkshire* 1 1 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0
West Sussex 3 3 0 0 1 0 1 1 0 3 0 0 0 0 3 0 1 0 0 0
Windsor and
Maidenhead*
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Wokingham* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
SOUTH WEST
Bath and North
East Somerset*
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Bournemouth 18 15 3 0 5 7 4 0 2 16 1 0 0 1 12 3 5 0 0 3
Bristol* 2 2 0 0 0 1 1 0 0 0 0 0 0 2 0 0 0 0 0 0
Cornwall & Isles
of Scilly
21 17 4 2 4 5 7 2 1 13 0 0 0 8 5 2 2 0 0 0
Devon 22 17 5 2 3 10 4 0 3 19 0 0 0 3 7 2 5 0 0 0
Dorset 5 3 2 0 1 4 0 0 0 4 0 0 0 1 2 0 0 0 0 0
Gloucestershire 9 8 1 0 1 7 0 1 0 8 0 0 0 1 3 2 2 0 2 0
North Somerset* 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Plymouth 7 5 2 1 4 2 0 0 0 2 0 0 0 5 5 2 1 0 0 0
Poole 6 3 3 1 2 3 0 0 0 4 1 0 0 1 2 1 1 0 0 0
Somerset 11 7 4 0 1 3 2 4 1 6 0 0 0 5 6 1 2 0 0 0
South
Gloucestershire*
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Swindon 6 5 1 0 3 2 1 0 0 4 0 0 1 1 3 4 0 1 0 0
Torbay 1 1 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0
Wiltshire 7 4 3 1 2 2 2 0 0 4 0 0 1 2 1 2 3 1 0 0
Note: In addition there were a number of cases that could not be allocated to specific DA(A)T areas because they were
of no fixed abode and/or the jurisdiction in which the inquest was held covers more than one DA(A)T. Some cases were
usually resident outside the UK. Some DA(A)Ts are covered by coroner’s jurisdictions that did not submit information (or
only partial information) to the np-SAD; they are marked thus - *.
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Table E: np-SAD cases in 2009 by Primary Care Trust and Strategic Health Authority
areas in England and Substance Misuse Advisory Regional Team areas in Wales
(16 years and over)
Area Number and annual
death rate per 100,000
population – usual area
of residence
Number and annual
death rate per 100,000
population – place of
death
No Rate No Rate
ENGLAND (SHA and PCT)
NORTH EAST SHA 86 4.10 87 4.14
County Durham 10 2.41 8 1.92
Darlington 1 1.24 0 0.00
Gateshead 11 7.03 10 6.39
Hartlepool 3 4.11 3 4.11
Middlesbrough 11 9.92 13 11.72
Newcastle-upon-Tyne 2 0.88 3 1.33
North Tyneside 24 14.89 25 15.51
Northumberland 4 1.56 4 1.56
Redcar and Cleveland 4 1.56 4 1.56
South Tyneside 0 0.00 0 0.00
Stockton on Tees Teaching 6 3.92 6 3.92
Sunderland Teaching 7 3.05 8 3.48
NORTH WEST SHA 280 5.02 283 5.07
Ashton, Leigh and Wigan 1 0.40 1 0.40
Blackburn with Darwen 13 12.20 15 14.07
Blackpool 7 6.01 8 6.87
Bolton 16 7.71 16 7.71
Bury 7 4.78 7 4.78
Central and Eastern Cheshire 6 1.63 6 1.63
Central Lancashire 17 4.63 17 4.63
Cumbria Teaching 17 4.15 16 3.90
Halton and St Helens 7 2.93 5 2.09
Heywood, Middleton and Rochdale 14 8.62 16 9.85
Knowsley 0 0.00 1 0.83
Lancashire East 27 8.83 23 7.52
Liverpool 39 10.85 42 11.69
Manchester 31 8.27 33 8.80
North Lancashire Teaching 18 6.52 20 7.24
Oldham 6 3.51 6 3.51
Salford 2 1.12 3 1.68
Sefton 6 2.65 4 1.77
Stockport 4 1.75 4 1.75
Tameside and Glossop 15 7.51 14 7.01
Trafford 3 1.75 1 0.58
Warrington 10 6.36 11 6.99
Western Cheshire 6 3.10 6 3.10
Wirral 8 3.19 8 3.19
YORKSHIRE AND HUMBER SHA 170 4.05 167 3.97
Barnsley 4 2.20 4 2.20
Bradford and Airedale Teaching 22 5.71 23 5.97
Calderdale 1 0.62 1 0.62
Doncaster 10 4.26 9 3.83
East Riding of Yorkshire 9 3.27 10 3.63
Kirklees 14 4.40 12 3.77
Leeds 36 5.73 39 6.21
NHS Hull 12 5.74 11 5.26
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Area Number and annual
death rate per 100,000
population – usual area
of residence
Number and annual
death rate per 100,000
population – place of
death
No Rate No Rate
North East Lincolnshire Care Trust
Plus
8 6.24 8 6.24
North Lincolnshire 6 4.76 5 3.97
North Yorkshire and York* 10 1.53 8 1.23
Rotherham 4 1.96 3 1.47
Sheffield 18 4.12 18 4.12
Wakefield District 16 6.13 16 6.13
EAST MIDLANDS SHA 119 3.34 121 3.40
Bassetlaw 2 2.20 2 2.20
Derby City 14 7.32 12 6.27
Derbyshire 21 3.55 20 3.38
Leicester City 10 4.30 10 4.30
Leicestershire County and Rutland 14 2.52 15 2.70
NHS Lincolnshire* 13 2.27 15 2.62
NHS Northamptonshire 19 3.50 20 3.68
Nottingham City 12 5.00 14 5.83
Nottinghamshire County Teaching 14 2.59 13 2.41
WEST MIDLANDS SHA* 137 3.16 137 3.16
Birmingham East and North 14 4.52 17 5.49
Coventry Teaching 5 2.02 4 1.62
Dudley 3 1.21 5 2.02
Heart of Birmingham Teaching 10 4.90 11 5.39
Herefordshire 4 2.72 4 2.72
North Staffordshire 10 5.70 8 4.56
Sandwell 5 2.20 3 1.32
Shropshire County 3 1.26 4 1.68
Solihull* 6 3.66 6 3.66
South Birmingham 14 5.10 14 5.10
South Staffordshire 15 3.04 15 3.04
Stoke-on-Trent 8 3.99 10 4.98
Telford and Wrekin 6 4.68 5 3.90
Walsall Teaching 4 1.99 2 0.99
Warwickshire 12 2.80 12 2.80
Wolverhampton City* - - - -
Worcestershire 18 3.97 17 3.75
EAST OF ENGLAND SHA 131 2.86 123 2.68
Bedfordshire 14 4.29 13 3.98
Cambridgeshire* 0 0.00 0 0.00
East and North Hertfordshire 10 2.35 11 2.58
Great Yarmouth and Waveney 6 3.45 6 3.45
Luton 10 6.80 8 5.44
Mid Essex 2 0.68 1 0.34
Norfolk 37 5.96 35 5.64
North East Essex 6 2.25 4 1.50
Peterborough 7 5.41 7 5.41
South East Essex 15 5.54 15 5.54
South West Essex 1 0.32 1 0.32
Suffolk 11 2.29 12 2.50
West Essex 3 1.35 2 0.90
West Hertfordshire 9 2.12 8 1.88
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Area Number and annual
death rate per 100,000
population – usual area
of residence
Number and annual
death rate per 100,000
population – place of
death
No Rate No Rate
LONDON SHA 211 3.46 224 3.67
Barking and Dagenham 4 3.16 1 0.79
Barnet 5 1.91 3 1.14
Bexley 1 0.56 1 0.56
Brent Teaching 0 0.00 3 1.37
Bromley 3 1.24 3 1.24
Camden 15 7.65 19 9.68
City and Hackney Teaching 13 7.61 15 8.78
Croydon 5 1.86 7 2.60
Ealing 11 4.44 11 4.44
Enfield 3 1.33 4 1.78
Greenwich Teaching 5 2.83 4 2.27
Hammersmith and Fulham 17 11.75 20 13.82
Haringey Teaching 2 1.10 1 0.55
Harrow 0 0.00 0 0.00
Havering 4 2.16 3 1.62
Hillingdon 17 8.52 17 8.52
Hounslow 15 8.46 14 7.89
Islington 13 8.25 15 9.52
Kensington and Chelsea 10 6.62 7 4.64
Kingston 5 3.87 5 3.87
Lambeth 14 6.23 20 8.90
Lewisham 7 3.37 7 3.37
Newham 0 0.00 1 0.52
Redbridge 5 2.51 6 3.01
Richmond and Twickenham 10 6.91 10 6.91
Southwark 10 4.44 8 3.55
Sutton and Merton 0 0.00 0 0.00
Tower Hamlets 5 2.92 8 4.67
Waltham Forest 3 1.71 3 1.71
Wandsworth 2 0.84 1 0.42
Westminster 7 3.44 7 3.44
SOUTH EAST COAST SHA 145 4.19 145 4.19
Brighton and Hove City 48 22.56 48 22.56
East Sussex Downs and Weald 14 5.15 15 5.51
Eastern and Coastal Kent 38 6.46 37 6.29
Hastings and Rother 8 5.52 8 5.52
Medway 2 1.00 2 1.00
Surrey 23 2.62 25 2.85
West Kent 7 1.31 7 1.31
West Sussex 5 0.79 3 0.47
SOUTH CENTRAL SHA 114 3.50 113 3.47
Berkshire East* 5 1.63 3 0.98
Berkshire West* 4 1.10 4 1.10
Buckinghamshire 11 2.75 10 2.50
Hampshire 40 3.87 41 3.97
Milton Keynes - - - -
NHS Isle of Wight 6 5.17 6 5.17
Oxfordshire 18 3.62 17 3.42
Portsmouth City Teaching 12 7.31 12 7.31
Southampton City 18 9.30 20 10.33
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Area National and annual
death rate per 100,000
population – usual area
of residence
National and annual
death rate per 100,000
population – place of
death
No Rate No Rate
SOUTH WEST SHA 119 2.79 116 2.72
Bath and North East Somerset* 0 0.00 0 0.00
Bournemouth and Poole Teaching 22 8.75 24 9.54
Cornwall & Isles of Scilly 21 4.77 21 4.77
Devon 24 3.85 23 3.69
Dorset 6 1.78 5 1.48
Gloucestershire 9 1.90 9 1.90
NHS Bristol* 2 0.58 2 0.58
North Somerset* 0 0.00 0 0.00
Plymouth Teaching 8 3.87 7 3.38
Somerset 11 2.58 11 2.58
South Gloucestershire* 1 0.48 0 0.00
Swindon 6 3.85 6 3.85
Torbay Care Trust 1 0.90 1 0.90
Wiltshire 8 2.20 7 1.93
Note: In addition there were a number of cases that could not be allocated to specific PCT areas because they were of
no fixed abode and/or the jurisdiction in which the inquest was held covers more than one PCT. Some cases were
usually resident outside the UK. Some PCTs are covered by coroner’s jurisdictions that did not submit information (or
only partial information) to the np-SAD; they are marked thus - *.
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Profile of cases meeting the criteria for monitoring the
Government’s drug strategy
This section considers cases meeting the
definition used to monitor the Government’s
drug strategy, i.e. ‘drug-misuse’. To derive
these cases, the following two categories of
cases are excluded from the np-SAD ones: (a)
deaths of non-drug abusers where no
Controlled Drugs were found at post mortem
or where a specific compound analgesics was
found at post mortem; and (b) deaths of drug
abusers where no Controlled Drugs were
found at post mortem or where a specific
compound analgesics was found at post
mortem and the mechanism of death was
hanging, drowning, accident, etc. Of the 1,524
cases reported to the Programme, 76% (n =
1,152) met the criteria for classification as a
‘drug misuse’ death (Appendix 2).
1. Demography
Similar patterns were reported to previous
years. The majority of cases were male (81%).
The median age at death was 38 years (semi-
inter quartile range = 6.9), with three-quarters
(75%) being under the age of 45 years. Where
ethnicity was known 93% were White. Where
addict status was known, 78% had a history of
drug-dependence or use. Just over half (54%)
of cases were unemployed, and 45% of cases
were living alone or of no fixed abode at the
time of their death (Table 1.7).
2. Location of death
Three-quarters (75%) died either at the
deceased’s home address or other private
residential address, about one-sixth (17%)
died in hospital and the remainder (8%) died
elsewhere (e.g. public open space, public
facilities or railway station).
3. Underlying cause(s) of death
The categories of underlying cause of death
(ICD-10 codes) were as follows:
 Accidental poisoning (X40-X47): 80.7%
 Intentional self-poisoning (X60-X67):
7.7%
 Poisonings of undetermined intent (Y10-
Y14): 8.2%
 Other (e.g. natural causes, drowning,
hanging, unascertained): 3.4%
4. Manner of death
The manner of death in these cases was as
follows:
 Natural: 1.5%
 Accidental: 82.3%
 Suicidal: 7.8%
 Homicidal: 0.1%
 Undetermined: 7.9%
 Unclassified/not specified: 0.4%
5. Substances implicated in death
Psychoactive substances were implicated in
1,144/1,152 deaths (99%). The principal
substances implicated in drug-related deaths
were: heroin/morphine (60%) and alcohol in
combination with other drugs (34%). Other
classes of drugs making a sizeable
contribution (10% or over) to deaths were:
methadone (24%); Hypnotics/sedatives (21%);
other opiates/ opioid analgesics (20%); anti-
depressants (11%) and cocaine (11%).
Heroin/morphine as the sole implicated drug
accounted for 21% of deaths (Table 1.8).
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Table 1.7: Demographic characteristics of cases reported to np-SAD meeting the criteria
for monitoring the Government’s drug strategy, England, 2009
Variable Category Number (%)
Total 1,152 (100.0)
Gender Male 930 (80.7)
Female 222(19.3)
Employment status Unemployed 625(54.3)
Employed 289 (25.1)
Childcare/house person 14 (1.2)
Student 19 (1.6)
Retired/sickness/invalidity 85(7.4)
Other 2 (0.2)
Not known 118 (10.2)
Living arrangements Alone 476 (41.3)
With others 453 (39.3)
No fixed abode 38 (3.3)
Other 64 (5.6)
Not known 121 (10.5)
Table 1.8: Psychoactive substances implicated in deaths reported to np-SAD meeting the
criteria for monitoring the Government’s drug strategy, England, 2009
Drug category Number (%) of cases where
no other substance was
implicated
Number (%) of cases
where drug was
implicated
Total of cases with
psychoactive drug implicated
1,144(100.0) 1,144 (100.0)
Alcohol-in-combination(1) - 388 (33.9)
Amphetamines 15 (1.3) 32 (2.8)
Anti-depressants 18 (1.6) 126 (11.0)
Anti-epileptics 0 (0.0) 11 (1.0)
Anti-Parkinson’s 0 (0.0) 2 (0.2)
Anti-psychotics 3 (0.3) 21 (1.8)
Cannabis 2 (0.2) 16 (1.4)
Cocaine 24 (2.1) 130 (11.4)
Ecstasy-type drugs 1 (0.1) 4 (0.3)
GHB 5 (0.4) 14 (1.2)
Heroin/morphine 235 (20.5) 687 (60.1)
Hypnotic/sedatives 11 (1.0) 240 (21.0)
Methadone 54 (4.7) 273 (23.9)
Other opiates/opioid
analgesics
48 (4.2) 231 (20.2)
(1) Alcohol on its own does not meet the criteria for ‘drug misuse’ case.
Age and substances implicated followed
similar patterns as previously reported;
heroin/morphine (65.0%) was most frequently
implicated amongst those aged 15-44 years. In
those aged 45 years and over, heroin/
morphine (45.5%) was most frequently
implicated, followed by other opiates/opiate
analgesics (31.7%) and methadone (21.7%)
See Table 1.9 for further details.
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Table 1.9: Age and drug implicated in deaths reported to np-SAD meeting the criteria for
monitoring the Government’s drug strategy, England, 2009
Age-group
(years)
Number (%) where
drug was
implicated
Drug category (alone or in combination) most
frequently implicated in each age group
All ages 1,144 (100.0) Heroin/morphine (60.1%)
14 & under - -
15–24 77 (6.7) Heroin/morphine (62.3%)
25-34 348 (30.4) Heroin/morphine (63.8%)
35-44 429 (37.5) Heroin/morphine (66.4%)
45-54 183 (16.0) Heroin/morphine (51.9%)
55-64 71 (6.2) Other opiates/opioid analgesics (46.5%)
65 & over 36 (3.1) Other opiates/opioid analgesics (52.8%)
6. Other aspects
Information on other aspects of the decedents’
circumstances was also reported on the np-
SAD data collection form; such as release
from prison, hepatitis and HIV/AIDS status.
These are illustrated below.
6.1 Release from prison
A total of 52 cases were found who had been
in prison at some time. Most (over 80%) of
them had been released from prison recently.
Four died on the same day they left prison and
two the following day. Heroin use was
implicated in all of these fatalities, only one
was on a methadone prescription. Out of
these 52 cases, 46 were male and 6 were
female. The manner of death in these cases
was: accidental overdose (44); drowning (1);
hanging (1); and other causes (5). Two cases
had been prescribed methadone, which was
present in the post-mortem toxicology tests.
The principal substances implicated were:
heroin/morphine (15 as sole mention; 24 in
combination); other opiates/opioid analgesics
(2, 5); methadone (2, 13); anti-depressants (0,
1); hypnotics/sedatives (0, 10); and cocaine
(0, 3). There were 10 deaths where alcohol
was in combination with at least one other
substance.
6.2 Hepatitis and HIV/AIDS
Altogether, 18 cases were identified where the
individual was positive for either hepatitis or
HIV/AIDS. Only one case was female. The
underlying cause of death in most of these
cases was typically drug abuse, drug toxicity
or natural causes. Hepatitis was mentioned in
all but one of the 17 cases as a contributory
cause of death. For hepatitis cases, 10 were
specified as hepatitis C, and in 7 cases the
type of hepatitis was not given. Controlled
drugs in combination with other drugs were
implicated in 7 cases, and alcohol- in-
combination in another 7 cases. There was
only one case involving HIV/AIDS.
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Ten year trends in death 2000-2009
This section examines deaths that occurred
between 2000 and 2009 using the definition
used to monitor the Government’s drug
strategy. The analysis is based on a ‘panel’
approach, that is, only areas which reported in
every single year of the ten-year period were
examined. This method enhances the
statistical robustness of the findings and the
conclusions that can be derived from them.
Seventy coronial areas are represented,
accounting for 69% of all cases reported. In all,
a total of 13,228 cases meet the criteria for
inclusion in the sample analysed here, for the
ten-year period.
Table 1.10: Demographic characteristics of cases reported to np-SAD meeting the criteria
for monitoring the Government’s drug strategy, panel of coroners’ areas, 2000-
2009
Variable Category Number (%)
Total 13,228 (100.0)
Gender Male 9,885 (74.7)
Female 3,343 (25.3)
Employment status Unemployed 6,661 (50.4)
Employed 3,823 (28.9)
Childcare/house person 225 (1.7)
Student 253 (1.9)
Retired/sickness/invalidity 1,338 (10.1)
Other 95 (0.7)
Not known 833 (6.3)
Living arrangements Alone 5,273 (39.9)
With others 5,719 (43.2)
No fixed abode 651 (4.9)
Other 693 (5.2)
Not known 892 (6.7)
History of drug use History 7,697 (58.2)
No history 3,653 (27.6)
Not known 1,878 (14.2)
Place of death Defined residential address 8,865 (67.0)
Hospital 3,205 (24.2)
Other locations 1,080 (8.2)
Not specified 78 (0.6)
Ethnicity White 10,239 (77.4)
Black 224 (1.7)
Asian 135 (1.0)
Other 178 (1.3)
Not known 2,452 (18.5)
1. Demography
Summary information for some of the key
demographics is given in Table 1.10 for the
period as a whole. The information has not
been broken down by year since there was
very little variation either across the decade or
in terms of changes from year-to-year.
Previous annual reports have noted the
consistency in many of these attributes over
time especially in terms of the proportion of
ethnic groups represented, those aged less
than 45 years, gender, living arrangements,
employment status, place of death, and
manner of death.
Figure 1.9 shows the trend (using a 2-year
moving average) in the number of deaths
meeting the criteria for the Drug Strategy
definition that occurred in a panel of English
coronial areas from 2000 to 2009. The number
of deaths fell steadily from a peak in 2001 to
2005 before rising again by 2007. Although
there appears to be a decline in the last year
or so, this fall may not be as pronounced as
the graph indicates as more inquests relating
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to deaths in 2008 and 2009 are completed and
notified to the Programme. Upward revisions
to figures for these two years reported on
should be expected.
Figure 1.9: Trend in number of deaths meeting the Drug Strategy criteria, selected panel
of coronial areas, 2000-2009
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The number of cases broken down by gender
is presented in Figure 1.10. There have been
some fluctuations in the male:female ratio
(range 2.4:1 to 3.6:1) over the decade, but with
no discernible overall trend. Overall, there
were 15 deaths of individuals aged less than
15 years, tending to be fewer in recent years.
The number of deaths amongst those aged 15
to 24 years tended to fall over time, as did
those in the 25-34 age-group (Figure 1.11). An
increasing proportion of deaths were
accounted for by those in the 35-44 and 45-54
age-groups, and to a lesser in the 55-64 age-
group. In the oldest age-group (65 years and
over) there was a fairly stable pattern of death.
The median age at death increased
progressively year on year from 34.8 to 39.5
years between 2000 and 2009. Where known,
the proportion of cases with a known history of
drug abuse or dependence fell from 70% to
67% over the decade, although there were
year-to-year variations.
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Figure 1.10: Trend in number of deaths meeting the Drug Strategy criteria, selected panel
of coronial areas, by gender, 2000-2009
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Figure 1.11: Trend in proportion accounted for by age-group of deaths meeting the Drug
Strategy criteria, selected panel of coronial areas, 2000-2009
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2. Substances implicated in death
Figure 1.12 shows the substances most
commonly implicated, whether alone or in
combination, in death. The figure indicates the
proportion of selected substances implicated in
death rather than the proportion of cases in
which the substances is involved. In terms of
cases, heroin/morphine accounted for the
largest proportion (25.7%), followed by
alcohol-in-combination (19.2%), and other
opiates/opioid analgesics (13.6%). The other
most frequently implicated drugs were:
hypnotics/sedatives (11.6%), anti-depressants
(10.8), methadone (8.5%), cocaine (7.1%),
and amphetamine-type substances
(amphetamine, MDMA, etc: 3.5%). These
proportions did not change dramatically over
time, although there appears to have been an
overall decline in the contribution made by
hypnotics/sedatives, and an increasing
presence of methadone.
Figure 1.12: Trend in substances implicated in deaths meeting the Drug Strategy
criteria, selected panel of coronial areas in England, 2000-2009
0%
20%
40%
60%
80%
100%
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Year
Heroin/morphine Alcohol in combination Other opiates Hypnotics/sedatives
Cocaine Methadone Anti-depressants Amphetamine-type
Breakdown for English regions
Tables F, G and H provide a profile of cases
in the English regions which are the same as
the National Treatment Agency’s areas. The
annual rate of ‘drug misuse’ deaths per
100,000 population ranged from 1.83 in the
South West to 3.89 in the North West. The
proportion of males ranged from 76.1% to
87.4%. The North East appears to have
proportionately more deaths in the 15-24
year age-group than other regions. Where
ethnicity is known, most deaths amongst
minority communities appear to occur in the
following regions: Yorkshire & Humber; East
Midlands; Midlands; London; and the South
East. However, numbers are low. The
proportion of cases with a known history of
drug use or addiction ranges from 50.5 to
66.3%.
In each region, the overall profile of drugs
commonly implicated in death is consistent
with the national picture. However, there
appear some drugs with a higher presence in
some regions compared to others. For
example, other opiates/opioid analgesics
were implicated in one-third of cases in the
North West compared to 12.6% in the West
Midlands. Hypnotics/sedatives were involved
in 47.6% of deaths in the North East
compared to only 8.9% in London. Suicides
appear to be more common in the East and
South East of England.
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Table F: Profile of Drug Strategy deaths in English regions – Northern England
Government Office Region North East North West Yorkshire &
Humber
Demographics No % No % No %
Population mid-2009 aged 16
years and over
2,125,800 5,600,800 4,286,900
‘Drug misuse’ deaths reported 63 218 135
Number of deaths/100,000
population aged 16 and over
2.96 3.89 3.15
Gender
Male 54 85.7 166 76.1 108 80.7
Female 9 14.3 52 23.9 26 19.3
Age-group (years)
Under 15 0 0.0 0 0.0 0 0.0
15-24 10 15.9 14 6.4 9 6.7
25-34 31 49.2 65 29.8 38 28.1
35-44 14 22.2 77 35.3 64 47.4
45-54 5 7.9 39 17.9 18 13.3
55-64 2 3.2 14 6.4 6 4.4
65 and over 1 1.6 9 4.1 0 0.0
Ethnicity
White 54 85.7 122 56.0 106 78.5
Black 0 0.0 0 0.0 4 3.0
Asian 0 0.0 2 0.9 1 0.7
Other 0 0.0 2 0.9 1 0.7
Unknown 9 14.3 92 42.2 23 17.0
Drug use/addiction history
Yes 33 52.4 112 51.4 81 60.0
No 9 14.3 45 20.6 13 9.6
Unknown 21 33.3 61 28.0 41 30.4
Selected main drugs
implicated*
Heroin/morphine 32 50.8 103 47.2 80 59.3
Methadone 15 23.8 61 28.0 43 31.9
Hypnotics/sedatives 30 47.6 51 23.4 20 14.8
Cocaine 4 6.3 18 8.3 11 8.1
Amphetamines 0 0.0 16 7.3 4 3.0
Ecstasy-type drugs 0 0.0 1 0.5 0 0.0
Other opiates/opioid analgesics 11 17.5 72 33.0 19 14.1
Anti-depressants 8 12.7 25 11.5 15 11.1
Anti-psychotics 1 1.6 5 2.3 2 1.5
* Percentages may add to more than 100% because of more than one substance being
implicated
Manner of death
Natural 0 0.0 5 2.3 2 1.5
Accidental 48 76.2 173 79.7 122 90.4
Suicidal 5 7.9 19 8.8 3 2.2
Homicidal 0 0.0 0 0.0 0 0.0
Undetermined 10 15.9 19 8.8 8 5.9
Unascertained/unknown 0 0 1 0.5 0 0.0
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Table G: Profile of Drug Strategy deaths in English regions – Central England
Government Office Region East of England East Midlands West Midlands
Demographics No % No % No %
Population mid-2009 aged 16
years and over
4,675,000 3,635,400 4,378,200
‘Drug misuse’ deaths reported 86 110 111
Number of deaths/100,000
population aged 16 and over
1.84 3.03 2.54
Gender
Male 69 80.2 91 82.7 97 87.4
Female 17 19.8 19 17.3 14 12.6
Age-group (years)
Under 15 0 0.0 0 0.0 0 0.0
15-24 5 5.8 9 8.2 11 9.9
25-34 27 31.4 34 30.9 33 29.7
35-44 28 32.6 40 36.4 40 36.0
45-54 17 19.8 11 10.0 16 14.4
55-64 4 4.7 10 9.1 10 9.0
65 and over 5 5.8 6 5.5 1 0.9
Ethnicity
White 41 47.7 89 80.9 84 75.6
Black 1 1.2 2 1.8 1 0.9
Asian 0 0.0 1 0.9 5 4.5
Other 2 2.3 1 0.9 1 0.9
Unknown 42 48.8 17 15.5 20 18.0
Drug use/addiction history
Yes 53 61.6 57 51.8 56 50.5
No 17 19.8 15 13.6 16 14.4
Unknown 16 18.6 38 34.5 39 35.1
Selected main drugs
implicated*
Heroin/morphine 56 65.1 67 60.9 80 72.1
Methadone 18 20.9 24 21.8 25 22.5
Hypnotics/sedatives 20 23.3 21 19.1 22 19.8
Cocaine 15 17.4 6 5.5 4 3.6
Amphetamines 1 1.2 4 3.6 0 0.0
Ecstasy-type drugs 0 0.0 1 0.9 1 0.9
Other opiates/opioid analgesics 13 15.1 25 22.7 14 12.6
Anti-depressants 12 14.0 10 9.1 8 7.2
Anti-psychotics 2 2.3 1 0.9 3 2.7
* Percentages may add to more than 100% because of more than one substance being
implicated
Manner of death
Natural 1 1.2 0 0.0 1 0.9
Accidental 67 77.9 84 76.4 94 84.5
Suicidal 11 12.8 9 8.2 7 6.3
Homicidal 0 0.0 1 0.9 0 0.0
Undetermined 6 7.0 16 14.5 9 8.1
Unascertained/unknown 1 1.2 0 0.0 0 0.0
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Table H: Profile of Drug Strategy deaths in English regions – Southern England
Government Office Region London South East South West
Demographics No % No % No %
Population mid-2009 aged 16
years and over
6,254,900 6,839,400 4,308,800
‘Drug misuse’ deaths reported 169 181 79
Number of deaths/100,000
population aged 16 and over
2.70 2.65 1.83
Gender
Male 145 85.8 138 76.2 61 77.2
Female 24 14.2 43 23.8 18 22.8
Age-group (years)
Under 15 0 0.0 0 0.0 0 0.0
15-24 4 2.4 11 6.1 4 5.1
25-34 50 29.6 53 29.3 19 24.1
35-44 73 43.2 59 32.6 37 46.8
45-54 28 16.6 37 20.4 13 16.5
55-64 10 5.9 11 6.1 4 5.1
65 and over 4 2.4 10 5.5 2 2.5
Ethnicity
White 103 60.9 133 73.4 55 69.6
Black 10 5.9 5 2.8 2 2.5
Asian 2 1.2 1 0.6 0 0.0
Other 11 6.5 2 1.1 2 2.5
Unknown 43 25.4 40 22.1 20 25.3
Drug use/addiction history
Yes 112 66.3 107 59.1 48 60.8
No 27 16.0 36 19.9 12 15.2
Unknown 30 17.8 38 21.0 19 24.1
Selected main drugs
implicated*
Heroin/morphine 105 62.1 117 64.6 47 59.5
Methadone 39 23.1 29 16.0 19 24.1
Hypnotics/sedatives 15 8.9 43 23.8 18 22.8
Cocaine 51 30.2 19 10.5 2 2.5
Amphetamines 1 0.6 4 2.2 2 2.5
Ecstasy-type drugs 0 0.0 1 0.6 0 0.0
Other opiates/opioid analgesics 32 18.9 28 15.5 17 21.5
Anti-depressants 17 10.1 21 11.6 10 12.7
Anti-psychotics 1 0.6 4 2.2 2 2.5
* Percentages may add to more than 100% because of more than one substance being
implicated
Manner of death
Natural 3 1.8 3 1.7 2 2.5
Accidental 152 89.9 147 81.2 61 77.2
Suicidal 8 4.7 21 11.6 7 8.9
Homicidal 0 0.0 0 0.0 0 0.0
Undetermined 6 3.6 8 4.4 9 11.4
Unascertained/unknown 0 0.0 2 1.1 0 0.0
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Commentary
The demographic profile of drug-related
deaths in England remains consistent with
previous reports; a higher proportion of males
to females, White, with a typical age of 25-44.
‘Drug misuse’ deaths amongst those aged 15-
24 appear to have dropped over the past ten
years. The number and proportion of deaths of
known drug users aged more than 40 years at
the time of death notified to the Programme
also increased over the past decade. Deaths
have doubled from 14 to 31 for those of Black
ethnicity between 2008 and 2009.
Accidental poisoning still remains the most
frequent underlying cause of death across all
age-groups. However, older females are more
likely to die of intentional self-poisoning,
especially those over 50 years old. Suicides
amongst those dying of ‘drug misuse’ were
less likely than in other populations, since
suicide commonly involves more prescribed
medication, such as anti-depressants and/or
hypnotics/ sedatives.
The most frequent drugs implicated in deaths
of males were heroin/morphine, whilst for
females it was anti-depressants, closely
followed by heroin/morphine. Other
opiates/opioid analgesics play a more
important part on drug overdoses in older age-
groups, especially amongst the over 50s.
Deaths reported for 2009 suggest that the
involvement in death of amphetamines and
cocaine have decreased, whilst methadone
and heroin/morphine have increased. This
pattern is similar to that in ’drug misuse’ cases.
There has been a decline in monovalent
deaths; in 2009 they accounted for 35% of
cases whereas in 2008 they were implicated in
42%. Heroin/morphine combined with alcohol
remains to be the most frequent
polysubstance combination over the past ten
years, followed by heroin/morphine combined
with hypnotics/sedatives.
The most commonly prescribed medications
implicated in death were anti-depressants,
followed by hypnotics/sedatives. The
implication of prescribed medications
increases with age. The type of medication
implicated also varies with age; three-quarters
of those 35 years and older were on
prescribed medication compared with their
counterparts. Heroin/morphine (typically
morphine-based pain-killers) increased in age
especially for those over 70 years. The use of
such medications by older age-groups
probably reflects the increased need for pain-
relief as individuals grow older. When
prescribed, heroin/morphine and methadone
were most likely to be implicated in deaths of
older drug users. It appears that approximately
60% of hypnotics/sedatives, other
opiates/opioid analgesics and methadone-
related deaths are more likely to arise from
illicit than licit substances.
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Chapter 2 Drug-related deaths in Wales
This chapter describes the pattern of drug-
related deaths in Wales reported by coroners
to the np-SAD that meet the Programme’s
case criteria.
1. Demography
Notifications of 102 drug-related deaths
occurring in 2009 were received from coroners
in Wales. It is possible that this number may
increase as inquests are subsequently
completed for deaths that occurred in 2009.
Furthermore, information for two of the
coroner’s areas in North Wales was
unavailable when preparing this report. The
number of such deaths reported in last year’s
annual report was 62 in 2008. Details of a
further 27 deaths in 2008 were received since
the publication of the last Annual Report.
In 2009 there was a rate of 4.16 drug-related
deaths per 100,000 population aged 16 years
and over, compared with 3.18 in 2007 and
3.65 in 2008. These rates are low by
comparison with England and Scotland but
similar to those in Northern Ireland.
The majority (86%) of the cases in 2009 were
male (Table 2.1). The median age at death
was 34.2 years (semi-interquartile range = 6.6)
(Figure 2.1). Four-fifths (81%) of cases were
under 45 years. About two-thirds (63%) were
unemployed, and half (52%) lived with others.
Where ethnicity was known, most (97%)
decedents were White; however, ethnic
background was not given in 37% of all cases.
Addict status was known in 64 cases, 69% of
which had a history of dependence or drug
use.
Table 2.1: Demographic variables for drug-related deaths reported by coroners meeting
np-SAD criteria, Wales, 2009
2. Location of death
Most fatalities (80%) occurred at a defined
residential address (i.e. the deceased’s home
address or other private residential address).
Ten percent occurred in hospital and 10%
elsewhere.
3. Cause(s) of death
Four-fifths (81%) of cases died from accidental
poisoning, 6.8% from intentional self-
poisoning, and in 4/102 of cases the intent
was undetermined. Three of the deaths were
traumatic and another one related to mental
disorders due to harmful drug use. The
remaining cases were related to other causes
of death.
Variable Category Number (%)
Total 102 (100.0)
Gender Male 88 (86.3%)
Female 14 (13.7%)
Employment status Employed 27 (26.5%)
Unemployed 64 (62.7%)
Childcare/house person 0 (0.0%)
Students/pupils 1 (1.0%)
Retired/sickness/invalidity 8 (7.8%)
Not known 2 (2.0%)
Living arrangements Alone 35 (34.3%)
With others 53 (52.0%)
No fixed abode 5 (4.9%)
Other 4 (3.9%)
Not known 5 (4.9%)
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Figure 2.1: Drug-related deaths reported by coroners meeting np-SAD criteria, by age and
gender, Wales, 2009
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4. Substances implicated in death
4.1 All substances
Psychoactive drugs were directly implicated in
95 (93%) cases. The principal substances
implicated were: heroin/morphine (55%);
alcohol-in-combination (32%); other opiates/
opioid analgesics (24%); hypnotics/sedatives
(23%); methadone (21%); anti-depressants
(16%); and cocaine (5%) (Table 2.2).
Figure 2.2 takes into account data where one
of the following drugs was known to be
implicated: alcohol-in-combination; amphet-
amines; anti-depressants; anti-epileptics;
cocaine; heroin/morphine; methadone; or other
opiates/opioid analgesics.
4.2 Single substances
Monovalent deaths accounted for 40% of all
fatalities where psychoactive substances were
implicated. The following substances, as the
sole implicated drug, accounted for 31/38 of
these deaths: heroin/morphine; methadone;
and other opiates/ opioid analgesics (Table
2.2).
Table 2.2: Psychoactive substances implicated in deaths reported by coroners meeting
np-SAD criteria, Wales, 2009
Drug category Number (%) of cases where no
other substance was implicated
Number (%) of cases
where drug was
implicated
Total 95 (100.0) 95 (100.0)
Alcohol-in-combination - 30 (31.6)
Amphetamines 2 (2.1) 2 (2.1)
Anti-depressants 2 (2.1) 15 (15.8)
Anti-epileptics 1 (1.1) 3 (3.2)
Anti-Parkinson’s 0 (0.0) 1 (1.1)
Anti-psychotics 0 (0.0) 3 (3.2)
Cannabis 0 (0.0) 0 (0.0)
Cocaine 2 (2.1) 5 (5.3)
Ecstasy-type drugs 0 (0.0) 0 (0.0)
GHB 0 (0.0) 1 (1.1)
Heroin/morphine 19 (20.0) 52 (54.7)
Hypnotic/sedatives 0 (0.0) 22 (23.2)
Methadone 7 (7.4) 20 (21.1)
Other opiates/opioid
analgesics
5 (5.3) 23 (24.2)
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death.
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Figure 2.2: Drug-related deaths reported by coroners meeting np-SAD criteria, by
selected psychoactive drug implicated, Wales, 2009
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5. Age and drug implicated in death
Heroin/morphine accounted for most deaths in
the 15-24, 25-34 and 35-44 age-groups (Table
2.3). In each of the remaining age-groups
several substances were equally likely to be
implicated. Looking at the over 45 years age-
group as a whole, the most commonly
implicated substances were anti-depressants
and other opiates/opioid analgesics (6 cases
each).
Table 2.3: Age and psychoactive drug implicated in deaths reported by coroners meeting
np-SAD criteria, Wales, 2009
Age-group (years) Number (%) Drug category (alone or in combination)
most frequently implicated in each age-
group
All ages 95 (100.0) Heroin/morphine (55%)
15-24 18 (18.9) Heroin/morphine (72%)
25-34 38 (40.0) Heroin/morphine (63%)
35-44 27 (28.4) Heroin/morphine (44%)
45-54 12 (12.6) Anti-depressants (25%)
Methadone (25%)
Other opiates/opioid analgesics (25%)
55-64 3 (3.2) Anti-depressants (67%)
Other opiates/opioid analgesics (67%)
65 & over 4 (4.2) Alcohol-in-combination 1 case)
Anti-depressants (1 case)
Heroin/morphine (1 case)
Other opiates/opioid analgesics (1 case)
6. Gender and drug implicated in death
The pattern of other drug-specific fatality was
somewhat different in male and female cases.
Among males, the most frequently mentioned
drugs were: heroin/morphine (53%); alcohol-
in-combination (30%); hypnotics/sedatives
(22%); other opiates/opioid analgesics (19%);
methadone (18%); and anti-depressants
(14%).
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Among female cases, the drugs mentioned
were: other opiates/opioid analgesics (43%);
heroin/morphine (36%); methadone and
alcohol-in-combination (both 29%); and
hypnotics/sedatives and anti-depressants
(both 21%. Compared to male cases, female
cases had higher proportions of fatality
associated with other opiates/opioid
analgesics (43% vs. 19%), methadone (29%
vs. 18%), and anti-depressants (21% vs.
14%). Furthermore, there were no fatalities
due to amphetamine, cocaine, ecstasy-type
drugs, or GHB among females.
7. Regional data
This section contains information based on
various geographical units. Table 2.4 provides
information by Coroner’s jurisdiction on the
number of cases reported in 2008 and 2009,
the number per 100,000 population aged 16
years and over, and the proportion of all
inquests accounted for by drug-related deaths.
Tables 2.5 and 2.6 provide information by
Drug and Alcohol Action Team area on the
number of deaths per 100,000 population
aged 16 and over, and key findings in respect
of key demographics and principal drugs
implicated in death. Finally Table 2.7 gives the
number of deaths per 100,000 population
aged 16 and over for the four Substance
Misuse Advisory Regional Team areas (which
are co-terminous with the four police force
areas).
In those areas for which data were available at
the time of preparing this report, the highest
number of deaths per 100,000 population
(aged 16 years and over) were found in the
Swansea and North West Wales coroners’
areas, whilst there no cases in Ceredigion
(Table 2.4). Cocaine would appear to be a
more significant role in deaths in North Wales
than in other areas, and amphetamine a
greater role in Bro Taf. Methadone and
hypnotics/sedatives made a major contribution
to deaths in the Dyfed-Powys SMART area. In
Iechyd Morgannwg, heroin/morphine was the
dominant drug implicated in death (Table 2.6).
Table 2.4: Deaths reported, rates per 100,000 (aged 16 and over), and proportion of all
inquests, Wales, 2008 and 2009
Coroner’s
Jurisdiction
Addit-
ional
2008
deaths
reported
in
2009/10(1)
Cumul
ative
total
num-
ber of
deaths
2008
Annual
death
rate per
100,000
populat-
ion
2008 (2)
Annual
% of all
inquest
s held
in
2008(3)
Num-
ber of
deaths
2009
Annual
death
rate per
100,000
populat-
ion
2009 (2)
Annual
% of all
inquests
held in
2009
Bridgend &
Glamorgan
Valleys
12 19 5.56 8.02 10 2.12 5.52
Cardiff & the Vale
of Glamorgan
0 2 0.56 1.83 18 5.00 4.95
Carmarthenshire 0 9 6.15 9.09 10 6.83 12.35
Central North
Wales
- 3 1.75 1.20 - - -
Ceredigion 0 0 0.00 0.00 0 0.00 0.00
Gwent 1 7 1.55 4.61 19 4.22 11.31
Neath & Port
Talbot
0 7 6.24 14.58 4 3.57 5.19
North East Wales - 5 2.18 2.17 - - -
North West
Wales
0 13 8.47 7.98 14 9.12 10.69
Pembrokeshire 0 4 4.19 5.13 4 4.19 5.63
Powys 1 4 3.69 6.35 4 3.69 6.45
Swansea 13 17 9.05 8.85 22 11.72 11.22
Note: (0) refers to either no drug-related deaths or death rates of less than 0.01, whilst (–) indicates that no reports
were submitted for the specific period from that jurisdiction or area. In subsequent reports these rates may increase
as more inquests on deaths in 2009 are held and/or notified to the np-SAD. These rates should therefore be
regarded as minimum rates.
(1) Notified after the publication of the np-SAD Annual Report, 2009.
(2) The rate per 100,000 population is based on published mid-year population estimates for local government
administrative areas for the years in question.
(3) Includes updated information submitted in 2009/10.
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Table 2.5: Deaths by Drug and Alcohol Action Team area (16 years and over) – number
and rate per 100,000 population, Wales, 2009
Drug and Alcohol Action Team National and annual
death rate per 100,000
population – usual area
of residence
National and annual
death rate per 100,000
population – place of
death
No Rate No Rate
Bro Taf 24 4.04 25 4.21
Dyfed Powys 18 4.33 18 4.33
Gwent 21 4.66 21 4.66
Iechyd Morgannwg 24 5.88 24 5.88
North Wales* 12 2.16 14 2.52
Note: There were 3 cases that were usually resident outside Wales and thus could not be allocated to a specific
DA(A)T. Some DA(A)Ts are covered by coroner’s jurisdictions that did not submit information (or only partial
information) to the np-SAD; they are marked thus - *.
Table 2.6: Deaths by Drug and Alcohol Action Team area (16 years and over) –
demographics and drugs implicated, Wales, 2009
Drug and
Alcohol Action
Team
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Bro Taf 25 19 6 5 9 7 3 1 0 18 1 0 0 6 17 4 4 1 2 0
Dyfed Powys 18 14 4 2 6 4 4 1 1 18 0 0 0 0 5 8 10 0 0 0
Gwent 21 18 3 4 12 5 0 0 0 3 0 0 0 18 9 5 3 1 0 0
Iechyd
Morgannwg
24 24 0 6 7 8 2 0 1 21 0 0 1 2 18 0 4 1 0 0
North Wales” 14 13 1 1 4 3 3 1 2 2 0 0 0 12 3 3 1 2 0 0
Note: There were 3 cases that were usually resident outside Wales and thus could not be allocated to a specific
DA(A)T. Some DA(A)Ts are covered by coroner’s jurisdictions that did not submit information (or only partial
information) to the np-SAD; they are marked thus - *.
Table 2.7: Deaths by Substance Misuse Advisory Regional Team areas in Wales (16
years and over), 2009
SMART National and annual
death rate per 100,000
population – usual area
of residence
National and annual
death rate per 100,000
population – place of
death
No Rate No Rate
North Wales* 12 2.16 14 2.52
Dyfed Powys 18 4.33 18 4.33
South Wales 48 4.79 49 4.89
Gwent 21 4.66 21 4.66
Note: In addition there were a number of cases that could not be allocated to specific SMART areas because they
were of no fixed abode. Some cases were usually resident outside the UK. Some SMARTs are covered by coroner’s
jurisdictions that did not submit information (or only partial information) to the np-SAD; they are marked thus - *.
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8. Commentary
There was a higher ratio of male to female
drug-related deaths in Wales during 2009
than in other countries within the UK; this
was especially so in Iechyd Morgannwg and
North Wales. Those who died tended to be
younger than in other areas, for example in
Gwent all those who died were less than 45
years. A greater proportion of cases were
unemployed than elsewhere.
The nature of deaths were also different in
Wales compared to England and Northern
Ireland, In particular, there was a higher
proportion of accidental overdoses and a
lower proportion of cases where the intent was
not clear. Whilst the profile of psychoactive
substances implicated in deaths was broadly
similar to other regions, there was a greater
role played by heroin/morphine and other
opiates/opioid analgesics.
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Chapter 3 Drug-related deaths in Northern Ireland
This chapter describes the pattern of drug-
related deaths in Northern Ireland. The
Northern Ireland Statistics and Research
Agency (NISRA) provided the data analysed in
this section, from registrations recorded by the
General Register Office for Northern Ireland.
Coroners in Northern Ireland routinely submit
returns on drug-related deaths after
conducting an inquiry, similar to that in
England and Wales.
1. Demography
Notifications of 65 drug-related deaths
occurring in 2009 were received from NISRA
and coroners which meet the np-SAD case
criteria. The number of such deaths was 81 in
2007 and 59 in 2008 (including 29 notifications
received since the publication of last year’s
report). This leads to an increase of about 10%
in drug-related deaths between 2008 and
2009. However, details of further deaths for
2008 and 2009 may be subsequently notified
to NISRA by coroners. In 2009 there was a
rate of 4.62 drug-related deaths per 100,000
population aged 16 years and over, compared
with 5.80 in 2007 and 4.23 in 2008. These
rates are low by comparison with England and
Scotland but similar to those for Wales.
Three-fifths (62%) of the cases in 2009 were
male (Table 3.1). The median age at death
was 41.5 years (semi-interquartile range =
11.9) (Figure 3.1). Two-thirds (66%) of cases
were under 45 years. Just over a half (54%)
were unemployed, half (48%) lived with others.
Where ethnicity was known (n = 57), all
decedents were White. Addict status was
known in 37/65 cases, 14 (38%) of which had
a history of dependence.
Table 3.1: Demographic variables for drug-related deaths reported by NISRA and
coroners meeting np-SAD criteria, Northern Ireland, 2009
2. Location of death
Most fatalities (82%) occurred at a defined
residential address (i.e. the deceased’s home
address or other private residential address).
Fifteen percent occurred in hospital and 3%
elsewhere.
3. Cause(s) of death
Based on the information available from
coroners, 31% of cases died from accidental
poisoning, 5% from intentional self-poisoning.
In 62% of cases the intent was undetermined.
Two cases died of natural causes.
Variable Category Number (%)
Total 65
Gender Male 40 (61.5)
Female 25 (38.5)
Employment status Employed 13 (20.0)
Unemployed 35 (53.8)
Childcare/house person 1 (1.5)
Student/pupil 1 (1.5)
Retired/sickness/invalidity 11 (16.9)
Not known 4 (6.2)
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Figure 3.1: Drug-related deaths reported by NISRA and coroners meeting np-SAD criteria,
by age and gender, Northern Ireland, 2009
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4. Substances implicated in death
4.1 All substances
Psychoactive drugs were directly implicated in
all but four cases. The principal substances
implicated were: other opiates/opioid
analgesics (33); hypnotics/sedatives (32);
alcohol-in-combination (27); anti-depressants
(24); and anti-psychotics (7) (Table 3.2). This
profile is different to that seen in England and
Wales and more similar to that seen in
Scotland in terms of the large proportion of
hypnotics/ sedatives involved (GROS, 2010).
Figure 3.2 takes into account data where one
of the following drugs was known to be
implicated: alcohol-in-combination; amphet-
amines; anti-depressants; anti-epileptics; anti-
Parkinson’s; anti-psychotics; cannabis;
cocaine; ecstasy-type drugs; GHB; heroin/
morphine; hypnotics/sedatives; methadone;
and other opiates/opioid analgesics.
4.2 Single substances
The following substances, as the sole
implicated drug, accounted for 11/65 (17%)
deaths: anti-depressants; heroin/morphine and
other opiates/ opioid analgesics (Table 3.2).
Table 3.2: Psychoactive substances implicated in deaths reported by NISRA and coroners
meeting np-SAD criteria, Northern Ireland, 2009
Drug category Number of cases where no
other substance was implicated
(N = 61)
Number of cases where
drug was implicated
(N = 61)
Alcohol-in-combination - 27
Amphetamines 0 2
Anti-depressants 4 24
Anti-epileptics 0 1
Anti-Parkinson’s 0 2
Anti-psychotics 0 7
Cocaine 0 3
Heroin/morphine 3 9
Hypnotic/sedatives 0 32
Methadone 0 3
Other opiates/opioid
analgesics
4 33
Note: Column totals may not sum to 61 since more than one substance may be implicated in a death.
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5. Age and drug implicated in death
In all age groups, except those aged 55-64
years, hypnotics/sedatives were the leading
substances implicated. However, in these
groups, except the 25-34 age-group, other
opiates/opioid analgesics were implicated in
equal numbers. This class of drugs was the
most frequently mentioned substance
contributing to fatality in the 55-64 age-group
(Table 3.3).
Figure 3.2: Drug-related deaths reported by NISRA and coroners meeting np-SAD criteria,
by psychoactive drug implicated, Northern Ireland, 2009
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Table 3.3: Age and psychoactive drug implicated in deaths reported to NISRA meeting np-
SAD criteria, Northern Ireland, 2009
Age-group (years) Number where
substance
implicated
Drug category (alone or in combination)
most frequently implicated in each age group
All ages 61 Other opiates/opioid analgesics (33)
15-24 7 Hypnotics/sedatives (5)
Other opiates/opioid analgesics (5)
25-34 15 Hypnotics/sedatives (8)
35-44 18 Hypnotics/sedatives (9)
Other opiates/opioid analgesics (9)
45-54 7 Alcohol-in-combination (4)
Anti-depressants (4)
Hypnotics/sedatives (4)
Other opiates/opioid analgesics (4)
55-64 9 Other opiates/opioid analgesics (5)
65 & over 5 Alcohol-in-combination (3)
Anti-depressants (3)
Hypnotics/sedatives (3)
Other opiates/opioid analgesics (3)
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6. Gender and drug implicated in death
The pattern of other drug-specific fatality was
somewhat different in male and female
cases. Among males, the most frequently
mentioned drugs were: hypnotics/sedatives
(22); other opiates/opioid analgesics (19);
alcohol-in-combination (18); anti-depressants
(15); heroin/morphine (7); anti-psychotics (5);
cocaine (3); amphetamines (2); and
methadone (2).
Among female cases, the drugs mentioned
most commonly were: other opiates/opioid
analgesics (14); hypnotics/sedatives (10);
alcohol-in-combination (9); anti-depressants
(9); anti-psychotics (2); heroin/morphine (2).
Compared to male cases, female cases had
a higher proportion of fatality associated with
other opiates/ opioid analgesics (61% vs.
50%). Furthermore, there were no fatalities
due to amphetamine, cocaine, and anti-
epileptics among females.
7. Commentary
The number of deaths notified to the
Programme from sources in Northern Ireland
showed a modest increase in 2009. The
demographic profile of those dying in 2009 is
similar to previous years.
The profile of the psychoactive substances
implicated in these cases is broadly similar to
previous years. The role of specific types of
drugs in drug-related mortality continues to
show significant differences to those
occurring in England and to a lesser extent in
Wales. There are proportionately fewer
deaths involving heroin/morphine and
methadone. However, there is a greater role
played by hypnotics/sedatives and anti-
depressants. The relatively higher
involvement of hypnotics/sedatives is similar
to the pattern in Scotland, and to a lesser
extent in Wales.
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Chapter 4 Drug-related deaths in Scotland
This section describes the pattern of drug-
related deaths in Scotland. The Scottish Crime
and Drug Enforcement Agency (SCDEA) on
behalf of the Association of Chief Police
Officers in Scotland (ACPOS) collate data on
drug-related deaths obtained from Scottish
police forces. These data are used to populate
a police/SCDEA national database which is
maintained by the SCDEA. As such the data
supplied to the SCDEA remain the property of
the submitting force that is also responsible for
its accuracy and submission to the database.
Drug-related death cases are those that meet
the definition used by the Association of Chief
Police Officers (Scotland) – “where there is
prima facie evidence of a fatal overdose of
controlled drugs. Such evidence would be
recent drug misuse, for example controlled
drugs and/or a hypodermic syringe found in
close proximity to the body and/or the person
is known to the police as a drug misuser
although not necessarily a notified addict.”
Thus, most suicides in Scotland are excluded.
Figures for ‘drug misuse’ deaths registered in
2009 have been recently published by the
General Register Office for Scotland.1
1. Demography
Notifications of 479 drug-related deaths
occurring in 2009 were received by the
SCDEA, covering the following police force
areas: Central Scotland (2.1%); Dumfries &
Galloway (1.9%); Fife (5.9%); Grampian
(9.0%); Lothian & Borders (18.6%); Northern
(3.1%); Strathclyde (49.5%); and Tayside
(10.0%).
The majority (78%) of cases were male (Table
3.1). The median age at death was 35.1 years
(semi-interquartile range = 6.6) (Figure 4.1).
86% of cases were under 45 years. Where
ethnicity was known, 99% were White.
1 GROS. (2010). Drug-Related Deaths in Scotland in
2009. Edinburgh: General Register Office (Scotland). 17
August 2010. Available at:http://www.gro-
scotland.gov.uk/files2/stats/drug-related-
deaths/drd2009/drd2009.pdf. Accessed on 17 August
2010
2. Location of death
In line with data protection, the SCDEA
database structure does not record
information on living arrangements and place
of death. Such information was available in
only three Scottish cases; all died at home.
3. Cause(s) of death
Of the fatalities (95.6%) were considered to be
accidental (i.e. clearly non-deliberate)
poisoning. Deaths due to natural causes
(1.9%) and mental disorders due to
psychoactive substances (2.5%) accounted for
the remaining cases.
4. Substances implicated in death
4.1 All substances
Psychoactive drugs were not directly
implicated in about 2.3% of cases (n = 11). Of
the remaining 468 cases, the principal
substances implicated were: heroin/morphine
(69%); hypnotics/sedatives (29%); methadone
(36%); alcohol in combination with other
substances (31%); other opiates/ opioid
analgesics (11%); and cocaine (8%) (Table
4.2).
Figure 4.2 takes into account data where one
of the following drugs was known to be
implicated: alcohol-in-combination; anti-
depressants; cocaine; ecstasy-type drugs;
heroin/morphine; methadone; hypnotics/
sedatives; or other opiates/opioid analgesics.
4.2 Single substances
The following substances, as the sole
implicated drug, accounted for 150 (32%)
deaths: heroin/morphine (21%); methadone
(8%); other opiates/opioid analgesics (1%);
cocaine (1%); amphetamines (<1%) and
hypnotics/sedatives (<1%) (Table 4.2).
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Table 4.1: Demographic variables for drug-related deaths as reported by Scottish police
forces to the SCDEA, 2009
Table 4.2: Psychoactive substances implicated in drug-related deaths as reported by
Scottish police forces to the SCDEA, 2009
Drug category Number (%) of cases where
no other substance was
implicated
Number (%) of cases
where drug was
implicated*
Total 468 (100.0) 468 (100.0)
Alcohol-in-combination - 147(31.4)
Amphetamines 2 (0.4) 6 (1.3)
Anti-depressants 1 (0.2) 16 (3.4)
Anti-epileptics 0 (0.0) 0 (0.0)
Anti-Parkinson’s 0 (0.0) 0 (0.0)
Anti-psychotics 1 (0.2) 4 (0.9)
Cannabis 0 (0.0) 0 (0.0)
Cocaine 6 (1.3) 37 (7.9)
Ecstasy-type drugs 0 (0.0) 2 (0.4)
GHB 1 (0.2) 1 (0.1)
Heroin/morphine 98 (20.9) 321(68.6)
Hypnotic/sedatives 3 (0.6) 135 (28.8)
Methadone 37 (7.9) 166 (35.5)
Other opiates/opioid analgesics 4 (0.9) 50 (10.7)
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death.
Variable Category No %
Total 479 100.0
Gender Male 372 77.7
Female 107 22.3
Age-group (years) Under 15 1 0.2
15-24 68 14.2
25-34 167 34.9
35-44 178 37.2
45-54 58 12.1
55-64 7 1.5
65 & over 0 0.0
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Figure 4.1: Drug-related deaths as reported by Scottish police forces to the SCDEA, by
age and gender, 2009
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Figure 4.2: Drug-related deaths as reported by Scottish police forces to the SCDEA, by
selected psychoactive drug implicated, 2009
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5. Age and drug implicated in death
In cases aged 15 years and over,
heroin/morphine was the most frequently
mentioned drug contributing to fatality (Table
4.3).
This was also the case for all of these
individual age-groups. The sole case of an
individual aged less than 15 years involved a
combination of other opiates/opioid analgesics
and hypnotics/sedatives.
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Table 4.3: Age and psychoactive drug implicated in drug-related deaths as reported by
Scottish police forces to the SCDEA, 2009
Age-group (years) Number (%) Drug category (alone or in combination)
most frequently implicated in each age
group
All ages 468 (100.0) Heroin/morphine (68.6)
14 & under 1 (0.2) Other opiates/opioid analgesics &
hypnotics/sedatives (1 case)
15–24 66 (14.1) Heroin/morphine (62.1%)
25-34 161 (34.4) Heroin/morphine (73.3%)
35-44 175 (37.4) Heroin/morphine (68.6%)
45-54 58 (12.4) Heroin/morphine (69.0%)
55-64 7 (1.5) Heroin/morphine (57.1%)
65 and over 0 (0.0) -
6. Gender and drug implicated in death
In males (n = 366) and females (n = 102),
heroin/morphine was the most frequently
mentioned drug, accounting for 71% and 59%
of fatalities respectively. However, the pattern
of other drug-specific fatality was somewhat
different in male and female cases.
Among males, the most frequently mentioned
drugs were: heroin/morphine (71%); alcohol-
in-combination (66%); methadone (32%);
hypnotics/sedatives (29%); other opiates/
opioid analgesics (11%); and cocaine (9%).
Furthermore, there appears to be a higher
proportion of cases of drug-specific fatality
among males compared to females in respect
of alcohol-in-combination (66% vs. 24%).
Among female cases, the most frequently
mentioned drugs were: heroin/morphine
(59%); methadone (49%); hypnotics/sedatives
(28%); alcohol-in-combination (24%); other
opiates/opioid analgesics (6%); anti-
depressants (6%); and cocaine (5%).
Compared to male cases, it appears that
female cases had a higher proportion of
fatality associated with methadone (49% vs.
32%); and anti-depressants (6% vs. 3%).
7. Regional data
The number of drug-related deaths reported
by police to the SCDEA and meeting the np-
SAD case criteria fell from 312 in 2004 to 254
in 2005 and then rose to 374 in 2006. The
figure for 2007 was 357, but rose to a new
peak of 478 in 2008 (an increase of 34%).
This figure remained stable in 2009 (Table
4.4). The rates in the Fife, Grampian, Lothian
& Borders, Strathclyde and Tayside police
force areas are on a par with some of the
higher rates reported in England and Wales.
8. Commentary
Whilst data received by np-SAD from coroners
suggests that the number of drug-related
deaths increased in England, Wales and
Northern Ireland during 2009, information from
the Scottish police indicate stabilisation of
SCDEA cases. Figures released by the
General Register for Scotland show a slight
fall in deaths registered in 2009, using a
number of different definitions (GROS, 2010).
Where recorded by the SCDEA, the
demographic profile of those who died from
drug-related causes is similar to those in other
parts if the UK e.g. a higher proportion of
males to females, aged typically 25-44 years,
and White.
The overwhelming majority of deaths were
accidental drug overdoses. The level in
Scotland was much higher than in other
regions reflecting the different case definition
used by Scottish police forces. Opiates such
as heroin and methadone are implicated in the
majority of cases, and play a larger role than
in other regions. Alcohol-in-combination with
other substances and hypnotics/sedatives
(which are mostly diazepam and temazepam)
also feature prominently in Scottish deaths.
There have been falls in the involvement of
stimulants such as cocaine, amphetamines
and ecstasy-type drugs.
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Table 4.4: Deaths meeting np-SAD criteria as reported by Scottish police forces to the
SCDEA, per 100,000 population by police force area, 2007-9
.
Police force
area
Number
of
deaths
2007
Annual
death rate
per 100,000
population
2007 (1)
Number
of
deaths
2008
Annual
death rate
per 100,000
population
2008 (1)
Number
of
deaths
2009
Annual
death rate
per
100,000
population
2009 (1)
Central
Scotland
Police
9 3.11 13 4.48 10 3.02
Dumfries &
Galloway
Constabulary
4 2.69 8 5.38 9 6.06
Fife
Constabulary
22 5.78 33 9.12 28 7.70
Grampian
Police
33 6.16 47 8.71 43 7.89
Lothian &
Borders
Police
50 5.42 82 8.81 89 9.48
Northern
Constabulary
7 2.45 12 4.17 15 5.19
Strathclyde
Police
200 9.05 244 11.02 237 11.14
Tayside
Police
32 8.37 39 9.82 48 12.01
Scotland 357 6.94 478 9.25 479 9.22
(1) The rate per 100,000 population is based on published mid-year population estimates for local
government administrative areas for the years in question.
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Chapter 5 Drug-related deaths in the Islands
This chapter reports on deaths in 2009 and
examines the pattern of drug-related deaths in
the Islands between 2005 and 2009. Coroners
and their equivalents in Guernsey, Jersey and
the Isle of Man routinely submit returns on
drug-related deaths to the np-SAD that meet
the Programme’s case criteria.
As there are comparatively few cases in a
single year, even when combining data for the
Islands together, data for 2005-9 have been
aggregated together so that the findings are
more statistically robust.
1. Demography
To date, the Programme has been notified of 7
relevant deaths on Jersey and 5 on the Isle of
Man during 2009; Guernsey has no deaths to
report. A total of 56 drug-related deaths
occurred between 2005 and 2009: 13 in 2005,
10 in 2006, 12 in 2007, 9 in 2008 and 12 in
2009. This shows a stable situation in drug-
related deaths in three Islands between 2005
and 2009. The number of deaths in this 5-year
period was 4 in Guernsey, 32 in Jersey and 20
in the Isle of Man. In 2009 the number of
deaths per 100,000 population aged 16 years
and over was 9.39 for Isle of Man and 7.54 for
Jersey; there were no cases in Guernsey
(Tables 5.1 and 5.2).
Just over three-quarters (77%) of the cases
during the 5-year period were male (Table
5.3). The median age at death was 37.6 years
(semi-interquartile range = 10.9). A little over
two-thirds (68%) of cases were under 45 years
(Figure 5.1). Where ethnicity was known, the
overwhelming majority (96%) of decedents
were White, 41% were unemployed, half
(52%) lived with others. Addict status was
known in 30/56 cases, only 5% of which had a
history of dependence. Key demographics and
the principal drugs implicated in death during
2009 are given for the individual Islands in
Table 5.4.
Table 5.1: Changes in annual death rate per 100,000 population for np-SAD cases (16
years old and over), and annual percentage of all inquests held, by Island,
2008 and 2009
Island Number
of np-
SAD
deaths
2008
Annual
death rate
per 100,000
population
2008 (1)
Annual %
of all
inquests
held in
2008 (2)
Number
of np-
SAD
deaths
2009
Annual
death rate
per 100,000
population
2009 (1)
Annual %
of all
inquests
held in
2009 (2)
Guernsey 0 0.00 0.00 0 0.00 0.00
Jersey 6 7.97 11.76 7 9.39 14.00
Isle of
Man
3 4.47 7.89 5 7.54 12.82
Note: (0) refers to either no drug-related deaths or death rates of less than 0.01, whilst (–) indicates that no reports were
submitted for the specific period from that jurisdiction or area. In subsequent reports these rates may increase as more
inquests on deaths in 2009 are held and/or notified to the np-SAD. These rates should therefore be regarded as
minimum rates.
(1) Notified after the publication of the np-SAD Annual Report, 2009.
(2) The rate per 100,000 population is based on published mid-year population estimates for local government
administrative areas for the years in question.
(3) Includes updated information submitted in 2009/10.
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Table 5.2: Number and rate per 100,000 population (16 years and over) for np-SAD cases,
by place of residence and death, by Island, 2009
Island National and annual
death rate per 100,000
population – usual area
of residence
National and annual
death rate per 100,000
population – place of
death
No Rate No Rate
Guernsey 0 0.00 0 0.00
Jersey 6 6.03 7 7.54
Isle of Man 4 8.05 5 9.39
Note: Some cases were not usually resident in the Islands.
Table 5.3: Demographic variables for drug-related deaths meeting np-SAD criteria, the
Islands, 2005-2009
Table 5.4: Key demographics and principal drugs implicated in death for np-SAD cases,
by Island, 2009
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Guernsey 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Jersey 5 4 1 0 1 3 1 0 0 4 0 1 0 0 4 0 1 0 0 0
Isle of Man 7 7 0 1 2 3 0 0 1 7 0 0 0 0 3 1 1 0 0 0
Note: Some cases were usually resident outside the Islands.
Variable Category Number (%)
Total 56
Gender Male 43 (76,8)
Female 13 (23.2)
Employment status Employed 22 (39.3)
Unemployed 23 (41.1)
Childcare/house person 2 (3.6)
Student/pupil 1 (1.8)
Retired/sickness/invalidity 8 (14.3)
Living arrangement Alone 24 (42.9)
With others 29 (51.8)
Not known 3 (5.4)
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2. Location of death
Most fatalities (82%) occurred at a defined
residential address (i.e. the deceased’s home
address or other private residential address).
Thirteen percent occurred in hospital and 7%
elsewhere.
3. Cause(s) of death
Based on the information available from
coroners, 61% of cases died from accidental
poisoning, 29% from intentional self-poisoning,
and in 10% of cases the intent was
undetermined.
Figure 5.1: Drug-related deaths meeting np-SAD criteria, by age and gender, the Islands,
2005-2009
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4. Substances implicated in death
4.1 All substances
Psychoactive drugs were directly implicated in
54 cases while in two cases there was no
implication of any psychoactive substances.
The principal substances implicated were:
other opiates/opioid analgesics (23);
heroin/morphine (21); hypnotics/sedatives
(14); alcohol-in-combination (13); anti-
depressants (11); Methadone (5) and anti-
psychotics (3) (Figure 5.2).
Figure 5.2 takes into account data where one
of the following drugs was known to be
implicated: alcohol-in-combination; amphet-
amines; anti-depressants; anti-epileptics; anti-
Parkinson’s; anti-psychotics; cannabis;
cocaine; ecstasy-type drugs; GHB; heroin/
morphine; hypnotics/sedatives; methadone;
and other opiates/opioid analgesics.
4.2 Single substances
The following substances, as the sole
implicated drug, accounted for 24/56 (43%)
deaths: anti-depressants; heroin/morphine;
hypnotic/sedatives and other opiates/ opioid
analgesics (Table 5.5).
Table 5.5: Psychoactive substances implicated in meeting np-SAD criteria, the Islands,
2005-2009
Drug category Number of cases where no
other substance was implicated
(N = 54)
Number of cases where
drug was implicated
(N = 54)
Alcohol-in-combination - 13
Anti-depressants 2 11
Anti-psychotics 0 3
Heroin/morphine 10 21
Hypnotic/sedatives 1 14
Methadone 0 5
Other opiates/opioid
analgesics
11 23
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5. Age and drug implicated in death
In all ages, other opiates/opioid analgesics
(23) were the leading substances implicated,
followed by Heroin/morphine (21). However,
for individual age groups, heroin/morphine was
the leading implicated drugs among younger
age groups (less than 45 years).
Hypnotics/sedatives; other opiates/opioid
analgesics; and anti-depressants drugs were
the most frequently mentioned substance
contributing to fatality in the remaining age-
groups (Table 5.6).
Figure 5.2: Drug-related deaths np-SAD criteria, by psychoactive drug implicated, the
Islands, 2005-2009
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6. Gender and drug implicated in death
The pattern of other drug-specific fatality was
somewhat different in male and female cases.
Among males, the most frequently mentioned
drugs were: heroin/morphine (19); other
opiates/opioid analgesics (16);
hypnotics/sedatives (11); alcohol-in-
combination (10); anti-depressants (6);
methadone (5); anti-psychotics (5); and
cannabis, anti-psychotics and ecstasy-type
mentioned in one fatality.
Among female cases, the drugs mentioned
most commonly were: other opiates/opioid
analgesics (7); anti-depressants (5); alcohol-
in-combination (3); anti-psychotics (2);
heroin/morphine (2). There were no fatalities
due to methadone, cannabis and ecstasy-
types among females. Compared to male
cases, female cases had a higher proportion
of fatality associated with other opiates/ opioid
analgesics (53% vs. 37%) and anti-
depressants (39% vs. 15%).
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Table 5.6: Age and psychoactive drug implicated in deaths reported by Guernsey, Isle
of Man and Jersey coroners at the Islands meeting np-SAD criteria, 2005-
2009
Age-group (years) Number where
substance
implicated
Drug category (alone or in combination)
most frequently implicated in each age group
All ages 56 Other opiates/opioid analgesics (23)
Heroin/morphine (21)
Hypnotics/sedatives (14)
Alcohol in combination (13)
Anti-depressants (11)
Methadone (5)
Anti-psychotics (3)
Cannabis and Ecstasy-types (1 for each drug)
15-24 6 Heroin/morphine (4)
Other opiates/opioid analgesics (2)
Anti-depressants (2)
Hypnotics/sedatives (1)
25-34 14 Heroin/morphine (8)
Other opiates/opioid analgesics (6)
Methadone (2)
Anti-depressants (1)
Cannabis (3)
35-44 18 Heroin/morphine (7)
Alcohol in combination (7)
Other opiates/opioid analgesics (6)
Hypnotics/sedatives (5)
Methadone (3
Anti-depressants (1)
Anti-psychotics (1)
Ecstasy-type (1)
45-54 10 Hypnotics/sedatives (5)
Other opiates/opioid analgesics (4)
Anti-depressants (4)
Alcohol-in-combination (4)
Heroin/morphine (2)
Anti-psychotics (1)
55-64 4 Anti-depressants (3)
Other opiates/opioid analgesics (2)
Anti-psychotics (1)
65 & over 4 Other opiates/opioid analgesics (3)
Hypnotics/sedatives (3)
7. Commentary
The number of deaths notified to the
Programme from the Islands showed a
modest increase for the Isle of Man and
Jersey in 2009. Guernsey again had no
cases to report. The general demographic
profile of cases in the Islands is in line with
the pattern in the UK as a whole, although
far fewer appear to have had a known
history of drug dependence or use. .
When data for the three Islands are
combined together, the profile of the
psychoactive substances implicated in these
cases is broadly similar across the period
2005-9. The role of specific types of drugs in
drug-related mortality continues to show
significant differences to those occurring in
England and to a lesser extent in Wales.
There are proportionately fewer deaths
involving cocaine and methadone. However,
there is a greater role played by other
opiate/opioid analgesics; heroin/morphine;
and anti-depressants.
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Chapter 6 Drug-related deaths in the United Kingdom
1. Numbers of deaths reported
The total number of deaths that occurred
during 2009 in the UK reported to the National
Programme on Substance Abuse Deaths (np-
SAD) was 2,182. This number compares to
1,952 cases reported by the same sources
during the equivalent period in 2008. This
change represents an increase of 11.8% for
the UK in the number of notifications to the
Programme, but not necessarily in drug-
related mortality during this period.
Of the 2,182 drug-related deaths reported for
2009, England was 1,524; Scotland 479;
Wales 102; Northern Ireland 65; and the
Islands 12. In 2008 out of the 1,952 England
had 1,374; Scotland 477; Wales 62; Northern
Ireland 30; and the Islands 9.
As in the previous Annual Reports those
inquests which have not been completed will
be added to next year’s figure.
The number of cases reported from England
represents an increase of 10.9% over the
number reported during the equivalent period
last year. For Wales, Northern Ireland, and the
Islands reporting has been more
comprehensive than in previous years and
therefore it is not possible to be sure if the true
numbers have remained stable or otherwise.
Drug-related cases in Scotland recorded by
the SCDEA remained stable.
2. Demography
The majority (78%) of cases were male (Table
6.1). This proportion varied from 62% in
Northern Ireland to 86% in Wales. Where
ethnicity was known, the majority were White
(95%). The proportion of individuals living with
others ranged from 40% in England to 52% in
Wales. Nearly two-fifths (39%) of decedents
were known to be unemployed.
The median age at death was 38.0 years for
all sources combined; they ranged from 34.2
years in Wales to 41.5 years in Northern
Ireland. There were also differences in the
median ages broken down by gender; 37.3
years for males compared to 40.7 years for
females.
The above differences reflect distinctions in
the nature and purpose of the data sources,
the types of cases covered, and the volumes
of cases dealt with by them. These variations
also illustrate the limitations on making
comparisons between them.
np-SAD
International Centre for Drug Policy69
Table 6.1: Demographic variables for drug-related deaths, UK, 2009
Figure 6.1: Drug-related deaths by age and gender, UK, 2009
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Total 2,182 (100.0)
,
Gender Male 1,698 (77.8)
Female 484 (22.2)
Age-group (years) Under 15 2 (0.1)
15-24 201 (9.2)
25-34 646 (29.6)
35-44 769 (35.2)
45-54 344 (15.8)
55-64 143 (6.6)
Over 64 77 (3.5)
Location of death Defined residential address 1,264 (57.9)
Hospital 290 (13.5)
Other 129 (5.9)
Not known 499 (22.9)
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Figure 6.2: Drug-related deaths by age, UK, 2009
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Figure 6.3: Drug-related deaths by gender, UK, 2009
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3. Location of death
Where place of death was reported, about
75% died at a defined residential address (i.e.
the deceased’s home address or other private
residential address), 17% died in hospital and
7% died elsewhere (e.g. in a public place).
The proportion dying at a defined residential
address ranged from 73% in England to 81%
in Northern Ireland. The corresponding
proportions for deaths in hospital ranged from
10% in Wales to 18% in England. Such
information was available in only three
Scottish cases; all died at home. In line with
data protection, the SCDEA database
structure does not record information on living
arrangements and place of death.
4. Cause(s) of death
The majority of fatalities (72.3%) were
considered to be accidental (i.e. clearly non-
deliberate) poisoning, 8.5% from intentional
self-poisoning, and 9.2% for poisonings of
undetermined intent. The remaining cases
(10.0%) were related to other causes of death.
There are differences between different parts
of the UK and Islands in the proportions of
deaths accounted for by these main groupings
of underlying cause(s) of death (Table 6.2).
These reflect, in part, differences between the
SCDEA and np-SAD case definitions. A
detailed breakdown for all cases covered by
this report is given in Table 6.3.
Table 6.2: Main underlying causes of death, by country and territory, 2009
Underlying
cause of
death (%)
Country or territory
England Wales Scotland Northern
Ireland
Guernsey Jersey Isle
of
Man
UK &
Islands
Accidental
poisoning
65.9 80.4 95.6 27.7 0.0 71.4 60.0 72.3
Intentional
poisoning
11.4 6.9 0.0 4.6 0.0 14.3 20.0 8.5
Poisoning of
undetermined
intent
10.2 3.9 0.0 61.5 0.0 14.3 0.0 9.2
Other causes 12.5 8.8 4.4 6.2 0.0 0.0 20.0 10.0
Number of
deaths
1524 102 479 65 0 7 5 2182
Rate of drug-
related
deaths/100,000
population
aged 16
3.62 5.39 11.16 4.62 0.00 9.23 7.38 4.32
np-SAD
International Centre for Drug Policy 72
Table 6.3: Drug-related deaths by underlying cause(s) of death, UK and Islands, 2009
ICD-10 No. of cases
(n = 2,182)
% Description
X40
X41
X42
X43
X44
X45
X47
X49
22
134
1379
1
13
19
2
1
1.0
6.1
63.2
0.0
0.6
0.9
0.1
0.0
Accidental poisoning
Non-opioid analgesics, antipyretics and anti-
rheumatics
Anti-epileptic, sedative-hypnotic, Anti-parkinsonism
and psychotropic drugs, not elsewhere classified
Narcotics and psychodysleptics (hallucinogens), not
elsewhere classified
Other drugs acting on the autonomic nervous
system
Other and unspecified drugs, medicaments and
biological substances
Alcohol
Gases
Other & unspecified chemicals & noxious
substances
X60
X61
X62
X63
X64
X65
X67
11
78
82
1
9
1
4
0.5
3.6
3.8
0.0
0.4
0.0
0.2
Intentional self-poisoning
Non-opioid analgesics, antipyretics and anti-
rheumatics
Anti-epileptic, sedative-hypnotic, Anti-parkinsonism
and psychotropic drugs, not elsewhere classified
Narcotics and psychodysleptics (hallucinogens), not
elsewhere classified
Other drugs acting on the CNS
Other and unspecified drugs, medicaments and
biological substances
Alcohol
Gases
Y10
Y11
Y12
Y14
Y15
Y46
Y49.5
9
77
108
5
2
1
1
0.4
3.5
5.0
0.2
0.1
0.0
0.0
Poisoning of undetermined intent
Non-opioid analgesics
Anti-Parkinsonism drugs
Narcotics/psychodysleptics
Other/unspecified drugs
Alcohol
Adverse effects of anti-epileptics & anti-Parkinson’s
Adverse effects of antipsychotics
F10.0
F10.2
F11.0
F11.2
F13.0
F14.2
F14.5
F15.0
F15.2
F18.0
F19.1
F19.2
Z72.2
1
4
3
3
5
2
1
5
1
2
4
10
6
0.0
0.2
0.1
0.1
0.2
0.1
0.0
0.2
0.0
0.1
0.2
0.5
0.3
Mental & behavioural disorders due to psychoactive
substance use
Intoxication - alcohol
Chronic alcoholism
Intoxication - opiates
Dependence – opioids
Intoxication – hypnotics/sedatives
Dependence – cocaine
Psychotic disorder - cocaine
Intoxication – stimulants
Dependence – stimulants
Intoxication – volatile substances
Harmful use – multiple other
Dependence – multiple/other
Drug abuse, personal history
G40.9
G93.1
G97.8
2
1
1
0.1
0.0
0.0
Brain
Epileptic seizures
Brain damage, anoxic/hypoxic
Cerebral hypoxia, unspecified
J18.0
J18.9
J43
J69.0
J96.0
J96.9
R09.2
R95
1
1
1
1
1
2
1
1
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.0
Diseases of the respiratory system
Bronchopneumonia
Pneumonia, unspecified
Emphysema
Aspiration pneumonia
Acute respiratory failure
Respiratory failure/depression
Cardiorespiratory failure/arrest
Sudden infant death syndrome (‘cot death’)
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ICD-10 No. of cases
(n = 2,182)
% Description
I20-I25
I25.1
I33.0
I40.9
I42.2
I42.7
I49.9
I50.9
I51.8
I61.9
I70
I74.0
I82.8
1
6
1
2
1
1
1
2
2
1
2
2
1
0.0
0.3
0.0
0.1
0.0
0.0
0.0
0.1
0.1
0.0
0.1
0.1
0.0
Cardiovascular system – diseases, defects or
conditions affecting
Ischaemic heart diseases
Atherosclerotic heart disease
Acute & subacute infective endocarditis
Acute Myocarditis
Other hypertrophic cardiomyopathy
Cardiomyopathy due to drugs & other external
agents
Cardiac arrythmia
Cardiac failure, unspecified
Heart diseases
Intracerebral haemorrhage
Atherosclerosis
Arterial embolism/thrombosis
Embolism/thrombosis of other specified veins
J18.0
J18.9
J43
J69.0
J96.0
J96.9
R09.2
R95
1
1
1
1
1
2
1
1
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.0
Diseases of the respiratory system
Bronchopneumonia
Pneumonia, unspecified
Emphysema
Aspiration pneumonia
Acute respiratory failure
Respiratory failure/depression
Cardiorespiratory failure/arrest
Sudden infant death syndrome (‘cot death’)
K26
K70
K71
K74.6
K76.0
K85
1
7
1
1
1
1
0.0
0.3
0.0
0.0
0.0
0.0
Diseases of the liver
Duodenal ulcer
Alcoholic liver disease
Toxic liver disease (inc. drug-induced)
Other & unspecified liver cirrhosis
Fatty (change of) liver, not elsewhere classified
Acute pancreatitis
S09.7
S09.9
S12.9
2
2
1
0.1
0.1
0.0
Injuries
Multiple injuries of head
Head injuries unspecified
Fracture of neck, part unspecified
V05
V13
V23
V43.5
V47.5
V48.5
V89.2
2
1
2
2
3
4
2
0.1
0.0
0.1
0.1
0.1
0.2
0.1
Road traffic incidents
Pedestrian injured in collision with railway train
Pedal cyclist injured in collision with car, van, etc
Motorcycle rider injured in collision with car, etc
Car driver injured in collision with car, etc
Driver injured in collision with fixed/stationary object
Car driver injured in non-collision accident
Person injured in unspecified motor vehicle
accident – traffic
W76
X70
Y20
5
35
1
0.2
1.6
0.0
Hanging
Other accidental hanging and strangulation
Intentional hanging
Hanging, undetermined intent
R09.0
T59.9
T71
W78
W79
W83
X09
2
1
2
2
1
1
1
0.1
0.0
0.1
0.1
0.0
0.0
0.0
Asphyxia
Asphyxia, general
Toxic effects of other gases, fumes & vapours,
unspecified
Asphyxiation
Aspiration of gastric contents
Inhalation & ingestion of food obstructing airway
Suffocation by plastic bag
Inhalation of smoke and fumes
W66
W69
W70
2
3
1
0.1
0.1
0.0
Drowning & submersion
Whilst in bath tub
Whilst in natural water
After fall into natural water
W17
W19
5
1
0.2
0.0
Falls
Other fall from one level to another
Unspecified fall
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ICD-10 No. of cases
(n = 2,182)
% Description
A22.7
A40.0
A41.9
B17.1
C34
D07.5
E10
E84.0
E87.2
L02.4
M06.9
M72.6
T07
T88.7
X31
X85
W26
1
1
1
1
1
1
3
1
3
1
1
1
8
1
1
1
1
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.1
0.0
0.0
0.0
0.4
0.1
0.0
0.0
0.0
Other
Anthrax septicaemia
Septicaemia due to streptococcus, Group A
Septicaemia, unspecified
Acute hepatitis C
Malignant neoplasm of bronchus & lung
Carcinoma in situ, prostate
Diabetic ketoacidosis
Cystic fibrosis with pulmonary manifestations
Metabolic acidosis, exc. diabetic acidosis
Abscess, furuncle and carbuncle of limb
Rheumatoid arthritis, unspecified
Necrotising fasciitis
Multiple injuries, unspecified
Unspecified adverse effect of drug/medicament
Exposure to excessive natural cold
Assault by drugs
Contact with knife, sword or dagger (stab wound)
R99 15 0.6 Unascertained
Where possible, causes of death have been grouped together in terms of the mechanisms of death. At present, although all
causes of death on the death certificate (together with other information if available) are taken into consideration in classifying
underlying cause of death, the principal cause of death is used here by np-SAD to allocate the ICD-10 code. In order to achieve
a greater level of consistency, a hierarchical system was introduced for classifying the underlying cause of death using ICD-10
criteria for deaths involving multiple substances. Deaths that involve a combination of narcotics and other psychoactive drugs are
coded as narcotic deaths. Where possible a code which specifies intentionality is used.
5. Substances implicated in death
Psychoactive drugs were not directly
implicated in about 5.8% of cases (n = 127).
Of the remaining 2055 cases, the principal
substances implicated were: heroin/morphine
(53%); alcohol in combination with other
substances (32%); hypnotics/sedatives (23%);
methadone (23%); other opiates/ opioid
analgesics (20%); anti-depressants (16%) and
cocaine (9%).
Table 6.4 shows that whilst there are
commonalities across the various parts of the
UK and Islands in terms of the main
psychoactive substances given above being
implicated in death, there are noticeable
regional differences. For example, hypnotics/
sedatives play a proportionately greater role in
Northern Ireland and Scotland.
Heroin/morphine and methadone play lesser
roles in Northern Ireland when compared to
the rest of the UK, whereas other
opiates/opioid analgesics played a greater
role. The lesser role plated by methadone can
be explained, in part, by the fact that
methadone is not prescribed as widely in
Northern Ireland as in other areas. Anti-
depressants also play a greater role in
Northern Irish deaths. By contrast they hardly
feature in SCDEA cases; however, this reflects
the fact that the definition used by the SCDEA
does not cover the general population or
suicides but accidental overdoses involving
controlled drugs.
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Table 6.4: Psychoactive substances (%) implicated in drug-related deaths, by country and
territory, 2009
Country or territory
Drug category England Wales Scotland Northern
Ireland
Guernsey Jersey Isle
of
Man
UK &
Islands
Total 1419 95 468 61 0 7 5 2055
Alcohol-in-
combination
31.5 31.6 31.4 44.3 0.0 14.3 60.0 32.0
Amphetamines 2.3 2.1 1.3 3.3 0.0 0.0 0.0 2.1
Anti-depressants 18.4 15.8 3.4 39.3 0.0 0.0 20.0 15.5
Anti-epileptics 1.3 3.2 0.0 1.6 0.0 0.0 0/0 1.1
Anti-Parkinson’s 0.4 1.1 0.0 3.3 0.0 0.0 0.0 0.4
Anti-psychotics 3.6 3.2 0.9 11.5 0.0 14.3 0.0 3.3
Cannabis 1.6 0.0 0.0 0.0 0.0 0.0 0.0 1.1
Cocaine 10.0 5.3 7.9 4.9 0.0 0.0 0.0 9.1
Ecstasy-type drugs 0.4 0.0 0.4 0.0 0.0 0.0 0.0 0.4
GHB 1.0 1.1 0.1 0.0 0.0 0.0 0.0 0.8
Heroin/morphine 49.2 54.7 68.6 14.8 0.0 42.9 80.0 52.9
Hypnotics/sedatives 19.4 23.2 28.8 52.5 0.0 14.3 20.0 22.7
Methadone 19.8 21.1 35.5 4.9 0.0 14.3 0.0 23.0
Other
opiates/opioid
analgesics
21.2 24.2 10.7 54.1 0.0 42.9 20.0 20.0
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death.
6. Commentary
Whilst data received by np-SAD from coroners
suggests that the number of drug-related
deaths increased in England, Wales and
Northern Ireland during 2009, information from
the Scottish police indicate stabilisation of
SCDEA cases. In fact, figures just released by
the General Register for Scotland show a
slight fall in deaths between 2008 and 2009
(GROS, 2010).
Overall, demographic profiles of those who
died from drug-related causes are similar
across the various countries within the UK e.g.
a higher proportion of males to females, aged
typically 25-44 years, White, and the majority
of cases living with others, there are
differences within this general pattern.
Most deaths were accidental drug overdoses,
occurring at a private residential address
(typically at home or the home of a friend).
Opiates such as heroin, methadone and opioid
analgesics are implicated in the majority of
cases. Other substances playing major roles in
deaths include alcohol-in-combination with
substances, hypnotics/sedatives, anti-
depressants, and cocaine. However, there are
also regional variations in these patterns.
Whilst there appears to have been an increase
in the number of cases involving heroin and
methadone, there has been a noticeable
decline in the role of stimulants (cocaine,
amphetamines, and ecstasy-type drugs) in
death. The patterns obtaining in different parts
of the UK, and possible reasons for the recent
changes in recreational drug use, are
examined in the following chapters.
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Chapter 7 Commentary and emerging themes
Introduction
This chapter provides up-to-date information
on emerging trends and issues to those who
investigate drug-related deaths (DRDs) and
those who are trying to prevent such
fatalities. The main trends and issues
highlighted here emerge from the submitted
forms, communications from coroners, and
other relevant sources. This section also
draws on published sources and intelligence
from forensic toxicological agencies.
General patterns
The total number of deaths that occurred
during 2009 in the UK reported to the
National Programme on Substance Abuse
Deaths (np-SAD) was 2,182. This number
compares to 1,952 cases reported by the
same sources during the equivalent period in
2008. This change represents an increase in
the number of notifications to the
Programme, but not necessarily in drug-
related mortality during this period. Similarly,
the increase in the number of cases reported
from England, Wales, and Northern Ireland
do not necessarily mean an increase in
deaths related to drug use. Drug-related
cases in Scotland recorded by the SCDEA
remained stable.
The demographic profile of fatalities reported
by coroners to the np-SAD remains
consistent with previous reports. There was
an increase in the proportion of deaths
where the underlying cause of death was
accidental poisoning (up from 76.4% to
80.7%) with corresponding falls in the
proportions recorded as intentional self-
poisoning and poisoning of undetermined
intent.
Opiates/opioids (i.e. heroin/morphine;
methadone; other opiates/opioid analgesics),
alone or in combination with other drugs
continue to account for the majority of all
cases. Heroin/morphine alone or in
combination with other drugs, accounted for
the highest proportion (60%) of ‘drug misuse’
fatalities in 2009, an increase over the 2008
level of 55%. There was a fall in the
proportion of cases involving the stimulants
cocaine (from 15.7% to 11.4%),
amphetamines (from 4.8% to 2.8%), and
ecstasy-type drugs (from 2.7% to 0.3%).
These patterns are also reflected at country
level. Over recent years there has been a
trend towards multiple substances, including
alcohol, being implicated in deaths. In 2009,
there was a further decline in monovalent
deaths.
Exposure to a history of drug use or
addiction increased with age. Other
opiates/opioid analgesics play a more
important part on drug overdoses in the older
age-groups, especially amongst the over
50s. For those aged less than 50,
heroin/morphine remains the dominant
substance implicated in death. Intentional
overdoses in the over 50s accounted for half
of all such deaths in all age-groups.
Generally, the role of prescribed medication
in death increases with age.
Prescribed heroin/morphine and methadone
are most commonly involved in deaths where
these substances are directly implicated in
death. Other opiates/opioid analgesics,
hypnotics/sedatives, and anti-depressants
prescribed to individuals are less likely to be
involved in their deaths.
The number and proportion of deaths of drug
users aged more than 40 years at the time of
death with a known history of drug abuse or
dependence notified to the np-SAD
increased over the past decade. The median
age at death of individuals with such a drug
history was 32.4 years in 2000; by 2008 this
had risen to 37.2 years.
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Emerging issues
As part of its surveillance function, in recent
years the np-SAD Annual Report has
reported on new substances which are
appearing on the drug scene and which have
either been noted in post mortem
toxicological reports and/or implicated in
deaths reported to the Programme. In the
main, new substances appear first in the
toxicological reports and then sometime later
in the cause of death.
Mephedrone
Forensic toxicologists have reported
increased seizures of ‘legal highs’ derived
from methcathinone, particularly
mephedrone or methylmethcathinone
commonly known as “bubbles” and “meow-
meow”. An increasing number of alerts have
been issued by some drug treatment
agencies and Accident & Emergency
Departments (Wood et al, 2010). Some of
these cases have now gone to inquest or
through similar formal investigations by
Procurators Fiscal in Scotland, and have
been reported to np-SAD. The Programme
was aware at the end of July of least 52
deaths in the UK and Islands where
mephedrone is alleged to have been
consumed; some of these have turned out
not to be related to mephedrone use. The
current situation, as presently known, is as
follows:
 Total number of fatal cases where
mephedrone has been detected = 38
 Cases where mephedrone was the
sole direct cause of death = 2
 Cases where mephedrone and
methadone were jointly the direct
cause of death = 1
 Cases where mephedrone was
implicated but also underlying health
issues = 2
 Cases where mephedrone impacted
with other substances on mental
state leading to hanging = 2
 Cases where natural cause of death
but mephedrone was contributory
factor with antidepressant
medication = 2
 Cases awaiting completion of
Coroner/Procurator Fiscal inquiries =
29
MDPV (methylenedioxypyrovalerone)
The first seizure of MDPV was referred to the
FSS in the third quarter of 2009. By the end
of the first quarter of this year a total of 35
seizures had been sent for testing. This
substance became a Class B drug in April
this year. To date, only two cases have been
notified to the Programme where MDPV was
found in the post-mortem toxicology; both
deaths occurred in the first 4 months of
2010.
NRG-1 (Naphyrone)
In spring 2010 there were reports of new
substances chemically altered to circumvent
new controls on ’legal highs ’ becoming
available to purchase in ‘head-shops’ and
over the Internet. Naphyrone and other
generically related substances became
Class B drugs from 23 July 2010. Since the
composition of such products, marketed as
bath salts or plant food, is not necessarily
what is stated on the packaging consumers
are at risk of potential adverse health
consequences (Davies et al, 2010). Test
purchases do indicate that some of the
products being sold in recent months contain
prohibited substances such as mephedrone,
methylone, butylone and MDPV (Brandt et
al, 2010; Ramsey et al, 2010). The
Programme is actively monitoring deaths
reported by coroners for such substances.
Heroin contaminated with anthrax
Since late 2008 there have been
substantiated and authoritative reports of
heroin (or its cutting agents) contaminated
with anthrax, confirmed by laboratory
investigations. From December 2009 to 30
July 2010 a total of 47 cases (including 13
fatalities) have been reported in Scotland
from 8 of its 14 Health Board areas. Three
cases have been reported in England: a
fatality in Blackpool in early February, and
two cases in London (one of whom died in
late March 2010). So far only one of these
cases has been reported to np-SAD, but
others are expected in due course.
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Conclusions
Opiates, mainly heroin/morphine and
methadone, still account for the majority of
drug-related deaths in the UK. There is
evidence both from np-SAD data and other
authoritative sources that the role of these
substances in such deaths further increased
during 2009.
The falls noted above for cases involving the
stimulants cocaine, amphetamines, and
ecstasy-type drugs may well be due to the
growing use in recent years of so-called
‘legal highs’ such as ketamine, the
piperazines and GHB/GBL. Whilst these are
still available their popularity has declined
slightly, in part as a consequence of them
having been brought under the control of the
Misuse of Drugs Act 1971. At the same time,
other novel substances – principally
methcathinones and related chemicals –
have emerged onto the recreational drug
scene in Western Europe but especially the
British Isles.
The rapidity with which these new
substances have emerged appears to be at
an increasing rate. In the past, the market for
new psychoactive substances to explore
evolved steadily over much longer periods of
time. It is now difficult to gauge with any
certainty what will be the next ‘big thing’ that
will capture the attention of the experimenter
or regular recreational drug user.
Furthermore, there is a lack of information
provided to the potential consumer by the
retailer as to the true nature of the
ingredients in the substance being
purchased. Therefore, it important that the
np-SAD, in collaboration with other
surveillance systems, continues to monitor
reports from the treatment and forensic
toxicology fields and coroners’ records so as
to be able to alert health professionals about
emerging issues, and to suggest to Coroners
and pathologists what they might look out
for. The following chapter provides such
audiences with an overview of the role
played in death by some of the traditional
substances implicated, as well as the
emerging ones.
It is important, however, not to overlook the
fact that opiates/opioids still account for the
majority of drug-related deaths in England
and other pats of the UK. Together with
hypnotics/sedatives (chiefly benzodiazepines
such as diazepam and temazepam) the
involvement of heroin in deaths has
increased over the past year. The injection of
heroin contaminated with anthrax is a
serious risk factor for adverse health
consequences and death at present,
especially in Scotland. As heroin can be
stockpiled for several years before being
released onto the market it is importance that
vigilance is maintained by heroin users and
those who treat them for any tell-tale signs of
infection, thereby preventing premature
death.
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Chapter 8 Role of drugs in death
This chapter outlines how the main
substances of abuse (prescribed and non-
prescribed) cause death. It has been written
with the following audiences in mind –
coroners, pathologists, toxicologists and
clinicians. Because of the nature of this
subject, the discussion will mainly revolve
here around the pharmacological and clinical
issues related to the single psychoactive
substances. Whenever possible, indications
have been given in terms of how long active
ingredients remain in the body (i.e. half-life),
and the ranges (where available) for toxic
and fatal levels of these substances.
Furthermore, for each substance described
here some information highlighting the
various factors which may influence the
toxicity of a substance has been provided,
e.g. tolerance, drug/drug interactions, slow
metabolism, length of half-life, idiosyncratic
reactions, and substance synergies.
Synergistic combinations of substances
Quite frequently, drug-related deaths involve
a cocktail of drugs, such as opiates,
stimulants, alcohol and benzodiazepines. It
is evident that much still needs to be done in
educating users of the risks associated with
polydrug use. Some prescribed medications,
such as anti-epileptics, can affect specific
drugs, such as methadone metabolism; both
prescribers and users need to be aware of
these risks. Benzodiazepines and alcohol
individually act only relatively weakly to
depress the respiratory system, but patients
beginning treatment with benzodiazepines
should be warned about possible interactions
of benzodiazepines with alcohol.
Heroin, methadone, codeine and
buprenorphine
Quaglio et al (2001) evaluated the causes of
2,708 deaths in heroin addicts. Overdose
was found to be the major cause (37%),
followed by HIV/AIDS (32.5%), road
accidents (9.4%), suicide (5.5%), and liver
diseases (3.5%). Liver disease may however
be secondary to blood-borne viruses
associated with injecting (e.g. Hepatitis B,
Hepatitis C) as well as increased alcohol use
in these patients. Overdose has been
reportedly related to respiratory depression,
aspiration of vomit and pulmonary oedema
(ACMD, 2000). Central nervous system
(CNS) depression is likely however to be the
most important and first issue here, which
leads to respiratory depression and then to
the other medical consequences. On the
other hand, the dominance of the widely-held
belief that heroin-related fatalities are a
consequence of overdose may be
challenged (Mirakbari, 2004). In fact, the
presence of other drugs (primarily CNS
depressants such as alcohol and
benzodiazepines) are commonly detected at
post mortem (ACMD, 2000).
Heroin main metabolites: 6-mono-
acetylmorphine (6-MAM) and morphine
As a synthetic opioid, methadone causes
death in a similar way to heroin (Corkery et
al, 2004; Ghodse, 2010). However, what sets
methadone apart from other opioids is its
potential for delayed toxicity. The principal
mechanisms for methadone-related deaths
are: respiratory depression; airway
obstruction; pulmonary oedema and
bronchopneumonia. Respiratory depression
develops 12-14 hours after ingestion of
methadone, particularly in those who have
had or have only a weak tolerance to the
drug. Tolerance can be lost through
abstinence while imprisoned or by having
successfully completed in-patient opiate
detoxification. Death due to aspiration of
vomit can occur from a combination of the
emetic effects of heroin/methadone and its
depression of the cough reflex. Pulmonary
oedema is also a common cause of fatalities
amongst addicts overdosing on heroin/
methadone, as well as those on non-opioid
drugs. It can have a relatively quick onset
and thus can become a major factor in
death. Linked to pulmonary oedema is
bronchopneumonia.
The metabolism of methadone is very slow in
those who have just entered methadone
maintenance treatment (MMT) compared to
those who have been fully induced and
stabilised. A number of studies have found
fatal post mortem (blood) concentrations in
the range 0.2 mg/l - 4.5 mg/L, with the mean
ranging from 0.8 mg/L to 1.4 mg/L (Corkery
et al, 2004). It has been suggested that a
lethal dose of methadone amongst non-
dependent subjects is between 0.8 to 1.5
mg/kg of body mass, which may parallel (on
average) an intake of 50 mg for adults and
10 mg for children. A serum methadone
concentration of over 0.4 mg/L may be
enough to cause death from respiratory
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depression, yet levels of up to 1 mg/l have
been found in living patients receiving
treatment.
Methadone main metabolites: 2-ethylidene-
1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP);
and 2-ethyl-5-methyl-3,3-diphenylpyrroline
(EMDP)
It is not infrequent to meet in the clinics with
codeine/dihydrocodeine misusers. Codeine
has a low affinity for opioid receptors and the
analgesic effect of codeine may be due to its
conversion to morphine. The adult lethal
dose of codeine has been reported to be
between 0.5 to 1.0 g (Inchem, 2010). This
dose may cause convulsions and
unconsciousness, and death from respiratory
failure may result within 4 hours. Moffat
(1986) estimated the minimum lethal adult
dose at 800 mg. Drug concentrations in
codeine fatalities are
approximately 2.8 mg/L in blood and 103.8
mg/L in urine (Baselt and Cravey, 1989).
Death from codeine overdose is relatively
rare. An association with alcohol or other
CNS depressants increases the risk of
fatalities.
Codeine main metabolites: morphine;
norcodeine; glucuronides and
sulphates of both the unchanged drug and its
metabolites (Moffat, 1986)
Buprenorphine, a partial agonist, has a less
well defined effect on the respiratory function
than that usually expected for opiates, with a
ceiling effect on both respiratory depression
and analgesic action with increasing doses.
A ceiling on the respiratory depression is
possibly a valuable therapeutic safeguard
although the situation is different for sensitive
individuals, in whom these drugs may cause
severe respiratory distress (Schifano,
2007b). From this point of view,
buprenorphine is often considered a
relatively safe compound. On the other hand,
an increase has been observed in
buprenorphine-related deaths in the UK
since high dose formulation entered the
market with respect to previous years
(Schifano et al, 2005). This trend should be
carefully monitored over the next few years,
given that the high dosage of buprenorphine
formulation constitutes a potent risk factor for
premature mortality among addicts. Most of
the buprenorphine–related death cases
involve a combination of different
compounds and alcohol suggesting that it is
less safe than widely suggested, especially
among polysubstance abusers.
Benzodiazepines are frequently identified in
conjunction with buprenorphine. One might
wonder if the real cause of death, in these
cases, is due to a particular pharmacokinetic
interaction (both buprenorphine and
benzodiazepines are CYP3A substrates)
and/or to a synergistic effect of the two
drugs. Buprenorphine is also frequently
taken in conjunction with other opiates and
painkillers, an observation that could be
consistent with the complex presentation of
opiate misuse and pain.
Buprenorphine main metabolites:
buprenorphine-3-O-glucuronide;
norbuprenorphine N-dealkyl buprenorphine
Cocaine
Many of the cardiovascular effects of cocaine
have been attributed to the sympathomimetic
actions of the drug. Both the peripheral
nervous system and the brain have been
studied as potential sites for the
sympathomimetic actions of cocaine
(Schifano and Corkery, 2008). As a
consequence, there may be several
detrimental effects of cocaine, particularly on
the cardiovascular system, including:
hypertension and tachycardia; arrhythmias;
myocardial infarction with/without coronary
atherosclerosis; coronary atherosclerosis
and/or intimal smooth muscle cell
proliferation; increased platelet aggregation;
myocarditis; small vessel spasm; rupture of
the ascending aorta. Cocaine can produce
arrhythmias either through the production of
myocardial ischemia or as a direct result of
ion channel alterations. Excessive
catecholamines, combined with sodium and
potassium channel blockades, give rise to a
wide variety of supra-ventricular and
ventricular arrhythmias (Wood et al, 2009).
Cocaine may induce myocardial ischemia by
increasing the work of the heart. Cocaine
can also increase the demand for oxygen by
elevating the blood pressure and heart rate.
Cocaine can cause a wide range of other
problems including: neurological (e.g.
cerebrovascular accidents, i.e. strokes,
seizures); gastrointestinal (e.g. abdominal
pain, bowel infarction); and respiratory
symptoms (e.g. respiratory collapse,
pulmonary oedema). Cocaine can induce
hyperthermia as a result of increased
metabolism, peripheral vasoconstriction, and
an impairment of the thalamus to control
body temperature
The lethal dose of cocaine is highly variable
due to individual differences in sensitivity
among users (Kaye and Darke, 2003).
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Although deaths have been reported after a
single dose of a few hundred milligrams,
there are cases in which a dose of several
grams has not proved fatal. Moreover,
overdose can occur regardless of the
administration route. However, injecting
cocaine is likely to pose the greatest risk of
overdose, followed by smoking, and then
intranasal use (Kaye and Darke, 2003).
In the UK, a steady increase over the years
in cocaine/crack cocaine-related fatalities
has been reported (Ghodse et al 2008;
Schifano and Corkery, 2008). There may be
a few possible explanations, not necessarily
contradictory, for the overall increase in
number of cocaine/crack cocaine-related
deaths reported. These include: increase in
cocaine/crack cocaine consumption in a
polydrug fashion, including opiates/opioids,
misuse context, and higher reporting rates of
cocaine/crack cocaine on death certificates
(Schifano and Corkery, 2008). Alternatively,
since only a minority of fatalities involve a
monovalent cocaine/crack cocaine
intoxication, increase in death mentions
might reflect increase in fatalities related to
cocaine in combination with other drugs,
such as ecstasy (Schifano et al, 2006). Huge
media interest surrounded some of the high
profile cases of cocaine-related incidents
occurring in the last decade or so in the UK
and this may have increased awareness of
the possible consequences of drug
consumption. In turn, this may have led to
improved surveillance, monitoring and
recording of this substance in investigations
of sudden and/or unexpected deaths.
According to figures from the UK,
cocaine/crack cocaine was the sole drug
mentioned on death certificates in 36% of the
total number of related fatalities in England
and Wales (Schifano and Corkery, 2008).
Cocaine main metabolites: benzoylecgonine,
and ecgonine methyl ester. If taken with
alcohol: cocaethylene may be identified as
well. Anhydroecgonine methylester (AEME)
can be a useful marker for the detection of
cocaine smoking in clinical and forensic
cases.
Alcohol
The blood ethanol concentrations associated
with intoxication reflect the rate of intake, the
degree of tolerance acquired by previous
regular consumption and the simultaneous
effects of other drugs. A rapid rise in blood
ethanol concentration produces a greater
degree of intoxication than a gradual rise to
the same level and substantial tolerance
develops in regular drinkers (Morgan and
Ritson, 2010). In non-habitual drinkers, blood
ethanol concentrations of between 30 to 70
mg/100ml (6.5 to 15.2 mmol/l) can lead to
definite impairment of cognitive function,
motor co-ordination and sensory perception
whereas concentrations of 150 to 250
mg/100ml (32.6 to 54.4 mmol/l) generally
give rise to obvious intoxication. On the other
hand, habitual drinkers may sustain blood
ethanol concentrations of 300 mg/100ml
(65.2 mmol/l) or more without signs of
inebriation (Morgan and Ritson, 2010).
More severe alcohol intoxication leads to
increasing drowsiness and then coma, with
depressed tendon reflexes, hypotension and
hypothermia; respiration becomes shallow
and difficult. Death may result from
respiratory depression or following inhalation
of vomit. The blood ethanol concentration at
which death occurs varies considerably; it
may occur with blood ethanol concentrations
< 400 mg/100ml (87 mmol/l) although
survival has been recorded with blood
alcohol concentrations > 700 mg/100ml
(152.2 mmol/l; Morgan and Ritson,2010).
Co-ingestion of alcohol with other CNS
depressants such as benzodiazepines and
opiates/opioids can lead to respiratory
depression and death.
Alcohol main metabolite: acetaldehyde
Benzodiazepines
Benzodiazepine agonists and other agonist
ligands at the benzodiazepine site achieve
their therapeutic effects by enhancing the
actions of the inhibitory neurotransmitter
gamma-aminobutyric acid (GABA) at its
receptor site (Schifano, 2009). The
benzodiazepines have a binding site on the
GABA receptor, which forms a channel
through the membrane and opens and
closes to control chloride flow into the cell.
When benzodiazepine agonists are on their
receptor site, GABA produces a more rapid
pulsatile opening of the channel, and the flow
of chloride is increased. There are several
other drugs which are also ligands of the
GABA-chloride ion receptor complex, notably
the barbiturates, chloral hydrate and the
newer non-benzodiazepine hypnotics,
zopiclone, zolpidem and zaleplon (“Z”-
drugs). Benzodiazepines are fairly safe in
overdose if taken alone. Even massive
overdoses, if taken without other CNS
depressants, are almost never fatal
(Schifano, 2009).
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Main metabolites of diazepam: N-desmethyl
metabolites: nordiazepam
Amphetamine/methamphetamine and
MDMA/ecstasy
The systemic side effects of both
amphetamine and methamphetamine
(‘crystal meth’ or ‘ice’) arise from their
peripheral actions as they act as indirect
sympathomimetic amines and may include:
tachycardia, hypertension, palpitations,
sweating, dry mouth, decreased gastro-
intestinal motility and dilated pupils.
Methamphetamine appears to cause cardio-
myopathy (in a way similar to that induced by
cocaine), but also pulmonary oedema;
myocardial infarction; ischaemic and
haemorrhagic strokes (Schifano et al, 2007;
Schifano et al, 2010).
Main metabolites of methamphetamine: p-
Hydroxymethamphetamine and p-
hydroxyamphetamine
Main metabolites of amphetamine:
norephedrine; 4 -hydroxynorephedrine
The adverse effects of MDMA may be
related to metabolism and two overlapping
metabolic pathways have been postulated.
The first (and predominant) is carried out
through the ring degradation by O-
dealkylation to the corresponding 3,4–
dihydroxy metabolites. The second pathway
leads, via chain degradation, to MDA. Both
MDA and MDMA metabolism is regulated by
the levels of the hepatic enzyme CYP2D6.
About 5-9% of Caucasians are deficient in
this enzyme, so that poor metabolisers may
be at greater risk of toxic responses to the
drug even at low doses. It is important to
note that race/ethnicity is a risk/protective
factor in MDMA/MDA toxicity. The COMT
enzyme is involved in the transformation of
3,4-dihydroxy-methamphetamine-HHMA (the
main MDMA metabolite) to 4-hydroxy-3-
methoxymethamphetamine-HMMA. About
25% of the Caucasian population present
with low COMT activity. HMMA may
stimulate the release of the anti-diuretic
hormone vasopressin so that excessive
levels of water retention, coupled with
hyponatraemia, can be observed. Therefore,
young women may be at greater risk. One
could conclude that the range of COMT
activity (due to genetic polymorphism) may
explain some of the inter-individual
differences in vasopressin secretion after
MDMA consumption. A small increase in
MDMA dosage can lead to a significant rise
in drug plasma concentration ('non linear'
pharmacokinetics). All of these factors taken
together might lead to the conclusion that
there may be, in at least some individuals, a
significant lack of dose-response relationship
after MDMA administration and explains why
toxic reactions may be unrelated to the
amount taken (Schifano, 2004).
Although there may be a biphasic MDMA
concentration in tablets in the UK, an
average ecstasy tablet in the UK has been
reported to contain some 60-70 mg of
MDMA. Consequently, in a subject weighing
70 kg, one could conservatively conclude
that, with the ingestion of some 20-30
tablets, the equivalent of the lethal dose
(LD50) described in small animals can be
achieved. Up to 40-50 ecstasy tablets have
been described as the maximum dosage
taken on a single occasion and, at least in
the UK, heavy ecstasy consumers may binge
with some 15-25 tablets per occasion.
Although there are pronounced individual
differences with regard to the sensitivity to
MDMA toxic effects, life-threatening or lethal
outcomes have been seen with
concentrations between 0.11 and 7.0 mg/L
(Schifano, 2004). It is possible that other
factors, such as aggregation in close
environments (as in the case with clubs),
together with high ambient temperature and
possibly dehydration may play an important
role in increasing the risk of a fatal outcome.
Furthermore, a reverse
tolerance/sensitisation phenomenon can
occur in experienced stimulant users
(Schifano, 2004).
Main metabolites of MDMA/ecstasy: 3,4–
dihydroxy metabolites; MDA; 3,4-dihydroxy-
methamphetamine-HHMA. In some
individuals: 4-hydroxy-3-
methoxymethamphetamine-HMMA may be
identified.
Cannabis and synthetic cannabinoids
(‘Spice’ drugs)
Despite the widespread illicit use of cannabis
there are very few if any instances of people
dying from an overdose and fatalities
involving Δ9-tetrahydrocannabinol (THC) 
might happen most often after intravenous
injection of cannabis oil. According to the
Merck Index the LD50 (dosage lethal to 50%
of rats tested) of Δ
9-THC by inhalation is 42
mg/kg of body weight (O’Neil, 2005). That is
the equivalent of a 75 kg man inhaling the
THC found in some 10-20 high-potency (e.g.
150-300 mg each in terms of THC content)
joints in one session, assuming no THC is
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lost through smoke loss or absorption by the
lungs (Schifano, 2007a). With low-potency
(e.g. 5-25 mg THC content) joints such toxic
levels are very difficult to be ingested.
Probably for this reason, it was previously
thought that it is practically impossible to
overdose on cannabis, as the user would
certainly either fall asleep or otherwise
become incapacitated from the effects of the
drug before being able to consume a fatally
toxic quantity of THC. However, nowadays it
is not unusual to meet in clinics with users
smoking some 15-20 high-strength joints per
day (Schifano, 2007a). For an overview of
cannabis-related mortality see the np-SAD
annual report for 2007 (Ghodse et al, 2007:
27-9).
Synthetic cannabinoids are functionally
similar to Δ
9-tetrahydrocannabinol (THC), the
active principle of cannabis (EMCDDA,
2010a). Like THC, they bind to the same
cannabinoid receptors in the brain. In late
2008, several cannabinoids were detected in
herbal smoking mixtures or so-called
incense/room odorisers. Typical of these
were “Spice Gold”, “Spice Silver” and
“Yucatan Fire”, but many other products later
appeared. These products are typically sold
via the Internet and in ‘head shops’. Most
common synthetic cannabinoids include
(EMCDDA, 2010a): naphthoylindoles (e.g.
JWH-018, JWH-073 and JWH-398);
phenylacetylindoles (i.e. benzoylindoles, e.g.
JWH-250); cyclohexylphenols (e.g. CP
47,497 and homologues of CP 47,497);
classical cannabinoids (e.g. HU-210;
EMCDDA, 2010a). Only little is known about
the detailed pharmacology and toxicology of
the synthetic cannabinoids. It is possible
that, apart from high potency, some
cannabinoids could have particularly long
half-lives potentially leading to a prolonged
psychoactive effect. In addition, there could
be considerable inter-and intra-batch
variability in smoking mixtures, both in terms
of substances present and their quantity.
Thus, there might be a higher potential for
overdose than with cannabis (EMCDDA,
2010a).
Cannabis main metabolites: Δ 9 -
tetrahydrocannabinol-11-oic acid (THC-11-
oic acid); 11-nor-Δ 9 -tetrahydrocannabinol-
9-carboxylic acid (9-THC-COOH).
Synthetic cannabinoids main metabolites:
Methods for the forensic analysis of blood
samples for the recent intake detection of
synthetic cannabinoids are available in some
laboratories. However, the detection of
metabolites in urine samples is not yet fully
developed (EMCDDA, 2010a).
Piperazines
1-Benzylpiperazine (BZP) is part of a small
group of benzyl-substituted piperazines
(EMCDDA, 2010b). Despite claims by some
tablet and capsule suppliers that they are
herbal products, piperazine and its
derivatives are synthetic substances that do
not occur naturally. The large-scale misuse
of certain piperazine derivatives (often
known as ‘party pills’) started in New
Zealand several years ago, but became
common in Europe only after 2004. BZP is a
central nervous system (CNS) stimulant with
around 10% of the potency of d-
amphetamine (EMCDDA, 2010b). Animal
studies have demonstrated that BZP
stimulates the release and inhibits the
reuptake of dopamine, serotonin and
noradrenalin (EMCDDA, 2010b). There have
been a few instances of fatalities involving
BZP and other piperazines, typically
involving other drugs (see Section IV of this
report for more information on such
fatalities).
BZP main metabolites: 4-hydroxy-BZP; 3-
hydroxy-BZP; 4-hydroxy-3-methoxy-BZP;
piperazine; benzylamine; and N-
benzylethylenediamine. The hydroxy-
metabolites are also excreted as glucuronic
and/or sulphuric acid conjugates in urine
(EMCDDA, 2010b).
Khat and synthetic cathinones
(mephedrone)
With respect to khat chewing, there is
concern that people who do not wash khat
before consuming it will ingest pesticides.
Such pesticides may contribute to the
development of cancer of the digestive
system and kidney failure among khat
chewers. Deaths have been reported that
were caused by poisoning following the
ingestion of pesticides/fertilisers used in the
cultivation of khat (Corkery et al, in press).
No such cases have been reported in the
UK. Parasitic infections, such as fascioliasis,
can also be transmitted through the
consumption of contaminated khat. Although
khat has a stimulatory effect during the first
few hours of consumption, its use can
increase the risk of road traffic accident
fatalities. There have been a few instances
reported in the UK of individuals who, having
experienced a psychotic illness as a result of
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khat consumption, killed others and/or
themselves.
There may be several mechanisms of deaths
arising from khat use (Corkery et al, in
press), including: (a) irritation from
substances in khat that causes a laryngeal
spasm; and (b) whilst chewing, a piece of
khat gets stuck in the trachea and cannot be
dislodged by repeated coughing. Both types
of incident can lead to choking and asphyxia.
Furthermore, it is thought that khat
consumption may be associated with acute
myocardial infarction and haemiplegia,
because of meningeal haemorrhages.
Although studies on animals have shown
that khat is hepatotoxic with increases in liver
enzymes and there has been histo-
pathological evidence of acute hepato-
cellular degeneration (Al-Mamary et al.,
2002), it has only been recently that clinical
human case reports have been published
(Brostoff et al., 2006, Saha and Dollery,
2006). One case report suggested that
hepatitis was probably due to right heart
failure which in turn was possibly due to
direct khat toxicity - as it did not respond to
withdrawal of statins or proton pump
inhibitors (Saha and Dollery, 2006).
Chapman et al. (2010) report on six cases of
khat chewers (including two females0 with
severe, acute hepatitis that resulted in death
or liver transplantation. These all had similar
histopathological findings, typically multi-
lobular necrosis, with two having chronic liver
disease. As no other cause for their liver
disease was found, and since re-exposure to
khat-chewing resulted in further liver
damage, a high concentration of cathinone
was found in a sample of damaged liver
tissue 3 weeks after the patient’s last khat
use, there were no significant features to
suggest an autoimmune or immunoallergic
process in these cases, it was concluded
that khat consumption was the aetiological
cause of the liver injury in these individuals.
Repeated episodes of sub-clinical hepatitis
may evolve into chronic liver disease over
time, as demonstrated by the presence of
chronic liver disease in two subjects who
used khat on a long-term basis.
During the last few months, British media
and newspapers have been reporting
fatalities almost daily allegedly related to
mephedrone consumption, but only a few of
them have already been confirmed. A report
over a mephedrone related fatality first
appeared in Sweden in 2009, referring to an
18 year old girl’s death in December 2008.
No other drugs, apart from mephedrone,
were identified by the toxicological
screenings. Previously, a Danish teenager
found in possession of mephedrone died in
May 2008, although toxicology reports were
inconclusive. Data collected by the National
Programme on Substance Abuse Deaths
(np-SAD) suggest that by end of May 2010
there have been at least 43 suspected
deaths related to mephedrone in England, 8
of in Scotland and 1 in Guernsey (Schifano
et al, in preparation). Among them,
preliminary analysis carried out in at least 38
out of these 52 cases have provided positive
results for the presence of mephedrone at
post mortem, with 1 having been confirmed
as the result of the adverse effects of
methadone and mephedrone in combination.
Remaining cases are, to date, awaiting
further investigations. One could also argue
that not all suspected cases may have been
identified. From this point of view, it is
important to emphasize that a number of
reported fatalities implicate mephedrone
consumption in combination with other
substances and recreational drugs, such as
alcohol, cannabis, cocaine, amphetamine,
methadone, methylone and 4-MTA (Schifano
et al, in preparation).
Khat main metabolites: cathinone;
norpseudoephedrine/cathine; norephedrine
Mephedrone main metabolite: the
metabolism might follow the following
pathway: N-demethylation to the primary
amine, reduction of the keto moiety to the
respective alcohol, and oxidation of the tolyl
moiety to the corresponding alcohols and
carboxylic acid is the major metabolic
pathway, followed by N-dealkylation.
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Appendix 1: The national programme on Substance
Abuse Deaths (np-SAD)
Aims and objectives
The Programme’s principal aim is to reduce
and prevent drug-related deaths in the UK due
to the misuse of drugs, both licit and illicit, by
collecting, analysing, and disseminating
information on the extent and nature of death.
The Programme offers a comprehensive
prevention package to Drug (and Alcohol)
Action Teams (DA(A)Ts), Primary Care Trusts
(PCTs) and Strategic Health Authorities
(SHAs) with a mission to tackle the problem of
drug-related deaths.
The Programme’s objectives are to:
 Collect and collate drug-related mortality
data
 Develop and maintain a computerised
surveillance system
 Identify substances implicated in drug-
related deaths – including new drugs and
new combinations
 Monitor and examine patterns and trends,
e.g. geographic, demographic, substances
implicated in death, method of death
 Act as an early warning system for new
trends in mortality and drug misuse
 Use data as an indicator to estimate the
prevalence of substance-related problems
and assess the hazards associated with
substance abuse
 Collaborate with relevant agencies in
research on substance-related mortality
locally, nationally and internationally
 Inform and facilitate discussion on the
prevention of drug-related deaths, whether
accidental or intentional
 Provide data for local and national drug
abuse policy formulation and programme
planning
 Disseminate information on drug-related
mortality to the scientific community,
clinicians, policy makers and other
interested parties
Surveillance data management
Data collated for this programme is stored on
the np–SAD coroners’ database which was
established in 1997. Its purpose is to provide
information for the Programme’s surveillance
system of monitoring drug-related deaths
reported by coroners, procurators fiscal and
other agencies.
Data collection
All coroners in the UK (see Appendix 3) are
issued with copies of the standard data
collection form (see Appendix 4). They are
invited to complete the forms on all deaths that
meet the criteria described in this report (see
Appendix 2) and return them to the np-SAD at
the ICDP office at St. George’s, University of
London for coding and entry onto the
database.
Data submission is mostly directly on paper by
coroners or their staff. There is also manual
completion of the np-SAD data collection form
or print-out of completed computer-generated
forms using bespoke software. Forms are
submitted when inquests are complete – either
singly or in batches. Some data are received
electronically. Manual extraction of data by
team members is undertaken at some
coroners’ courts – mostly in London.
A monitoring process is undertaken to
ascertain the quality of the information
received from coroners, as well as the extent
to which all relevant cases are being identified
and submitted. This assists in further
improving the quality of the various outputs
that the Programme seeks to provide.
Data entry and coding
A great deal of consideration was given to the
area of data coding to ensure that comparison
with other databases was possible and that
the final analyses would be useful to readers.
For example, cases were coded for area of
residence of the deceased.
To enable comparison with various national
and international datasets all causes of death
have been coded according to the
International Classification of Diseases (ICD-
10). This is an international standard for the
classification of diseases and health-related
problems published by the World Health
Organisation (1992). The online version (ICD-
10 2007) has been employed for coding all
substances implicated in death separately
according to its therapeutic drug category, i.e.
hypnotics/sedatives, anti-depressants, opiates,
etc.
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The ‘intentionality‘ of deaths based on the
coroner’s verdict and/or or other additional
information employing ICD-10 codes is
inadequate for informing interested parties as
to whether certain categories of drug-related
deaths can be prevented.
Whilst the ‘cause’ of death (as given in the
preceding section) is concerned with the
disease or injury responsible for the lethal
sequence of events, the ‘manner’ of death
explains how the cause of death arose, i.e. a
natural or violent death. The categories for
‘manner of death’ have been adopted from the
UK practice (Explore Forensics) with the
additional categories for those where
intentionality is unclear or manner of death is
impossible to determine: natural, accidental,
suicidal, homicidal, undetermined, and
unclassified/not specified. Verdicts of
‘dependence on drugs’ or ‘non-dependent
abuse of drugs’ are regarded as ‘accidental’.
The ‘manner of death’ is derived from
information such as the verdict or ‘finding’,
history of drug misuse or dependence, post
mortem drugs, and other information; and is
based on the interpretation of the death by np-
SAD and clinical presentation/profile of the
individual case.
.
Statistical analysis
Due to the nature of the information collected
by the programme, i.e. drug-related deaths as
reported by the coroners, this is an
observational study. Hence, statistical
methods employed are based on proportions
and ratios. Where the data include proportions
of incidence for particular groups of interest,
the ratio of the proportions forms a measure of
the relative risk in one group compared with
that of another. These scales of measurement
are generally known as point estimates.
Although point estimates can be calculated
they do not represent the ‘true’ values. Each
point estimate is subject to random variation.
Confidence intervals (CI) provide an indication
of the range in the true values for the
population as a whole, which would be
expected in future investigations. The methods
used for quantitative data relied mainly on
complex assumptions of distributional form. It
may be the case that the assumptions are not
always satisfied. In such cases, methods
known as distribution-free methods can be
applied, also known as non-parametric tests
(e.g. Mann-Whitney). The data were analysed
using SPSS™ for Windows version 17.
Data storage
The anonymised data-set for coroners is held
on a SPSS database for analysis. All data
held, whether electronic or paper, is stored
securely and treated as confidential. Access
is restricted to Programme staff; only
aggregated and anonymised data are released
to third parties.
Other activities and resources
The Programme provides information to public
consultations, Parliamentary questions,
Ministerial briefings, as well as contributing to
the UK’s Early Warning System. As part of the
early warning function, emerging trends and
potential issues are brought to the attention of
policy-makers and coroners in a special
briefing.
The np-SAD team also conduct in-depth
psychological autopsies on individual cases
and carry out confidential inquiry exercises on
request. The team also provides analysis of
data for specific Drug and Alcohol Action
Teams (DAATs), Primary Care Trusts (PCTs)
and (Special Health Authorities) SHAs on
request.
Findings from the Programme’s annual report
and research articles published in peer-
reviewed journals articles also feed into both
the national and international research base.
For example, the key findings from the np-
SAD are included in the annual report from the
UK Focal Point to the EMCDDA, and in
various annual United Nations publications
In addition to the above activities, the
Programme
 Is the official custodian of the national UK
Addicts Index Access database and
paper files covering the period 1968-1997
 Holds a copy of the official Dead Addicts
datafile
 Is located in an academic centre with
input from relevant disciplines
 Brings to a broad range of expertise from
different professional backgrounds –
psychiatry, psychology, social science,
pharmacology, epidemiology, addictive
behavioural science, database, project
management, etc.
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 Has national and international
experience, collaborating in research and
training with bodies such as the World
Health Organisation, European
Monitoring Centre for Drugs and Drug
Addiction (EMCDDA), and the European
Collaborating Centres for Addiction
Studies.
National Steering Group
The np-SAD has a National Steering Group to
provide additional expertise to the Programme
through involvement and participation. Its
principal role is in giving advice on the full
range of its activities, including the national
surveillance of coroners and production of the
annual report.
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Appendix 2: Definitions of drug-related death
np-SAD definition
An np-SAD case is defined as a relevant death
where any of the following criteria are met at a
completed inquest, fatal accident inquiry or
similar investigation:
 One or more psychoactive substances*
directly** implicated in death;
 History of dependence or abuse of
psychoactive drugs;
 Presence of Controlled Drugs*** at post
mortem; or
 Cases of deaths directly due to drugs but
with no inquest.
Deaths where solvents and other volatile
substances are implicated alone are NOT
included. Information on this is collected by the
Department of Community Health Sciences at
St. George’s, University of London; further
information can be seen at
http://www.vsareport.org. Alcohol is included
only when implicated in combination with other
qualifying drugs.
* ‘Psychoactive’ substances are those having
a direct effect on perception, mood, cognition,
behaviour or motor function. Typically these
include opiates and opioid analgesics,
hypnotics, sedatives, anti-depressants, anti-
epileptics, anti-psychotics, hallucinogens and
stimulants such as amphetamines and
cocaine.
** ‘Directly implicated’ means that drugs were
considered by the coroner or other person
investigating the death to have been
instrumental in the coming about of the
deceased’s death (e.g. through poisoning or
intoxication), or causing their powers of
reasoning and/or perception to be so affected
as to induce them to take risks which they
would not have done had they been sober
(e.g. thinking they could fly).
*** ‘Controlled Drugs’ are those drugs
specifically classified by the Misuse of Drugs
Act 1971 as amended by subsequent
legislation. Controlled drugs include opioids,
cocaine, amphetamines, cannabis, GHB,
hallucinogens and most benzodiazepines.
Who is a drug abuser/dependent?
A drug abuser/dependent case is defined as
one with a history of substance abuse where
one or more of the following criteria are met:
 Reported as a known illicit drug user by
the coroner, based on evidence obtained
at inquest;
 Prescribed substitute medication for drug
dependence;
 Presence of an illicit drug at post mortem,
where not prescribed; or
 Presence of any additional information on
the coroner’s report suggestive of a
history of drug abuse, and where such a
history fulfils ICD-10 criteria: (F11-F16
and F19, using the 4-code subdivisions of
.0 (acute intoxication), .1 (harmful use),
and .2 (dependence syndrome).
Drug misuse definition
Cause of death categories included in the
headline indicator of ‘drug misuse’ deaths
used to monitor progress against the
Government’s drug strategy are defined in
terms of ICD-10 codes and Controlled Drug
Status. The relevant codes from ICD-10 are
given in brackets.
The definition comprises two types of deaths:
a) deaths where the underlying cause of death
has been coded to the following categories of
mental and behavioural disorders due to
psychoactive substance use (excluding
alcohol, tobacco and volatile solvents):
(i) opioids (F11);
(ii) cannabinoids (F12);
(iii) sedatives or hypnotics (F13);
(iv) cocaine (F14);
(v) other stimulants, including caffeine (F15);
(vi) hallucinogens (F16); and
(vii) multiple drug use and use of other
psychoactive substances (F19)
b) deaths coded to the following categories
and where a drug controlled under the Misuse
of Drugs Act 1971 was mentioned on the
death record:
(i) Accidental poisoning by drugs,
medicaments and biological substances (X40–
X44);
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(ii) Intentional self-poisoning by drugs,
medicaments and biological substances (X60–
X64);
(iii) Poisoning by drugs, medicaments and
biological substances, undetermined intent
(Y10–14);
(iv) Assault by drugs, medicaments and
biological substances (X85); and
(v) Mental and behavioural disorders due to
use of volatile solvents (F18)
Notes:
1. Deaths coded to opiate abuse which
resulted from the injection of contaminated
heroin have been included in the indicator.
This differs from the approach taken in
Scotland, where these deaths have been
excluded. This is because the General
Register Office for Scotland (GROS) is able to
identify deaths which occurred as a result of
the use of contaminated heroin, whereas in
England and Wales, these deaths cannot be
readily identified. In practice, in England and
Wales, they will only be included where the
drug was mentioned on the death record and
the death was coded to one of the ICD codes
on the ONS database of drug-related
poisonings and not to an infection code.
2. Specific rules were adopted for dealing with
compound analgesics which contain relatively
small quantities of drugs listed under the
Misuse of Drugs Act, the major ones being
dextropropoxyphene, dihydrocodeine and
codeine. Where these drugs are mentioned on
a death record, they have been excluded if
they are part of a compound analgesic (such
as co-proxamol, co-dydramol or co-codamol)
or cold remedy. Dextropropoxyphene has
been excluded on all occasions, whether or
not paracetamol or a compound analgesic was
mentioned. This is because
dextropropoxyphene is rarely, if ever, available
other than as part of a paracetamol compound.
However, codeine or dihydrocodeine
mentioned alone were included in the
indicator. This is because they are routinely
available and known to be abused in this form.
This approach is taken by both the Office for
National Statistics and the General Register
Office for Scotland.
3. Drugs controlled under the Misuse of Drugs
Act 1971 include class A, B and C drugs.
Definition used by SCDEA
Deaths reported to the SCDEA by Scottish
police forces are those which meet the
definition used by the Association of Chief
Police Officers (Scotland) – “where there is
prima facie evidence of a fatal overdose of
controlled drugs. Such evidence would be
recent drug misuse, for example controlled
drugs and/or a hypodermic syringe found in
close proximity to the body and/or the person
is known to the police as a drug misuser
although not necessarily a notified addict.”
Thus, most suicides in Scotland will be
excluded.
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Appendix 3: Coroner’s jurisdictions/ police force areas
reporting drug-related deaths, United
Kingdom & Islands
Administrative
county/area
Jurisdiction Description
(The) Queen's Household "The Coroner of the Queen's Household has
exclusive jurisdiction in respect of inquests and,
semble, inquiries which do not lead to inquests, on
persons whose bodies are lying within the limits of
any of the Queen's palaces or within the limits of
any other house where Her Majesty is then
demurrant and abiding in her own royal person,
notwithstanding the subsequent removal of Her
Majesty from such palace or house. The limits of
the palace or house are deemed to extend to any
courts, gardens or other places within the curtilage
of the palace or house but not further. Where a
body is lying dead beyond these limits, the coroner
of the Queen's Household has no jurisdiction."
ENGLAND
Avon Avon The city of Bristol and the districts of Bath &
North East Somerset, North West Somerset &
South Gloucestershire
Bedfordshire Bedfordshire & Luton The whole county of Bedfordshire and the
county of Luton
Berkshire Berkshire The whole county of Berkshire
Buckinghamshire Buckinghamshire The whole county of Buckinghamshire (excl.
Milton Keynes)
Milton Keynes The whole county of Milton Keynes
Cambridgeshire North & East Cambridgeshire The districts of Fenland & East Cambridgeshire
Peterborough The district of Peterborough
South & West Cambridgeshire The City of Cambridge, the districts of Huntingdon
and South Cambridgeshire
Cheshire Cheshire The whole county of Cheshire
Cornwall Cornwall The whole county of Cornwall (exc. Isles of
Scilly)
Isles of Scilly The Isles of Scilly
Cumbria North and West Cumbria The districts of Allerdale, Carlisle and Copeland.
South and East Cumbria The districts of Barrow-in-Furness, Eden, and
South Lakeland.
Derbyshire Derby & South Derbyshire The county of Derby and the districts of Erewash
& South Derbyshire. The district of Amber Valley
(except the parts in the Coroner’s Jurisdictions
of North Derbyshire). In the district of West
Derbyshire, the parishes of Alkmonton,
Ashbourne, Atlow, Biggin, Boylestone,
Bradbourne, Bradley, Brailsford, Clifton &
Compton, Cubley, Doveridge, Edlaston &
Wyaston, Fenny Bentley, Hognaston, Hollington,
Hulland, Hulland Ward, Hungry Bentley, Kirk
Ireton, Kniveton, Lea Hall, Longford, Mapleton,
Marston Montgomery, Mercaston, Norbury &
Roston, Offcote & Underwood, Osmaston,
Rodsley, Shirley, Snelston, Somersal Herbert,
Sudbury, Thorpe, Tissington, Yeaveley and
Yeldersley
North Derbyshire The District of Bolsover and North East
Derbyshire. The Boroughs of Chesterfield and
High Peak. In the Borough of Amber Valley the
parishes of Denthick, Lea and Holloway, South
Wingfield and Alfreton. The District of Derbyshire
Dales except the parishes in the Derby and
South Derbyshire Coroner’s District.
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Administrative
county/area
Jurisdiction Description
Devon Exeter & Greater Devon The districts of East Devon, Exeter, Mid Devon,
North Devon, Torridge, West Devon. That part of
the district of Teignbridge comprising the
parishes of Alphington, Ashton, Bovey Tracey,
Bridford, Christow, Chudleigh,
Doddiscombsleigh, Dunchideock, Dunsford,
Exminster, Hennock, Holcombe Burnell, Ide,
Kenn, Lustleigh, Manaton, Moretonhampstead,
North Bovey, Shillingford St George, Tedburn St
Mary, Trusham & Whitestone.
Plymouth & South West Devon The district of Plymouth. The district of South
Hams except the parishes in the Torbay and
South Devon coroner's district.
Torbay & South Devon The district of Torbay. The district of Teignbridge
except the parishes in the Coroner’s Jurisdiction of
Exeter and Greater Devon. That part of the district
of South Hams comprising the parishes of
Ashprington, Berry Pomeroy, Blackawton,
Cornworthy, Dartington, Dartmouth, Dean Prior,
Dittisham, Halwell, Harberton, Holne, Kingswear,
Littlehampton, Marldon, Rattery, Slapton,
Staverton, Stoke Fleming, Stoke Gabriel, Strete,
Totnes and West Buckfastleigh
Dorset Bournemouth, Poole &
Eastern Dorset
The counties of Bournemouth & Poole,
Christchurch, Purbeck and Wimbourne
Western Dorset The districts of West Dorset, North Dorset and
Weymouth & Portland
Durham Darlington & South Durham The county of Darlington and the districts of
Sedgefield and Teesdale {Wear Valley also
included]
North Durham The districts of Chester-Le-Street, Derwentside,
Durham and Easington
East Sussex Brighton & Hove The county of Brighton & Hove
East Sussex The whole county of East Sussex
Essex Essex & Thurrock (Essex No
1)
The districts of Basildon, Braintree, Brentwood,
Chelmsford, Colchester, Epping Forest, Harlow,
Maldon, Tendring, Thurrock and Uttlesford
Southend & South East Essex
(Essex No 2)
The districts of Southend, Rochford and Castle
Point
Gloucestershire Gloucestershire The county of Gloucestershire
Greater Manchester Manchester The district of Manchester
North Manchester The districts of Bury, Rochdale & Oldham
South Manchester The districts of Stockport, Tameside and
Trafford
West Manchester The districts of Wigan, Bolton and Salford
Hampshire Central Hampshire The districts of Winchester, Test Valley and
Eastleigh
North East Hampshire The districts of Basingstoke, Hart & Rushmoor
and that part of the district of East Hampshire
not contained in the Portsmouth & South East
Hampshire coroner's district
Portsmouth & South East
Hants
The county of Portsmouth and the districts of
Fareham, Gosport and Havant and, in the district
of East Hampshire, the parishes of Buriton,
Clanfield, Colemore and Priors Dean, East Meon,
Froxfield, Hawkley, Horndean, Langrish, Liss,
Petersfield, Rowlands Castle and Steep
Southampton & New Forest The county of Southampton and the district of
New Forest
Herefordshire Herefordshire The whole county of Herefordshire
Hertfordshire Hertfordshire The whole county of Hertfordshire
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Administrative
county/area
Jurisdiction Description
Humberside East Riding & Hull The counties of the East Riding of Yorkshire and
the city of Kingston-upon-Hull
Isle of Wight Isle of Wight The whole county of the Isle of Wight
Kent Central & South East Kent The district of Shepway. The borough of
Ashford. The district of Dover except those
parishes with the North East Kent coroner's
district. In the district of Swale, the parishes of
Boughton under Bleab, Doddington, Dunkirk,
Eastling, Faversham, Graveney & Goodnestone,
Hernhill, Luddenham, Lynsted, Newnham,
Norton & Buckland, Oare, Ospringe, Selling,
Sheldwich Badlesmere & Leaveland, Stalisfield,
Stone, Teynham, Throwley
Mid Kent & Medway The City of Rochester upon Medway, the districts
of Gillingham and Maidstone. The district of
Swale, with the exception of Faversham and the
parishes in the Coroner’s Jurisdiction of East Kent.
In the district of Tonbridge and Malling, the
parishes of Addington, Aylesford, Birling, Burham,
Ditton, East Malling & Larkfield, King's Hill,
Leybourne, Mereworth, Offham, Ryarsh,
Snodland, Trottiscliffe, Wateringbury & East
Peckham, Wouldham.
North East Kent The district of Thanet. The City of Canterbury. In
the district of Dover, the parishes of Ash,
Aylesham, Deal, Eastry, Eythorpe,
Goodnestone, Great Mongeham, Nonington,
Northbourne, Preston, Ringwould & Kingsdown,
Ripple, Sandwich, Sholden, Staple, Stourmouth,
Sutton by Dover, Tilmanstone, Walmer,
Wingham, Woodnesborough, Worth.
North West Kent The districts of Dartford, Gravesham, Sevenoaks
and Tunbridge Wells. The district of Tonbridge and
Malling, except the parishes in the Mid-Kent and
Medway Coroner's district.
Lancashire Blackburn, Hyndburn & Ribble
Valley
The districts of Blackburn, Hyndburn & Ribble
Valley
Blackpool & the Fylde The districts of Blackpool and Fylde
East Lancashire The districts of Burnley, Pendle and Rossendale
Preston & West Lancashire The districts of Lancaster, Wyre, Chorley, Preston,
South Ribble and West Lancashire
Leicestershire Leicester City & South
Leicestershire
The county of Leicester and the districts of
Blaby, Harborough, Oadby, Wigston
Rutland & North Leicestershire The county of Rutland and the districts of
Charnwood, Hinckley & Bosworth, Melton and
North West Leicestershire
Lincolnshire Boston & Spalding The districts of Boston and South Holland
North Lincolnshire & Grimsby The counties of North Lincolnshire and North
East Lincolnshire
Spilsby & Louth The district of East Lindsey, except the parishes
in the West Lincolnshire coroners' district. In the
district of West Lindsey, the parishes of Bigby,
Brocklesbury, Cabourne, Caistor, Claxby,
Grasby, Great Limber, Holton Le Moor, Keelby,
Kirmond le Mire, Legsby Linwood, Market
Rasen, Middle Rasen, Nettleton, Normanby le
Wold, North Kelsey, North Willingham, Osgodby,
Owersby, Riby, Rothwell, Searby cum Owmby,
Sixhills, Somerby, South Kelsey, Stainton le
Vale, Swallow, Swinhope, Tealby, Thoresway,
Thorganby and Walesby.
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Stamford In the district of South Kesteven, the parishes of
Aslackby & Laughton, Barholm & Stowe, Baston,
Billingborough, Bourne, Braceborough &
Wilsthorpe, Careby Aunby & Holywell, Carlby,
Castle Bytham, Corby Glen, Counthorpe &
Creeton, Deeping St James, Dowsby, Dunsby,
Edenham, Folkingham, Greatford, Haconby,
Horbling, Irnham, Kirkby Underwood, Langtoft,
Little Bytham, Market Deeping, Morton, Pointon &
Sempringham, Rippingale, Stamford, Swayfield,
Swinstead, Tallington, Thurlby, Toft with Lound &
Manthorpe, Uffington, West Deeping and Witham
on the Hill
West Lincolnshire The district of Lincoln. The district of North
Kesteven. The district of South Kestevan, except
the parishes in the Coroner’s Jurisdiction of
Stamford. The district of West Lindsey, except
the parishes in the Coroner’s jurisdiction of
Spilsby & Louth. In the district of East Lindsey,
the parishes of East & West Barkwith, Hatton,
Langton by Wragby, Panton, West Torrington,
Wragby.
London City of London City of London
Eastern London The London boroughs of Barking, Havering,
Newham, Redbridge & Waltham Forest
Inner North London The London boroughs of Camden, Hackney,
Islington & Tower Hamlets
Inner South London The London boroughs of Greenwich, Lambeth,
Lewisham & Southwark
Inner West London The London boroughs of Wandsworth & Merton,
the Royal Borough of Kensington & Chelsea,
and the City of Westminster
Northern London The London boroughs of Barnet, Brent, Enfield,
Haringey & Harrow
Southern London The London boroughs of Bexley, Bromley,
Croydon and Sutton
Western London The London boroughs of Ealing, Hammersmith,
Hillingdon, Hounslow and Richmond-upon-
Thames, and the Royal Borough of Kingston-
upon-Thames
Merseyside Knowsley, St Helens & Sefton The districts of Knowsley, St Helens and Sefton
Liverpool The district of Liverpool
Wirral The district of Wirral
Norfolk Greater Norfolk The city of Norwich, the districts of Breckland,
Broadland, King’s Lynn, North Norfolk, South
Norfolk, and West Norfolk
Great Yarmouth The borough of Great Yarmouth
Northamptonshire Northamptonshire The whole county of Northamptonshire
Northumberland North Northumberland The districts of Alnwick and Berwick-upon-Tweed
and so much of the districts of Castle Morpeth and
Wansbeck as lies north of the line for the time
being of the centre of the River Wansbeck
South Northumberland The districts of Blyth Valley & Tynedale, and so
much of the districts of Castle Morpeth &
Wansbeck as lie south of the line for the time
being of the centre of the River Wansbeck
North Yorkshire North Yorkshire Eastern The districts of Hambleton, Ryedale and
Scarborough
North Yorkshire Western The districts of Richmondshire, Craven,
Harrogate and Selby
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York The county of York. In the district of Harrogate,
the parishes of Nether and Upper Poppleton. In
the district of Ryedale, the parishes of Clifton
(without), Earswick, Haxby, Heworth (without),
Holtby, Huntington, Murton, New Earswick,
Osbaldwick, Rawcliffe, Skelton, Stockton-on-the-
Forest, Strensall, Towthorpe, Wigginton. In the
district of Selby, the parishes of Dunnington,
Elvington, Fulford, Heslington, Kexby, Naburn &
Deighton, Wheldrake.
Nottinghamshire Nottinghamshire The whole county of Nottinghamshire and the
City of Nottingham
Oxfordshire Oxfordshire The whole of the county of Oxfordshire
Shropshire Mid & North Shropshire The districts of Oswestry, North Shropshire,
Shrewsbury & Atcham
South Shropshire The districts of South Shropshire and Bridgnorth
The Wrekin The whole county of the Wrekin
Somerset Eastern Somerset The districts of Mendip and South Somerset
Western Somerset The districts of Sedgemoor, Taunton Deane and
West Somerset
South Yorkshire South Yorkshire East The district of Doncaster and Rotherham
South Yorkshire West The districts of Barnsley and Sheffield
Staffordshire South Staffordshire The districts of Cannock Chase, East
Staffordshire, Lichfield, South Staffordshire,
Stafford and Tamworth.
Stoke-on-Trent & North
Staffordshire
The county of Stoke-on-Trent, and the districts
of Newcastle-under-Lyme and Staffordshire
Moorlands.
Suffolk Suffolk The county of Suffolk.
Surrey Surrey The whole county of Surrey
Teesside Hartlepool The county of Hartlepool
Teesside The counties of Middlesbrough, Redcar &
Cleveland and Stockton-on-Tees.
Tyne & Wear Gateshead & South Tyneside The districts of Gateshead and South Tyneside
Newcastle-upon-Tyne The City of Newcastle-upon-Tyne
North Tyneside The district of North Tyneside
Sunderland The district of Sunderland
Warwickshire Warwickshire The whole county of Warwickshire
West Midlands Birmingham The districts of Birmingham & Solihull
Black Country The districts of Dudley, Sandwell, and Walsall
Coventry The district of Coventry
Wolverhampton The district of Wolverhampton
West Sussex West Sussex The whole county of West Sussex
West Yorkshire West Yorkshire Eastern The metropolitan district of Leeds and Wakefield
West Yorkshire Western The metropolitan districts of Bradford,
Calderdale and Kirklees
Wiltshire Wiltshire & Swindon The counties of Wiltshire and Swindon
Worcestershire Worcestershire The whole county of Worcestershire
WALES
Bridgend & Glamorgan Valleys The county boroughs of Bridgend, Merthyr Tydfil &
Rhondda, Cynon & Taff
Cardiff & the Vale of
Glamorgan
The county of Cardiff and the county borough of
the Vale of Glamorgan
Carmarthenshire The districts of Carmarthen, Llanelli and Dinefwr
Central North Wales The county of Denbighshire, the county borough
of Aberconwy & Colwyn.
Ceredigion The district of Ceredigion
Gwent The county of Monmouthshire, the county borough
of Blaenau Gwent, Caerphilly, Newport and
Torfaen
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Neath & Port Talbot The districts of Neath & Port Talbot. In the
borough of Lliw Valley, the communties of
Cilybebyll, Clydach, Cwmllnfell, Gwam-Cae-
Gurwen, Mawr, Pontardawe & Ystalyfera
North East Wales The boroughs of Flintshire and Wrexham. In the
district of Glyndwr, the communities of Ceiriog
Ucha, Chirk, Glyntraian, Llangedwyn, Llangollen,
Llangollen Rural, Llanrhaeadr-ym-Mochnant,
Llansantffraid Glyn Ceiriog, Llansilin &
Llantysilio.
North West Wales The counties of Anglesey, Caernarfonshire,
Merionethshire
Pembrokeshire The district of Preseli and South Pembrokeshire
(including Caldey Island and St Margaret's Island)
Powys The whole county of Powys
Swansea The district of Swansea. In the borough of Lliw
Valley, the communities of Gorseinon,
Gowerton, Grovesend, Llangyfelach, Llwchwr,
Penllergaer, Pontarsulais, Pont-Lliw.
NORTHERN
IRELAND
NORTHERN
IRELAND
Whole of Northern Ireland
THE ISLANDS
Guernsey Alderney, Brecqhou, Guernsey, Herm, Jethou,
Lihou, Little Sark, Sark
Jersey Jersey
Isle of Man Isle of Man
SCOTLAND
Argyll & Clyde Dumbarton Fiscal area (but figures included in Strathclyde
Police figures)
Central Scotland
Police
Clackmannanshire, Falkirk, and Stirling Council
areas
Dumfries &
Galloway
Constabulary
Dumfries & Galloway Council area
Fife Constabulary Fife Council area
Grampian Police City of Aberdeen, Aberdeenshire, and Moray
Council areas
Lothian & Borders
Police
East Lothian, City of Edinburgh, Midlothian,
West Lothian, and the Borders Council areas
Northern
Constabulary
Highland, Orkney Islands, Shetlands Islands,
and Western Isles Council areas, and parts of
Argyllshire (Ardnamuchan and Glencoe) and
Morayshire (Grantown-on-Spey and Cromdale)
Strathclyde Police Argyll and Bute, East Dumbartonshire,
Dumbarton and Clydebank, South Lanarkshire,
North Lanarkshire, East Ayrshire, North
Ayrshire, East Renfrewshire, City of Glasgow,
Inverclyde, South Ayrshire, and
Renfrewshire Council areas
Tayside Police Angus, City of Dundee, and
Perthshire and Kinross Council areas
Since the start of 2004, the following amalgamations of coroners' jurisdictions in England have occurred: East Berkshire,
Reading and West Berkshire to form one for the whole county of Berkshire (1 April 2004); East and West Cornwall to
form one for the whole county of Cornwall, but excluding the Isles of Scilly (1 February 2004); in Cumbria, Furness and
Southern Cumbria to form South Cumbria & Furness (1 April 2004); Hertford and West & North Hertfordshire to form one
for the whole county of Hertfordshire (1 October 2004); in Lincolnshire, Louth and Spilsby to form Spilsby & Louth (1
December 2003); in the West Midlands, Dudley, Sandwell, and Walsall to form Black Country (1 August 2004); in
Derbyshire, High Peak and Scarsdale to form North Derbyshire (1 February 2006); in Gloucestershire, Gloucester and
Cheltenham to form Gloucestershire (1 April 2006); in Suffolk, Greater Suffolk and Lowestoft to form Suffolk (1 August
2006). Further amalgamations have taken place in 2007, these changes will be reflected in future reports.
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The retirement of several coroners has resulted in some coroners taking on responsibility for additional jurisdictions. The
Isles of Scilly (regarded as part of Cornwall) are currently being looked after by the coroner for Plymouth & South West
Devon. Data for Herefordshire are also submitted now together with those for Worcestershire. The two jurisdictions in
Durham are now being looked after by the same coroner, but have not been formally amalgamated. The coroner for
Suffolk is also coroner for Southend & South East Essex.
In Northern Ireland, a process of amalgamation has been completed and since 1 April 2006 there has been a single
coroner’s area covering the whole of the Province. It is centred on the Greater Belfast office and served by three full-
time coroners, overseen by a High Court judge.
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Appendix 4: np-SAD data collection form
The National Programme on Substance Abuse Deaths (np-SAD)
NOTIFICATION OF DRUG-RELATED DEATHS
Section I Demographic information
Deceased forename(s): _____________________________ Gender:  Male  Female
Family name: ____________________Other names known by: _______________________
Date of birth: ______/______/______ Place of birth: ________________________________
Usual address:______________________________________________________________
_____________________________________________Postcode: __________________________
Ethnicity (tick one only)
White  Pakistani  Black African  Other, specify_________
 Chinese  Bangladeshi  Black Caribbean  Not known
 Indian  Black other, specify ______________
Occupational status (tick one only)
 Employed (manual)  Unemployed  Retired
 Employed (non-manual)  Childcare/houseperson  Student/pupil
 Self employed  Invalidity/sickness  Other, specify_________
 Not known
Living arrangements (tick one only)
 Alone  Self and children  No fixed abode
 With partner With parent(s)  Other, specify_______________
 With partner & children  With friend(s)  Not known
Section II Details of death
Date of death: _______/_______/_________
Place of death: (tick one only)
 Home  Residential premises (.e. hotel)  In custody
 Place of work  Street or highway  Place of recreation/sport
 Treatment centre  Educational establishment  Hospital
 Other place, specify________________________________________________________
Cause(s) of death (as given on the death certificate)
1(a)_______________________________________________________________________
(b) _______________________________________________________________________
(c) ________________________________________________________________________
2 _________________________________________________________________________
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The National Programme on Substance Abuse Deaths (np-SAD)
Toxicology
Please list drugs and alcohol present at post mortem (in order of importance, if known)
Drug/alcohol Level Drug/alcohol Level
B T U B T U
1 4
2 5
3 6
B = Blood; T = Tissues; U = Urine
Section III Coroner’s verdict
Section IV Background information
Recent history of drug use and other relevant information: e.g. evidence of injecting drug
use; evidence of ‘crack’ use; recently released from prison or discharged from treatment
programme; psychiatric history; known to alcohol/drug services; length of use; poly-substance
user; known health problems associated with substance misuse; last 24 hours of life (if
known), time police summoned, any drugs paraphernalia, etc.:
Was the deceased on prescribed psychoactive medication?  Yes  No  Not known
If yes, please list drugs:
1 _______________________________ 2 ___________________________
3 _______________________________ 4 ___________________________
5 _______________________________ 6 ___________________________
Was the deceased a drug addict or known drug abuser?  Yes  No  Not known
Section V Coroner’s details
Coroner’s name: __________________________Date inquest completed: ____/_____/_____
Jurisdiction: __________________________________ Office: _______________________
Signature: ___________________________________ Date: _______/________/________
Please send completed form to:
National Programme on Substance Abuse Deaths (np-SAD)
International Centre for Drug Policy
St George’s, University of London
FREEPOST LON 10141,
London SW17 0BR
For general enquiries: Tel 020 8725 2623 or Fax 020 8266 6494
This form is available electronically
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Copies available from
National Programme on Substance Abuse Deaths (np-SAD)
International Centre for Drug Policy (ICDP)
St George’s, University of London
Cranmer Terrace
London
SW17 0RE
Tel: +44 (0)20 8725 2623
Fax: +44 (0)20 8266 6494
E-mail: npSAD@sgul.ac.uk
Price - £15 (including packing and postage)
Issued in August 2010
Commissioned by the Department of Health
